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Abstract
Peripheral membrane proteins are structurally diverse proteins that are involved in funda-
mental cellular processes. Their activity of these proteins is frequently modulated through
their interaction with cellular membranes, and as a result techniques to study the interfa-
cial interaction between peripheral proteins and the membrane are in high demand. Due
to the fluid nature of the membrane and the reversibility of protein–membrane interac-
tions, the experimental study of these systems remains a challenging task. Molecular
dynamics (MD) simulations offer a suitable approach to study protein–lipid interactions
with high spatial and temporal resolution. Here, we present a summary of recent applica-
tions of MD simulations to study the interaction of different classes of membrane proteins
with lipid bilayers at the atomic level. Specific systems studied include membrane-bound
cytochrome P450 (CYP) enzymes, a class membrane proteins involved in the metabolism
of a wide range of molecules, the hemagglutinin fusion peptide (HAfp), a small peptide
that mediates the fusion process of the influenza virus to a host cell, and the T-cell
immunoglobulin and mucin domain (Tim) proteins, involved in the mechanism of lipid
recognition by T-cells.
In our studies of CYP3A4, the most abundant CYP isoform in the human body, we
have been able to characterize the membrane-bound form by employing a combined sim-
ulation/experimental approach. First, to obtain the membrane–bound form of CYP3A4,
the spontaneous membrane–association of the globular domain of the enzyme was cap-
tured (Chapter 3). and by linear dichroism measurements of nanodisc-bound CYP3A4
performed in parallel to characterize the orientation of the enzyme in the membrane,
yielding close agreement between simulations and experiment. The resulting membrane-
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bound structure of CYP3A4 was used in subsequent simulations to further probe different
functions of CYP3A4 in the membrane with atomic detail, including the mechanism of
membrane–mediated drug recruitment(Chapter 4), and the mechanism of drug-drug in-
teraction mediated by membrane-bound CYP3A4 (Chapter 5). The general simulation
approach to model membrane association of CYP3A4 was employed for CYP2J2, another
human CYP (Chapter 6). For CYP2J2, membrane–binding simulations revealed impor-
tant membrane–interacting residues (Ile-236 and Phe-239), and their role in membrane–
binding was examined experimentally using Trp-quenching fluorescence spectroscopy in
nanodiscs. It was shown that mutation of these residues greatly affects activity of the
enzyme, as well as its depth of insertion in nanodiscs, thus providing strong support for
the computational model developed by the HMMM simulation. Furthermore, the derived
membrane–bound model of CYP2J2 was employed to study the atomic details of fatty
acid binding to the enzyme (Chapter 7).
For HAfp, MD simulations were employed to characterize the membrane–bound form
of HAfp (Chapter 8). Despite employing a wide range of different initial orientations
of the peptide for simulations, HAfp insertion into the membrane was reproducibly cap-
tured in the majority of the performed simulations (18 out of 21), resulting in a convergent
membrane-bound form of the peptide. The simulations allowed to elucidate specific in-
teractions with the membrane that facilitate the insertion and orientation of the peptide,
consistent with experimental observations.
Membrane binding of Tim1, an important member of the TIM family, was studied
employing MD simulations (Chapter 9). The simulations revealed key protein-lipid elec-
trostatic interactions, that in addition to the PS-binding pocket identified from crystal
structures, confer the protein with a mechanism to identify PS-containing membranes.
The membrane–bound model derived with MD simulations was complemented by experi-
mental measurements (X-ray scattering), which revealed details about the orientation and
insertion of the protein in model lipid layers. Collectively, these approaches allowed us
to develop a dynamic structural model for Tim1 recognition of PS membranes, providing
atomistic insight this mechanism.
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Chapter 1
Introduction to Peripheral
Membrane Proteins ∗
Biological membranes are an essential component of all living cells, forming a dynamic
barrier that demarcates the boundaries of the cell and the compartments within them.
Due to this compartmentalization process, membranes are a fundamental signature of
life, arising early in evolutionary history to allow for gradients to be generated that can
be exploited in metabolism [1–3]. Control of this metabolism is orchestrated by a host
of membrane-associated proteins, which together account for ∼ 30% of the human pro-
teome [4,5] and for ∼ 60% of current drug targets [6], making these membrane-associated
proteins a perpetually popular topic of investigation.
Over the past decade, it has become very clear that the membrane itself is not a pas-
sive, fluid substrate as once thought [7], but rather is an active participant in regulating
∗This section is largely based on the three review articles.
(1) Javier L. Baylon, Josh V. Vermaas, Melanie P. Muller, Mark J. Arcario, Taras V. Pogorelov and
Emad Tajkhorshid, “Atomic–Level Description of Protein–Lipid Interactions Using an Accelerated Mem-
brane Model”. Biochimica et Biophysica Acta – Biomembranes, In Press, 2016.
(2) Josh V. Vermaas, Javier L. Baylon, Mark J. Arcario, Melanie P. Muller, Zhe Wu, Taras V. Pogorelov
and Emad Tajkhorshid, “Efficient Exploration of Membrane-Associated Phenomena at Atomic Resolu-
tion”. Journal of Membrane Biology, 248: 563-582, 2015.
(3) Christopher G. Mayne, Mark J. Arcario, Paween Mahinthichaichan, Javier L. Baylon, Josh V. Ver-
maas, Latifeh Navidpour, Po-Chao Wen, Sundarapandian Thangapandian and Emad Tajkhorshid, “The
Cellular Membrane as a Mediator for Small Molecule Interaction with Membrane Proteins”. Biochimica
et Biophysica Acta – Biomembranes, In Press, 2016
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the activity of membrane-associated proteins through its composition or spatial organi-
zation [8, 9]. Nowhere is this clearer than for peripheral membrane proteins, a subset
of membrane proteins that primarly interact with the surface of the membrane. These
structurally diverse peripheral proteins [10] are indispensable to cellular signaling [11,12].
Beyond coupling, peripheral proteins also detoxify small molecules [13], and initiate im-
portant biological processes to human health such as the blood coagulation cascade [14]
or viral fusion [15]. The centrality of membranes in the activity modulation of peripheral
membrane proteins is now well established, and the future of the field is in demonstrat-
ing the cause and effect between specific membrane-protein interactions and observable
phenotypes.
1.1 Structure and Composition of Biological Mem-
branes
Membranes are abundant in biology, acting as the effective barrier that compartmentalizes
life into cells and organelles that can accumulate resources and reproduce [16, 17]. This
compartmentalization of life allows for concentration gradients to exist between cellular
structures, which can be established or exploited by membrane-embedded proteins, such
as the creation and use of a proton gradient by the oxidative phosphorylation pathway in
mitochondria [18]. Indeed, dysregulation of membrane crossing events can have profound
effects leading to disease [19,20] or even death [21,22]. At the same time, some molecules
impact biological processes without crossing the bilayer, and instead partition into the
membrane and diffuse within a single bilayer leaflet while penetrating below the lipid
headgroups. This partitioning is fundamentally a result of the bilayer structure (Fig. 1.1)
and interactions of the small molecule with individual lipids.
Biological membranes are fluid structures, composed of two leaflets of amphipathic
lipid molecules where proteins sit and interact with each other and with other molecules.
Lipids are roughly composed of three chemically distinct regions: the hydrophillic head-
group, the hydrophobic fatty acid acyl tails, and a connector between the two, typically
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derived from glycerol (Fig. 1.1). Each individual lipid can accommodate a large number of
conformational states, particularly as it relates to its two acyl tails, bestowing a flexibility
that helps to eliminate any gaps in the membrane while permitting a hospitable envi-
ronment for specific types of molecules, hydrophic in nature, as required for partitioning.
Molecules that partition strongly into the hydrophobic core of the membrane tend to be
only weakly soluble in aqueous solution [23].
Figure 1.1: Membrane structure is defined by the structure of lipids. (Top left) Schematic representation
of a lipid, composed of polar headgroup, a ”backbone” molecule (e.g, glycerol for most phospholipids),
and fatty acid tails. (Top Right) Chemical structures of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS), two prototypical phospholipids
found in biological membranes. POPC and POPS have a net charge of zero and -1, respectively. (Bottom)
Schematic representation of a membrane. The assymetrical lipid distribution in biological membranes is
also highlighted. Different colors represent different lipids.
Membrane lipids come in a variety of different types, and they are tipically subdivided
by the molecule forming their headgroups. Phospholipids, containing a phosphate linking
the headgroup to the glycerol backbone, are the major class of membrane lipids (Fig. 1.1).
The most common phospholipid is phosphatydilcholine (PC), with a choline moiety as
its headgroup component. Other principal phospolipids found in biological membranes
include phosphatydilserine (PS), phosphatydilethanolamine (PE), phosphatydilglyrcerol
(PG), diphosphatydilglycerol (DPG, also known as cardiolipin), and phosphatydilinositol
(PI). Sphingomyelin (SM) is a phospholid that instead of glycerol, is derived from sphin-
gosine, an amino alcohol with a long carbon tail that also serves as backbone for other
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classes of lipids (sphingolipids). Headgroups have different sizes and number of charged
groups, such as positively charged amines and negatively charged carboxylates. PC and
PE lipids carry a net charge of zero, while PS, PG and PI carry a net charge of -1, and
cardiolipin carries a net charge of -2. This difference in headgroup size and charge plays
a key role in the interaction of the lipid bilayer with its surrondings, including proteins
that interact with the membrane surface.
An important feature of biological membranes is their assymetry. The two surfaces of
the membrane (e.g., inner and outer leaflets) have different components and are implicated
in different activities (Fig 1.1). Importantly, lipids are distributed unevenly among the
two leaflets. In many biological membranes, PC and SM lipids is typically located in
the outer leaflet of the membrane, while other lipids are preferentially found in the inner
leaflet, including the neutral PE and negatively charged lipids such as PS, PG and PI.
This assymetry has important implications in the way in which the lipid bilayer interacts
with it other components, including membrane proteins, to perform different functions.
1.2 Different Types of Membrane Proteins
Membrane proteins are responsible for the majority of dynamic processes that take place
in the membrane. While membranes act as dynamic barriers that define boundaries
and compartments, membrane proteins carry out most of the membrane functions [24].
Membrane proteins can function across the membrane or on its surface, which allows
the definition of transmembrane and surface-bound processes. Transmembrane functions
include the transport of molecules and signal transduction across the membrane [25–27],
while surface-bound functions are carried out only on one side of the membrane and
contribute to the metabolic activity of the corresponding compartment [28–30].
Membrane proteins can be generally classified in two main classes, namely integral
and peripheral membrane proteins [31] (Fig. 1.2). This classification is roughly based on
how difficult it is to experimentally remove a protein from the membrane [31]. Integral
membrane proteins establish strong nonpolar interactions with the hydrophobic core of
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the membrane, and nonpolar agents (such as detergents or organic solvents) are required
to extract them from the membrane [32]. In contrast, peripheral membrane proteins
interact with lipid headgroups located at the membrane surface, and can be removed by
modifying the ionic strength of the surrounding solution [33].
Figure 1.2: Schematic representation of membrane proteins. Membrane proteins can be broadly classfied
into integral and peripheral membrane proteins. Integral membrane proteins interact extensively with
the core of the membrane through hydrophobic domains (shown in red), and include transmembrane
(top left) and monotopic (top right) proteins. Peripheral proteins associate (shown in orange) with at
surface of the membrane, and can interact with lipid headgroups (bottom left) or with integral membrane
proteins (bottom right).
Integral membrane proteins are embedded into the membrane, extensively interacting
with the hydrophobic core of the lipid bilayer [24,31] (Fig. 1.2). The majority of this class
of proteins are transmembrane proteins containing hydrophobic domains that span the
membrane, and hydrophilic, extramembranous portions that are exposed to the cytosol,
esentially acting as physical contacts between the two compartments separated by the
lipid bilayer [24]. Transmembrane proteins commonly act as transporters, cell sufrace
receptors, cell adhesion molecules, and enzymes [27,29]. An important subclass of integral
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membrane proteins includes monotopic proteins, which have hydrophobic domains that
partially embed in the hydrophobic core of the membrane (Fig. 1.2). In contrast to
transmembrane proteins, monotopic proteins perform their functions only on one leaflet
of the lipid bilayer [24,29].
The other major class of membrane proteins are peripheral membrane proteins. This
class of proteins are bound to the surface of the membrane, by interacting with lipid
headgroups or with extramembranous domains of integral proteins [10, 33] (Fig. 1.2).
Many peripheral membrane proteins directly interact with the membrane by recognizing
specific lipid headgroups [34, 35], regions of certain lipid composition [36, 37], or even by
sensing membrane curvature [38–40] . In general, peripheral membrane proteins reversible
bind to the surface of the membrane through a combination of electrostatic and nonspecific
hydrophobic interactions [11]. Importantly, monotopic and peripheral membrane proteins
are topologically equivalent, since both classes of proteins are bound to the surface of the
membrane [24].
Figure 1.3: Examples of peripheral membrane proteins. For clarity, the membrane surface, composed
of lipid headgroups and first few carbons of the lipid tails, is shown in stick representation, while the
hydrophobic core of the membrane is shown in yellow.
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Peripheral membrane proteins are classified based on their function, and most work
at the lipid–water interface [30]. This group of proteins is very versatile, and present
a wide variety of shape and sizes (Fig. 1.3). Specific examples of peripheral proteins
include membrane–associated enzymes that function on lipophilic substrates [29] (e.g.,
cytochrome p450), small domains of signalling proteins (e.g., GLA domain [41–43]),
cytoskeletal-associated proteins (e.g., talin [44–47]), proteins that induce membrane bend-
ing (e.g., synaptotagmin [48, 49]), and neural proteins (e.g., α-synuclein [50–53]), among
many other types [10,30].
1.3 Interactions of Peripheral Membrane Proteins With
Biological Membranes
Peripheral membrane proteins associate with the membrane surface, consisting of the
lipid head group region and a few carbons of the lipid tails [11] (Fig 1.3). These pro-
teins contain structurally varying lipid-binding globular domains that recognize specific
membrane components [10]. The membrane itself acts as a signal to recruit peripheral
proteins, by modulating the lipid composition through leaflet dependent exposure of an-
ionic phospholipids (e.g. phosphatidylserine (PS)) [54, 55], or biosynthesis of particular
rare lipid species, such as phosphatidylinositides (PI) [56, 57] or cardiolipin [58, 59]. The
dynamic nature of biological membranes therefore gives rise to different mechanisms that
mediate association and interactions of peripheral membrane proteins [30]. Moreover,
membrane association often requires a combination of different mechanisms, for example
both electrostatic and hydrophic interactions, rather than just a single mechanism.
1.3.1 Electrostatic and Hydrophobic Interactions
Electrostatic and hydrophobic interactions are among the main mechanisms mediating
membrane association of peripheral proteins (Fig. 1.4). Typical biological membranes
consist of zwitterionic lipids, such as phosphatidylcholine (PC) and sphingomyelin (SM),
and a small fraction of negatively charged lipids, such as PS or PI [60]. The negative
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charge distribution found at the membrane surface can attract positively charged proteins
through long-range electrostatic interactions. Although highly nonspecific, these type of
electrostatic interactions are key for the activity and regulation of a number of proteins
that require their basic residues to interact with negatively charged lipids [61, 62].
Figure 1.4: Schematic representation of peripheral protein–membrane interactions. Membrane–binding
mechanisms include electrostatic interactions (left), hydrophobic interactions (middle), and covalently-
bound lipid anchoring (right).
A more sophisticated form of electrostatic interactions involves the recognition of spe-
cific lipid head groups in a Ca2+-dependant manner [10, 63]. Certain peripheral proteins
will only bind to negatively charged membranes if Ca2+ is presents at a particular concen-
tration [14, 64]. A prominent example of peripheral proteins interacting with biological
membranes through specific electrostatic interactions are blood coagulation factors, specif-
ically factor VII, IX and X, as well as prothrombin [41,65–67]. These factors include the
GLA domain, named so because its γ-carboxyglutamate content, a helical domain that
coordinates multiple Ca2+ ions (Fig. 1.3), which are crucial to mediate binding to PS-
contaning membranes [14,64,68].
Hydrophobic interactions are generally highly nonspecific [11], and are mediated by
hydrophobic domains of peripheral proteins. Typical domains involved in hydrophobic
interactions include hydropobic or amphipathic α-helices that insert into the nonpolar
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region of the membrane [69,70], or less structured loops that contain multiple hydropho-
bic side chains that act as membrane-anchors [10, 71]. Hydrophobic interactions usually
require certain degree of protein conformational change at the membrane interface, re-
sulting in exposure of hydrophobic side chains that are otherwise buried in the absence
of the membrane [72,73].
1.3.2 Lipid-Anchored Proteins
Another important mechanism mediating protein-membrane interactions involves the at-
tachment of covalently-bound lipid anchors to the peripheral protein [74] (Fig. 1.4). Dif-
ferent types of lipids, including fatty acids, isoprenoids, sterols, phospholipids, and gly-
cosylphosphatidylinositol (GPI) anchors, can be covalently attached to proteins through
co-translational or post-translational modifications [74, 75]. In addition, a modified pro-
tein can have more than one type of lipid attached, confering it with different membrane-
binding properties [76].
One of the most common post-translational modifications to peripheral membrane
proteins is the attachment of a fatty acid, typically the 14 carbon saturated fatty acid
myristate or the 16-carbon fatty acid palmitate, to specific residues of the protein. These
modifications typically facilitate the membrane binding of the modified protein [77, 78],
and can also improve its ability to identify specific membrane components [79].
Another important post-translational fatty acid modification is the covalent attach-
ment of a GPI anchor to the C-terminus of peripheral membrane proteins [80]. GPI-
anchored proteins are modified by the addition of saturated PI chains, facilitating the
anchoring of the modified protein to the outer leaflet of the plasma membrane. This
modification plays a role in signaling, endocytosis, and intercellular interactions including
adhesion and immune response [75,79,80].
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1.4 Characterizing Peripheral Protein-Lipid Interac-
tions
Despite the rapidly growing interest in characterizing lipid-protein interactions in periph-
eral proteins, the fluid nature of the lipid bilayer makes experimental studies on peripheral
proteins, especially the characterization of the membrane bound structure, extremely chal-
lenging. In cases where a crystal structure can be solved, dynamic properties, such as
ligand binding and large-scale conformational change upon membrane binding, cannot
be characterized based on resulting static structures. Furthermore, due to the transient
nature of the interaction between peripheral proteins and membrane lipids, crystallizing
the membrane-bound complexes of peripheral proteins for X-ray analyses is exceedingly
difficult. Other techniques, such as SAXS [81–83], EPR [84–86], NMR [87–89] including
high–resolution field cycling NMR [90–93], FRET [94, 95], fluorescence correlation spec-
troscopy [96–98], X–ray reflectivity [99, 100], neutron reflectometry [101, 102], and mu-
tagenesis studies can bridge the gap, and provide low-resolution information on protein-
lipid interactions such as determination of the binding face of the protein as it interacts
with a membrane interface. However, without the guidance of a structural model of the
protein-membrane complex, even when structures of constituent proteins are resolved,
hypothesis-driven experimental investigations into the biological mechanisms are limited
by the uncertainties inherent in missing the contribution of the membrane. Knowledge
of structures of protein-membrane complexes at atomic level of detail is thus of critical
importance.
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Chapter 2
Overview of the Methodology ∗
2.1 Molecular Dynamics (MD)
In addition to traditional experimental approaches, simulation with classical molecular
dynamics (MD) [103] is a compelling addition to study biological macromolecules, going
beyond the resolution of conventional experiment to provide models of these systems in
full atomic detail. Crucially, MD permits atomic events (such as a side chain rotation or
the formation of a salt bridge) to be observed on a single molecule level, allowing the effect
of specific mutations or binding events to be captured for biological assemblies [104]. The
high spatial and temporal resolution offered by MD is particularly important because lipid-
protein interactions are inherently dynamic, which can cause difficulties for experimental
observation. In classical atomistic MD simulations, all the particles of the system represent
atoms whose positions and velocities are determined by solving Newton’s equations of
motion over discrete timesteps [105]. The simulation is performed in an interative manner,
by calculating all the forces acting on each particle of the system for each timestep, and
∗This section is partially based in two review articles.
(1) Javier L. Baylon, Josh V. Vermaas, Melanie P. Muller, Mark J. Arcario, Taras V. Pogorelov
and Emad Tajkhorshid, “Atomic–Level Description of Protein–Lipid Interactions Using an Accelerated
Membrane Model”. Biochimica et Biophysica Acta – Biomembranes, In Press, 2016.
(2) Josh V. Vermaas, Noah Trebesch, Christopher G. Mayne, Sundarapandian Thangapandian, Mrinal
Shekhar, Paween Mahinthichaichan, Javier L. Baylon, Tao Jiang, Yuhan Wang, Melanie P. Muller, Eric
Shinn, Zhiyu Zhao, Po-Chao Wen and Emad Tajkhorshid, “Microscopic Characterization of Membrane
Transporter Function by in silico Modeling and Simulation”. Methods in Enzymology, In Press, 2016.
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then updating their positions and velocities accordingly [105, 106], as described in the
following sections.
2.1.1 Empirical Force Fields for MD Simulations
The interactions between the particles in the system are calculated based on an empiri-
cal force field, a predefined potential function that describes the internal dynamics and
intermolecular interactions of the components of the system. The force field typically
employed for biomolecular simulations contains terms to describe three main forces act-
ing on each particle of the system, namely bonded (including bond, angle and dihedral
contributions), van der Waals (VDW), and electrostatic interactions
U = Ubond + Uangle + Udihedral + UV DW + Uelec (2.1)
Bond, angle and dihedral terms in the force field are each represented by a harmonic
function [107]
Ubond = kd(d− d0)2 (2.2)
Uangle = kθ(θ − θ0)2 (2.3)
Udihedral = kφ(1 + cos(nφ− δ)) (2.4)
where kd, kθ and kφ are the bond length, bond angle, and dihedral angle force con-
stants, respectively. The values of the bond length, bond and dihedral angle at a par-
ticular configuration of the system are represented by d, θ and φ, respectively, while the
zero subscript represents the equilibirum value for each parameter. For the dihedral term,
n represents the multiplicity of the function, and δ is the phase shift. Values for force
and equilibrium constants for the bonded terms, refered to as force field parameters, are
derived from experiments and quantum mechanical calculations, and ideally, these pa-
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rameters should be able to reproduce chemical and thermodynamic properties of a given
biomolecular system [107]. Currently, there is a variety of force field parameters available
to perform MD simulations of multiple biomolecular systems, including proteins [108], nu-
cleic acids [109,110], lipids [111], carbohydrates [112], and more recently small, drug-like
molecules [113].
Nonbonded interactions, which include VDW and electrostatic interactions are rep-
resented by more complicated functions. By definition, the nonbonded interactions are
only accounted for atom pairs separated by at least three bonds. For VDW interactions,
a Lennard-Jones potential is employed
UV DW = ε
[(
Rijmin
rij
)12
−
(
Rijmin
rij
)6]
(2.5)
where ε is the well-depth of the Lennard-Jones potential, Rijmin is the distance at
which the potential is zero, and rij is the distance between atoms i and j. Lennard-Jones
Electrostatic interactions are calculated using a Coulombic potential
Uelec =
qiqj
rij
(2.6)
where qi and qj are the charges of atoms i and j, respectively, separated by a distance
rij, and epsilon is the effective dielectric contant. Partial atomic charges are assigned
based on analogy to available data, or by fitting to quantum mechanical data for model
compounds interacting with water [113].
Using Eq. 2.1, it is possible to calculate the potential energy of the system, which
includes contributions from bonded (Eqs. 2.2, 2.3, and 2.4) and nonbonded (Eqs. 2.5,
and 2.6) interactions from all the particles in the system.
The net force, ~F , acting on each particle is given by the negative gradient of the
potential energy U with respect to the position of the particle
~F = −~∇U (2.7)
During a MD simulation, the Newtonian equation of motion for a particle with mass
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m, given by
~F = m~a (2.8)
is integrated to propagate its position ~r and velocity ~v in time, t [114, 115]. Stable
integration of the particle’s position demands that the timestep is approximately ten times
shorter than the timescale of the fastest degree of freedom [116]. Typically, the fastest
degree of freedom in atomistic MD simulations are heavy atom vibrations, and thus the
timesteps are 2 fs each.
2.1.2 Simulation Conditions and Protocols
The MD simulations described in the following chapters were performed employing atom-
istic protein structures, derived from experiments or by homology model, placed in explicit
water, and including lipid (either as in HMMM or a conventional membrane), and ions.
Solvation and placing of ions was performed employing different plugins as implemented
in VMD [117].
All the simulations were performed using NAMD2 [118] utilizing the CHARMM27
force field with cMAP [107, 119] corrections for the protein and CHARMM36 [113] for
lipids. The TIP3P model was used for water [120]. Parameters for small molecules
were obtained by analogy [121, 122] from the CHARMM General Force Field [113], and
were further optimized employing the Force Field Toolkit [123]. The full-tailed systems
(including pure POPC or POPC/POPS mixtures) were simulated as an NPT ensemble
(i.e., constant temperature, preassure, and number of particles) at 1.0 atm and 310 K.
All the HMMM simulations were performed as an NPnAT ensemble . As mentioned
previously, the NPnAT ensemble was employed to efficiently modulate the area per lipid
during the membrane–binding simulations. All the simulations were carried out with
a time step of 2 fs. Constant pressure was maintained using the Nose´-Hoover Langevin
piston method [124,125], and constant temperature was maintained by Langevin dynamics
with a damping coefficient γ of 0.5 ps-1 applied to all atoms. Non-bonded interactions were
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cut off after 12 A˚ with a smoothing function applied after 10 A˚. The particle mesh Ewald
(PME) method [126] was used for long-range electrostatic calculations with a grid density
greater than 1 A˚-3.
The simulations started with a short equilibration run were heavy atoms of protein,
lipid headgroups and other molecules are constrained, while lipid tails, ions and water are
allowed to relax. This step was then followed by unconstrained simulations, with varying
lengths specific to the system. The MD simulations hereby described were performed
NAMD [127] using resources from the Extreme Science and Engineering Discovery En-
vironment (XSEDE), Blue Waters and other campus clusters of University of Illinois, or
Desmond on Anton [128]. Visualization of the resulting trajectories, as well as analysis,
was performed with VMD [117].
2.2 Accelerating Membrane Insertion of Peripheral
Membrane Proteins
The use of molecular dynamics (MD) simulations to resolve detailed models capable of cap-
turing specific lipid-protein interactions is an established method and can be fruitfully em-
ployed to guide experiment [129–137]. However, one of the drawbacks of conventional MD
is one of timescale, which becomes a major hurdle when simulating protein-lipid interac-
tions. Due to the relatively slow lateral diffusion of lipids (D ∼ 8×10−8 cm2s−1) [138,139],
over the course of 100 ns for a typical atomistic MD trajectory, individual lipids may only
exchange with their neighbors once. Thus the resulting membrane representation in con-
ventional atomistic simulations is often effectively static, preventing the description of
lipid motion and lateral diffusion necessary for lipid mixing and adequate sampling of
lipid-protein interactions in mixed bilayers found in vivo [10, 140], complicating our un-
derstanding of specific lipid-protein interaction.
Over the years, a number of computational approaches were developed to circumvent
the problem of slow lipid dynamics including coarse-grained [141–147] and implicit mem-
brane models [148–152]. Coarse-grained models work by mapping groups of atoms into
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beads, e.g., four heavy atoms and their associated hydrogens are represented as a single
bead, which increases simulation timescales by allowing for longer timesteps (due to the
increased mass of each particle) that occur more frequently (due to the reduced number
of particles) [141]. Coarse-grained approaches can handle mixed lipids and probe mem-
brane complex formation [147,153,154]. Implicit membrane models work by reducing the
membrane to a continuum representation, e.g., a spatial region within the system with a
different dielectric constant [155]. More recent implicit membrane models continue to be
developed [156–158], and are successfully used to study membrane protein dynamics [159]
due to the reduced particle count that enhances simulation rate.
Sh
or
t 
T
ai
le
d 
L
ip
id
s
}
O
rganic Solvent
Figure 2.1: The HMMM model is constructed using a combination of short-tailed lipids (foreground
grey, red, blue, and brown spheres), representing in full atomic detail the lipid head groups that are often
the main protein-interacting elements, with a liquid representation of the membrane core (yellow spheres
- the 1,1-dichloroethane organic solvent).
An alternative approach towards overcoming slow lipid exchange and sampling is to
re-engineer the lipid representation to increase its sampling. This is the approach taken
by the Highly Mobile Membrane Mimetic (HMMM) model, where the long acyl tails in
the bilayer center are replaced by an organic solvent designed to mimic the membrane
interior (Fig. 2.1) [160,161]. The short-tailed, fully atomistic lipids, placed at the organic
solvent/water interface to capture protein-lipid interactions, have a self-diffusion constant
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that is at least an order of magnitude higher than conventional lipids [136,161]. As a result,
insertion processes on the membrane interface will be significantly accelerated [162] while
accurately reproducing the energetics of molecular interactions at the interface [163].
Membrane-bound forms of peripheral proteins, peptides and other membrane–associated
molecular species, can be captured using an ensemble of relatively short but convergent
MD simulations [73,161,164–169]. Thus the HMMM can reveal specific protein-membrane
interactions at atomic detail with a substantially reduced computational cost, making it a
great companion to experimental techniques aiming at understanding membrane–bound
configurations of proteins, and, in particular, lipid dependence of their binding.
2.2.1 Preparation of the HMMM Membrane
In the work described in the following chapters, the HMMM membrane was constructed by
placing two leaflets of short-tailed lipids at the interface of water and 1,1-dichloroethane
(DCLE) [161]. For all the systems described here, the phosphatydylcholine (PC) head-
group was selected because of its relevance to membrane composition of eukaryotic cells.
In addition, the phosphatydylserine (PS) headgroup was employed in a mixture contain-
ing PC headgroups to study membrane binding of Tim1 protein (Chapter 9). In all
cases, the short-tailed were generated by shortening the lipid tails of a palmitoyl-oleoyl-
phosphatidylcholine (POPC) or palmitoyl-oleoyl-phosphatidylserine (POPS) molecule to
only 5 carbons.
The HMMM membrane was assembled [170] by constructing a DCLE box and placing
a number of short-tailed lipids on its large faces. The size of the membrane and the
number of lipid on each leaflet was varied according to the system. The resulting HMMM
membrane was then solvated, and energy minimized and equilibrated using an ensemble
with constant area. The ensemble with constant area was selected to efficiently modulate
the area per lipid of the HMMM membrane. Based on the experience with different
peripheral membrane proteins, a mild increase (5-8%) in the area with respect to its
experimental values can significantly accelerate the binding process. Finally, the resulting
equilibrated HMMM membrane was employed for membrane–binding simulations.
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2.2.2 Initial Setup of Membrane–Binding Simulations
Typically, MD simulations of peripheral membrane proteins start with a predefined place-
ment of the protein of interest in the membrane, usually based on expeimental measure-
ments, such as EPR spectroscopy [171]. Since membrane relaxation is a slow process,
placing a protein in a predefined position could potentially bias the results of the sim-
ulations, specifically the resulting insertion depth and the orientation of the protein in
the membrane. The enhanced lipid dynamics provided by the HMMM membrane al-
low capturing the spontaneous association and insertion of proteins, thus resulting in a
membrane–bound model of the protein than is not biased by initial placement of the
protein in the membrane.
Figure 2.2: System setup in HMMM simulations. Representative example of the typical HMMM setup,
employing the hemagglutinin fusion peptide (HAfp), described in Chapter 8 . Initially, the protein is not
in contact with the HMMM membrane. During the simulation, spontaneous association of the protein to
the membrane is captured, resulting in a membrane–bound model of the protein.
The typical HMMM setup, employed throughout the projects described in the fol-
lowing chapters, started by placing the protein of interest away from the lipids (i.e., a
position 7-10 A˚ above the PO4 plane of the cis leaflet), to ensure that the protein does not
contact the membrane prior to the simulation (Fig. 2.2). To test the convergence of the
membrane–binding simulations, different starting orientations of the protein with respect
to the membrane normal (z-axis) were employed. This initial setup was then followed by
multiple independent simulations to capture the membrane binidng and insertion of the
protein of interest, in order to obtain an increased sampling of membrane binding events.
During the HMMMM simulations, a small harmonic restraint (with a force constant k
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= 0.05 kcal mol-1 A˚-2) was applied to the carbonyl carbon atoms of the short-tailed lipids
along the membrane normal (z-axis), in order to mimic the atomic distributions of a full
lipid bilayer more closely, and to prevent the occasional lipid diffusion into the aqueous
phase, expected for these surfactant-like molecules.
2.2.3 HMMM Membrane Conversion Into Full-Tailed Lipid Bi-
layer
The HMMM was used to sample specific protein–lipid interactions more efficiently, estab-
lishing the most likely positions of the lipid head groups around the protein. After the
initial HMMM simulations, the short-tailed lipids were converted into full tail lipids for
further study in an environment that more closely mimics experimental conditions.
Figure 2.3: Lipid tail extension starting from HMMM models. After a membrane–bound model of
a protein is generated with the HMMM membrane, short-tail lipids are extended to full-tail lipids by
adding missing atom of the lipid tails, while preserving the initial protein–lipid contacts obtained in the
HMMM simulations. A representative example of this process is presented for Tim1, a system described
in Chapter 9.
For the systems described in the next chapters, lipid extension was performed starting
from snapshots obtained from HMMM simulations where the membrane–bound state
of the protein was captured. For the selected snapshots, the short-tailed bilayer was
transformed into a full-tailed bilayer (e.g., POPC or POPC/POPS mixture) by removing
19
the DCLE molecules and adding the missing carbons of the lipid tails, while preserving the
positions of the lipid atoms already present in the HMMM model, including headgroups
and initial few carbons of the lipid tails (Fig. 2.3). The positions of the newly added lipid
tail atoms were then optimized by adopting the coordinates of the corresponding atoms in
the extended lipid tails obtained from randomly selected full-tailed lipid molecules from
a previously equilibrated membrane. It is important to note that during these steps,
the original contacts established between the lipids and the protein during the HMMM
membrane-binding simulations were preserved.
The resulting full-tailed membrane systems were then minimized and equilibrated
while the heavy atoms of the protein and the short-tailed lipids already present before the
tail extension step were restrained (with a force constant k = 1 kcal mol-1 A˚-2) to allow
the for the newly added atoms to relax. Following this step, systems were equilibrated
without restraints to various lengths, as described in detail in the following chapters.
2.3 Combining MD Simulations With Molecular Dock-
ing to Investigate Protein-Ligand Interactions
A significant porition of the work hereby described included generating models of membrane–
bound enzymes. To further explore the mechanism of ligand binding in these proteins,
ensemble molecular docking was performed on multiple snapshots of the protein obtained
from MD simulations (Fig. 2.4). In cases where the substrate binding site of the enzyme
is not known, small molecule docking can be used to search for possible binding confor-
mations of a ligand in the protein [172–174]. The favorable protein-ligand conformations
identified through docking provide a clear picture of the key molecular interactions that
facilitate binding. This approach, based on the relaxed complex scheme [175, 176] that
combines MD with docking algorithms, allows to take into the account protein dynamics
in the presence of the membrane in order to get a better sense of the ligand binding
sites within the enzyme. Since the cavities leading to the active site of the membrane-
bound enzymes studied are small (e.g., with bottleneck radii < 2.5 A˚) and only transiently
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open [164], it is not clear how small molecules would access their binding sites by just
analyzing MD simulations. By taking advatange of molecular docking algorithms, it is
possible to capture transient binding sites present in MD simulations, and eventually
reconstruct ligand binding pathways, by performing additional MD simulations starting
from docked poses. Ensemble molecular docking was employed to study interactions of
prototypical substrates of CYP3A4 (Chapters 5 and 4), and fatty acids with CYP2J2
(Chapter 6).
Figure 2.4: A combined computational approach to study drug binding with MD simulations. (Right)
MD simulation-generated ensemble of conformations of CYP3A4 used in molecular docking, colored by
simulation time (beginning in red, middle in white, and end in blue). A set of residues in the active
site is shown to display the diverse side chain conformations represented by the MD-generated ensemble
(inset). The heme cofactor is shown in magenta sticks. (Left) 6 position-based clusters of docked poses
of the drug molecule are shown in different colors. This approach was employed to study prototypical
substrates of CYP3A4 (Chapters 5 and 4), and fatty acids with CYP2J2 (Chapter 6).
The protocol employed to efficiently combine molecular docking with MD simulations,
shown in Fig. 2.4, is as follows. To start, a large number of snapshots of the membrane–
bound protein were taken from long MD trajectories (within 100 ns and 1µs). The number
of snapshots ranged from ∼100 to ∼1000, in contrast to a single structure used in typical
docking studies. This approach allows to take into the account the dynamics of the protein
in the presence of the membrane, and probe cavities and putative binding sites that only
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transiently arise during the MD simulations.
For a particular ligand, protein–ligand interactions were modeled with the Lamarckian
genetic algorithm [177,178] with a grid box spanning the catalytic domain of the enzyme.
The top 10 docking poses for each snapshot were collected for further analysis, resulting
in thousands of docked poses. The resulting docked structures were then clustered on the
basis of their root-mean-square deviation (RMSD), using an RMSD cutoff that ranged
from 2 to 3.5 A˚ depending on the ligand, resulting in multiple clusters for each ligand.
An additional distance–based filter was applied to the resulting clusters, in order
to obtain docked poses that correspond to experimental data. Depending of the ligand,
filtering of the clusters was performed on the basis of the distance of the sites of metabolism
of the ligand to the active site of the enzyme (e.g., the heme iron, with a distance < 6 A˚), or
the distance of the ligand to peripheral binding sites observed in crystal structures [179].
Finally, the best docked pose for each cluster, based of the lowest docking score, was
selected as the initial configuration for additional MD simulations, resulting in multiple
independent systems where the protein–ligand complex in the membrane was simulated.
Moreover, to generate models where two ligands are bound to the enzyme, the molecular
docking protocol was iteratively applied starting from snapshots that also included the
first ligand in addition to the protein, obtained from MD simulations (Chapters 5).
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Chapter 3
Characterizing the
Membrane-Bound State of
Cytochrome P450 3A4 (CYP3A4) ∗
3.1 Introduction
Cytochrome P450 (CYP) constitutes a large family of heme-containing enzymes that are
present in a wide variety of organisms and involved in the metabolism of both xenobiotics,
e.g., drugs, and endogenous compounds such as steroidal hormones [180]. CYPs are
found in both soluble and membrane-bound forms. They function by oxidizing a broad
spectrum of both water-soluble and lipophilic molecules. One of the key aspects of their
function is the mechanism and pathway by which various molecular species gain access
to the active site of the enzyme, a process that is particularly important for membrane-
associated CYPs. The crystal structures of a large number of CYPs, both in apo and
substrate-bound forms, have been solved; however, they provide limited information on
these pathways [181]. In particular, substrate access through the membrane, which is
∗This chapter appeared as a research article in Journal of the American Chemical Society [164].
Javier L. Baylon, Ivan Lenov, Stephen G. Sligar, and Emad Tajkhorshid, “Characterizing the
Membrane-Bound State of Cytochrome P450 3A4: Structure, Depth of Insertion and Orientation”. Jour-
nal of the American Chemical Society, 135: 8542–8551, 2013.
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suggested to be the main mechanism for lipophilic and amphiphilic substrates to gain
access to the active site of CYPs [182,183], is largely unknown, as a complete description
of the involved pathways relies on the characterization of the enzyme structure, and more
importantly its dynamics, in its membrane-associated form.
Human CYPs are anchored in the cellular membrane by an N-terminal transmem-
brane alpha helix [184, 185]. However, a large body of evidence strongly suggests that
the globular, enzymatic part of the protein directly interacts with the surface of the
membrane [185–187]. Naturally, such direct interactions are key to the orientation and
partitioning of the enzyme on the surface of the membrane, which are the main determi-
nants of substrate’s efficient access to the enzyme from the membrane.
In humans, cytochrome P450 3A4 (CYP3A4) (Fig. 3.1) is the most abundant iso-
form. It is present in the liver and in the small intestine [188], and it is responsible for
the metabolism of more than 50% of clinically used drugs that are metabolized in the
body [13,189], indicating a high ligand promiscuity when compared to other human CYP
enzymes. Due to its broad involvement in drug metabolism, CYP3A4 plays a key role in
determining the bioavailability and, thereby, the effective plasma concentration of a wide
range of pharmacological compounds in the body. Similarly, CYP3A4 is a key element
in side effects of drugs in which the metabolites are the main source of toxicity, as well
as in drug-drug interactions due to its promiscuous substrate specificity and malleable
active site [190,191]. To date, over 1000 compounds, including inhibitors and inducers of
CYP3A4, have been identified that interact with and affect the activity of CYP3A4 [192].
Accumulating evidence has strongly indicated that the interaction of CYPs with the
cellular membrane contributes to the recruitment of liposoluble substrates to the active
site of the enzyme [182, 183]. Therefore, in order to understand its effects in the body,
it is crucial to understand the interaction of CYP3A4 with the membrane at an atomic
resolution. To date, several X-ray structures of CYP3A4 with a truncated N-terminal
transmembrane helix have been solved, both in the ligand-free form and bound to a
variety of ligands [179, 191, 194–197]. These structures have not only established that
CYP3A4 presents an overall fold similar to other CYPs (Fig. 3.1), they have also revealed
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Figure 3.1: Structure of CYP3A4. Two views, rotated by 90 ◦, showing the side (left) and bottom
(right) views of the globular domain of CYP3A4. A schematic of the location of the TM helix with
respect to the globular domain is included in the side view. The structure presents a fold similar to other
P450 enzymes, consisting of an N-terminal β-sheet domain and a helical C-terminal domain, containing
the cofactor heme (red stick representation) and the active site. The nomenclature used for the secondary
structure elements was adopted from [193]. The side-chains forming A-anchor are shown in orange stick
representation in both views and boxed in the side view. Also depicted in the figure is a schematic
representation of the HMMM membrane, highlighting the location of the organic phase and the short-
tailed lipids.
functionally relevant aspects, such as the ability of CYP3A4 to bind to a broad range
of molecules of different sizes [179, 191, 194–197] and a malleable active site that might
even allow binding of two ligands simultaneously [191], a feature that had been suggested
based on the atypical kinetic behavior exhibited by the enzyme [198–200].
Structural dynamics of human CYPs have been studied with molecular dynamics (MD)
simulations. Several previous MD studies of CYP3A4 aimed at studying the interaction
of the enzyme with some of its ligands, focusing on the gating mechanisms involved in the
access/egress of the ligands from the active site [201,202] and on the underlying mechanism
of the positive homotropic cooperativity observed upon binding of two ligands [203]. Other
simulation studies investigated the dynamics of water molecules in different human CYPs,
including CYP3A4 [204]. Despite providing insightful information about the dynamics of
25
CYP3A4, these studies were performed mostly without taking into account the interaction
of the enzyme with a membrane, which could affect both structural and dynamical
properties of CYP3A4. In a recent simulation study of membrane-bound CYP3A4
by Denisov et al. [205] it was shown that the interaction with the membrane affects
the opening/closing of the access tunnels observed in the crystal structures. Moreover,
MD studies with human CYP2C9 in the presence of the membrane have shown that the
interaction of the enzyme with the membrane favors the opening of additional access
tunnels not identified in the crystal structures [206,207].
An experimentally observable, yet unexplored aspect of CYP3A4 is the orientation of
the enzyme in its membrane-bound form. The angle between the heme plane and the
membrane plane, termed the heme tilt angle, has been estimated experimentally to be
between 38 and 78 ◦ for several other CYPs isoforms [208], but not for CYP3A4. For
CYP2C9, MD studies have suggested that the enzyme might even adopt two different
orientations upon membrane binding, corresponding to two different conformations of the
F-G loop of this isoform [207]. The orientation that the enzyme takes after binding to
the membrane might have implications not only in efficient substrate recruitment but
also in the rate of electron transfer from the CYP reductase necessary for the oxidation
reaction [207,209].
In order to study the binding and interaction of CYP3A4 with the membrane, we have
performed MD simulations employing a novel membrane representation, termed highly
mobile membrane-mimetic (HMMM), which was recently developed in our lab [161]. This
membrane model employs a biphasic solvent system [160] together with short-tailed lipids
located at the organic/water interface. Due to the reduced entanglement of the shortened
lipid tails and the fluid nature of the hydrophobic core, the HMMM membrane allows
for an increase of 1-2 orders of magnitude in the lateral diffusion of the lipids, thereby
accelerating the association of proteins with the bilayer without the need for external
biases or forces, while preserving the atomistic details of the interactions between the
protein and lipid headgroups [161]. In multiple independent simulations spontaneous
binding and insertion of the globular domain of CYP3A4 was captured, resulting in a
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convergent model for the membrane-bound form of CYP3A4, whose insertion depth and
orientation on the membrane are preserved after transforming the HMMM model to a
full lipid bilayer. Complementary to the simulations, a series of planar waveguide linear
dichroism measurements were performed to characterize the heme tilt angle of CYP3A4
bound to a Nanodisc, a membrane system that is water-soluble and preserves the structure
and activity of membrane proteins [210]. The measurements were performed by first
determining the dichroic ratio of a monolayer of Nanodisc-incorporated CYP3A4 protein,
and then calculating the orientation of the CYP3A4 within the lipid bilayer. Together, the
structural models resulting from the simulations and experimental measurements allow
for a detailed description of the enzyme in its membrane-bound form. Furthermore, the
simulations also reveal some of the membrane-induced conformational changes in CYP3A4
which might affect the accessibility of the active site to substrates approaching from the
membrane.
3.2 Methods
3.2.1 System Preparation
Preparation of the HMMM membrane. The HMMM membrane patch was con-
structed by placing two leaflets of short-tailed lipids at the interface of water and 1,1-
dichloroethane (DCLE), as described in detail elsewhere [161]. The phosphatydylcholine
(PC) headgroup was selected for this study because of its relevance to membrane com-
position of eukaryotic cells. The lipids used in the membrane patch were constructed
starting from palmitoyl-oleoyl-phosphatidylcholine (POPC) molecule as a template, and
shortening its lipid tails to only 5 carbons [161]. The HMMM membrane was then as-
sembled using the Packmol software [170] by constructing a DCLE box, with dimensions
of 100×100×10 A˚3 and containing 5,840 molecules of the organic solvent, and placing
300 short-tailed PC lipids on its large faces, with 150 lipids in each leaflet. The result-
ing structure was then solvated with water using the SOLVATE plugin of VMD [117],
yielding a system of ∼66,000 atoms. The solvated membrane mimetic system was energy
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minimized for 10,000 steps and simulated for 2 ns, using an NPnAT ensemble with con-
stant area, and with a target normal pressure and temperature of 1.0 atm and 310 ◦K,
respectively. A constant area of 11,236 A˚2 (106×106 A˚2) was employed, yielding an area
of ∼75 A˚2 per lipid (AL), which is ∼8 % higher than the experimental AL for POPC [211].
This was done in order to account for the area of the membrane that would be occupied
by the protein upon its insertion. Based on our experience with several other peripheral
proteins, a mild increase (5-8%) in the area can significantly accelerate the process. The
resulting membrane was employed in all the subsequent simulations of membrane binding
and dynamics of CYP3A4.
CYP3A4 model and initial configurations. The ligand-free crystal structure
of CYP3A4 [194] was obtained from the RCSB Protein Data Bank [212] (PDB entry
1TQN). The missing residues Lys-282, Glu-283, Thr-284, and Glu-285 were added using
the program MODELLER 9v10 [213]. Crystallographic water molecules were maintained
in the model. For the first part of this study the N-terminal transmembrane (TM) helix (27
residues), which is also missing from the crystal structures, was not modeled, as the main
aim was to independently characterize membrane binding and insertion of the globular
domain of the enzyme. In the second part of the study, two models including the TM
helix were constructed by adding the TM helix to one of the membrane-bound CYP3A4
structures obtained from the simulations in the first part of the study. One model included
all the N-terminal 27 residues of CYP3A4 (full length CYP3A4), while the other model
included a truncated TM helix, which does not include the first 12 residues and has a S18F
point mutation. These systems are referred to as WT-TM and Truncated-TM simulation
systems, respectively. The Truncated-TM model was designed and simulated to match
the sequence of CYP3A4 employed during the experimental measurements reported in
this study. The additional TM residues were added to the membrane-bound CYP3A4
using MODELLER 9v10 [213].
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3.2.2 Simulation Systems
In the first set of simulations, hereby referred to as membrane binding simulations, the
globular domain of CYP3A4 (i.e., without the TM helix) was placed in five different initial
orientations and between 7 and 13 A˚ above the surface of the membrane. These systems
will be referred to as Mem-1 through Mem-5 hereafter. The initial orientations were ob-
tained by first aligning the three principal axes of the protein to the xyz axes, respectively,
and then rotating the principal axis aligned to z in different planes, thus resulting in 5 dif-
ferent initial heme tilt angles. An additional layer of water was then added to the resulting
structure using the SOLVATE plugin, and a concentration of 100 mM Na+ and Cl− ions
was generated in the systems using the AUTOIONIZE plugin of VMD [117]. The resulting
initial systems then consisted of a box with dimensions 100×100×130 A˚3 and containing
∼140,000 atoms. In addition, and as a control, CYP3A4 was also simulated in an aque-
ous solution, i.e., in the absence of a membrane. For the solution simulation, CYP3A4
was solvated with water using the SOLVATE plugin of VMD with a minimum padding
of 10 A˚ in all directions, resulting in a box with dimensions of 89×95×107 A˚3 including
∼62,000 atoms. All systems were energy minimized for 10,000 steps and relaxed further
for 100 ps with the Cα atoms of the protein restrained (k = 5 kcal mol-1 A˚-2), except for
the residues that were modeled and added to the crystal structure. Then, systems Mem-1
through Mem-5 and the solvated CYP3A4 were simulated each for 50 ns, while systems
WT-TM and Truncated-TM were simulated each for 40 ns. For the HMMM simulations,
a harmonic constraint on the z-position, with a force constant k = 0.05 kcal mol-1 A˚-2, was
applied to the carbonyl atoms of the PC lipids, in order to restrain the position of the
short-tailed lipids to mimic the atomic distributions of a full lipid bilayer more closely
and to prevent their occasional diffusion into the aqueous solution, which is expected for
short-tailed lipids (surfactants).
In addition to the HMMM simulation systems, and in order to further examine the
stability and dynamics of the resulting membrane-bound CYP3A4 from these simulations,
a simulation employing a full POPC lipid bilayer was also performed. A membrane-bound
model of the globular domain of CYP3A4 was adopted from one of the last frames of one
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of the HMMM simulations described above. The lipid bilayer was then grown (trans-
formed) into a full lipid bilayer by removing the DCLE molecules and adding the missing
carbons of the lipid tails while preserving the positions of the lipid atoms already present
in the HMMM model (headgroups and initial few carbons of the lipid tails). In order
to further optimize the process, the positions of the newly added atoms in the lipid tails
were based on the coordinates of randomly selected lipid molecules from a separately
equilibrated POPC membrane. During these steps, the original contacts established be-
tween the lipids and CYP3A4 during the HMMM membrane-binding simulations were
preserved. This system, which is referred to as the POPC system, was then minimized
and equilibrated for 100 ps while constraining the heavy atoms of the protein, the short-
tailed lipids (already present before adding the new atoms) to allow for the newly added
atoms to relax. Following this step, the system was simulated without constraints for
40 ns.
All the simulations were performed using NAMD2 [118] utilizing the CHARMM27
force field with cMAP [119] corrections for the protein and CHARMM36 [113] for lipids.
The TIP3P model was used for water [120]. All simulations, except system POPC, were
performed as an NPnAT ensemble at 1.0 atm and 310 K, and with a time step of 2 fs.
The POPC system was simulated as an NPT ensemble. A constant area of 11,236 A˚2
(106×106 A˚2) was employed for NPnAT. Constant pressure was maintained using the
Nose´-Hoover Langevin piston method [124, 125], and constant temperature was main-
tained by Langevin dynamics with a damping coefficient γ of 0.5 ps-1 applied to all atoms.
Non-bonded interactions were cut off after 12 A˚ with a smoothing function applied after
10 A˚. The particle mesh Ewald (PME) method [126] was used for long-range electrostatic
calculations with a grid density greater than 1 A˚-3.
3.2.3 Specific Analysis
Identification of access tunnels to the active site. Access tunnels to the active site
were characterized using MolAxis [214], which identifies tunnels and cavities in macro-
molecules using computational geometry techniques. Snapshots of the protein were ob-
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tained every 100 ps from the last 40 ns of the trajectories, which in all the membrane
binding simulations corresponded to the period after CYP3A4 has completed its binding
and insertion into the membrane. The access tunnels to the active site were calculated
for each snapshot. In order to cluster the tunnels calculated for each different snapshots,
an average structure over the last 40 ns of the trajectory of the bound CYP3A4 for each
simulated system was obtained and the access tunnels of these average structures were
used as references for their respective system. Then, for each system, the spatial overlap
between each reference tunnel and each tunnel from the trajectory snapshots was calcu-
lated. Tunnels from different snapshots were assumed to be the same when they had a
spatial overlap of at least 70 % with the same reference tunnel. The bottleneck radius and
the bottleneck residues for each identified access tunnel were obtained from the MolAxis
calculations. All tunnels with a bottleneck radius ≥ 1.2 A˚ were included in the analysis
of open cavities within the protein.
3.2.4 Summary of Experimental Methods
Our experimental collaborators at the Sligar Lab (UIUC) expressed CYP3A4 proteins,
and incorporated them into Nanodisc systems. To measure the orientation of Nanodisc-
incorporated CYP3A4 protein, they also performed planar waveguide linear dichroism
measurements. The measurements were performed by first determining the dichroic ra-
tio of a monolayer of Nanodisc-incorporated CYP3A4 protein, and then calculating the
orientation of the CYP3A4 within the lipid bilayer. For a detailed description of the
experimental procedures, please see reference [164].
3.3 Results and Discussion
3.3.1 Spontaneous Membrane Binding and Insertion of CYP3A4
In order to study the binding of CYP3A4 to the membrane, five different orientations of
the globular domain of the enzyme (not including the TM helix) initially placed above
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Figure 3.2: Spontaneous insertion of CYP3A4 into the membrane. (Top) Snapshots taken at different
time points from the simulation system Mem-1. (Bottom right) Close-up view of the membrane bound
form of CYP3A4, highlighting residues inserting directly into and interacting with the membrane. The
hydrophobic side-chains of A-anchor, formed by residues Leu-44, Pro-45, Phe-46 and Leu-47, and of helix
G’ are shown in stick representation in orange and magenta, respectively. (Bottom left) Time evolution
of the average height of the center of mass of A-anchor and helices F’ and G’ in different simulations.
The average height is shown for the five simulations. The average positions of the phosphorous (PO4)
group and the nitrogen (choline) atoms of the lipid headgroups are shown in gray and brown dotted lines,
respectively.
the PC lipid bilayer were simulated, each for 50 ns (Mem-1 to Mem-5). Spontaneous
binding of CYP3A4 with the HMMM membrane was consistently observed in all the
simulations. Membrane binding did not require the use of external forces or biasing
potentials, thus resulting in an unbiased positioning of the enzyme at the lipid-water
interface within the first 10 ns of simulation. For the five different starting positions
tested, CYP3A4 first encounters the membrane through its hydrophobic helices F’ and
G’ (Fig. 3.1) and with a hydrophobic anchor composed of residues Leu-44, Pro-45, Phe-46
and Leu-47. This hydrophobic anchor, which is located between helices A” and A, and
that we term A-anchor hereafter, is one of the features that distinguishes CYP3A4 from
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other CYP isoforms. A-anchor has been hypothesized to mediate the interaction with
the membrane [179], together with the hydrophobic helices F’ and G’ [187, 194], based
on its location in the globular domain of the enzyme. After the first encounter with the
membrane, the enzyme is rapidly inserted into the membrane and remains bound to it
for the remainder of the simulation, as exemplified in Fig. 3.2 for simulation Mem-1. In
less than 10 ns, A-anchor establishes contacts with the lipid headgroups, as characterized
by monitoring the position of the anchor with respect to the PO4 and choline groups
(Fig. 3.2). In systems Mem-2 and Mem-5, A-anchor remains buried below the PO4 level
for the remainder of the simulation, while in systems Mem-1, Mem-3, and Mem-4 the
anchor fluctuates within the region between the PO4 and the choline groups. Interestingly,
and functionally highly relevant, A-anchor inserts deeper into the membrane than helices
F’ and G’. Helices F’ and G’ are stabilized at a level close to the lipid headgroups after 10 ns
(Fig. 3.2) but do not completely insert into the membrane, with helix G’ establishing a
closer contact to the membrane than helix F’. For the five independent membrane binding
simulations, the depth of insertion of A-anchor and of helices F’ and G’ converges to the
same range of values.
3.3.2 Orientation of Membrane-Bound CYP3A4
Experimentally, it is difficult to measure characteristic parameters of membrane-bound
proteins, such as depth of insertion or orientation. In the case of CYPs, it is possible to
measure their orientation by taking advantage of the optical properties of the heme moiety
buried in the active site. The orientation of some CYP isoforms associated to proteolipo-
somes or microsomes [208] has been measured experimentally, however such experiments
have not been reported for CYP3A4. A series of linear dichroism measurements were
performed in this study to calculate the orientation of CYP3A4 in POPC Nanodiscs. The
Nanodisc approach has been employed to study the metabolic mechanisms of CYP3A4
in a phospholipid bilayer [210]. The orientation of the Nanodisc-bound CYP3A4 was
calculated by measuring the angle between the heme moiety and the z-axis using the
dichroic ratio measured from the sample (see Methods). A total of eleven independent
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experiments were carried out. The calculated angles are presented in Table 3.1.
Table 3.1: Experimental measurements of the heme tilt angle for CYP3A4 bound to POPC Nanodisc.
Experiment 1 2 3 4 5 6 7 8 9 10 11 Average
Tilt Angle (◦) 61.1 57.7 57.5 61.1 58.8 52.0 60.0 55.9 62.9 67.3 62.9 59.7± 4.1
The heme tilt angle of CYP3A4 in the Nanodisc exhibits values between 52.0 ◦ and
67.3 ◦, with an average of 59.7 ◦. These measurements suggest that the CYP3A4 bound to
the POPC Nanodiscs adopts a specific orientation, rather than a non-specific adsorption
to the membrane surface.
From the simulations, the positioning of the globular domain of CYP3A4 after binding
to the membrane was studied more thoroughly by defining a set of angles that characterize
the orientation of its membrane-bound form. The orientation of CYP3A4 after association
with the membrane was characterized by measuring the heme tilt angle with respect to
the membrane normal (z-axis). The time evolution of the heme tilt angle for the five
simulated membrane systems (Mem-1 to Mem-5) is presented in Fig. 3.3. The tilt angle
converges to a value around 70 ◦ in about 10 ns, corresponding to the time of binding of
CYP3A4 to the membrane. For the remainder of the simulations, the tilt angle fluctuates
between 70 ◦ and 80 ◦. In Table 3.2, the initial and average values of the tilt angle for
each simulated system are shown, with the average obtained over the last 40 ns of the
simulation, i.e., the portion corresponding to the membrane-bound form of the enzyme.
The average heme tilt angle is calculated to be between 68.7 ◦ and 75.9 ◦ for individual
simulations, with an overall average of 72.2 ◦ over the five simulations. The calculated
average angles strongly support the convergence of the simulations; despite using very
different initial orientations in solution, the final tilt angles in all the simulations are
very similar and deviate only by a few degrees. This suggests that, as observed in the
experiments, CYP3A4 adopts a specific orientation upon binding to the membrane, with
the heme moiety oriented at approximately 70 ◦ with respect to the membrane normal.
In order to examine the structure and dynamics of the membrane-bound model for
CYP3A4 that was developed with the HMMM membrane model, we put the model to
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Table 3.2: Initial and average heme tilt angle calculated for CYP3A4 in five independent membrane-
binding simulations. Averages were calculated from the last 40 ns of each simulation corresponding to
the membrane-bound form of CYP3A4. The standard deviations are in parentheses.
Run Initial Tilt Angle (◦) Average Tilt Angle (◦)
Mem-1 55.2 75.9 (3.9)
Mem-2 33.9 69.1 (5.3)
Mem-3 51.9 72.9 (3.7)
Mem-4 59.9 74.4 (5.0)
Mem-5 81.0 68.7 (3.7)
Average 72.2 (3.2)
Figure 3.3: Orientation of CYP3A4 upon binding to the membrane. Time series of the heme tilt
angle for the five membrane simulations (Mem-1 to Mem-5). The heme plane was defined by fitting the
position of the four porphyrin nitrogen atoms to a plane. The angle θ is defined as the angle between the
membrane normal (z-axis) and the heme plane.
a test simulation performed in a full membrane. While we might not expect to capture
the complete insertion process using such a full representation for the membrane within
our limited simulation timescales (the main reason for using the HMMM model), we have
adopted the membrane-bound configuration from an HMMM simulation and performed
additional equilibrium simulations (40 ns) after transforming the lipids to full POPC lipid
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Figure 3.4: Effect of the transmembrane helix and realism of the membrane on the orientation of
CYP3A4. (Top) Initial configuration of the two simulated systems including a transmembrane helix.
(Middle) Time evolution of the heme tilt angle for the simulations including the transmembrane helix.
The average heme tilt angle for the WT-TM system is 72.6± 5.1 ◦ and for Truncated-TM is 73.4± 4.2 ◦.
(Bottom) Time evolution of the heme tilt angle for CYP3A4 bound to a full POPC membrane.
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molecules (see Methods). As depicted in Fig. 3.4, the membrane-bound configuration
is highly preserved; both the depth of membrane insertion and the orientation show
similar average values and range of fluctuation to those obtained from membrane binding
simulations.
Since the experiments presented in this work were carried out with a sequence of
CYP3A4 that includes a truncated TM helix, two additional simulations including a TM
helix were performed, with the models prepared as described in Methods. The average
heme tilt angle of these membrane simulations (Fig. 3.4), 72.6 ◦ for the WT-TM and 73.4 ◦
for the Truncated-TM, suggests that the orientation angle of CYP3A4 is not significantly
affected by the presence of the TM anchor. hether or not the helix is there the tilt
angle would not drastically change. The observation that the heme tilt angle is largely
independent of the presence of the TM helix suggests that the globular domain, not the
TM anchor, is the main determinant of the orientation of the membrane-bound enzyme.
3.3.3 Membrane-Induced Conformational Changes of CYP3A4
Despite the large number of crystallographic structures available for CYP3A4, no struc-
tural information for its membrane-bound state at an atomic level is available. This is
particularly critical since the structure of CYP3A4 might be affected by the membrane,
and the potential membrane-induced conformational changes could have a direct impact
on the access of substrates, especially large molecules, to the active site, an aspect that
is unclear from the crystal structures. Binding of CYP3A4 to the membrane does not
induce any global conformational changes in the enzyme within the simulated time, as
measured by the backbone root mean square deviation (RMSD) with respect to the X-
ray structure, which shows values < 2.5 A˚. The RMSD of the membrane-bound CYP3A4
does not deviate significantly from that of the aqueous simulation of CYP3A4 either,
suggesting that the overall fold of the enzyme is likely preserved upon binding to the
membrane, in agreement with the reported behavior of the CYP2C9 isoform when bound
to a conventional membrane in a previous MD study [206,207]. However, significant local
conformational changes at the membrane interface accompany the process of membrane
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binding of the enzyme. These conformational changes, which are mostly localized to the
membrane-protein interface, likely arise due to close interaction of specific residues and/or
regions of CYP3A4 with lipid molecules in the membrane, in particular helices F’ and G’
and A-anchor (Fig. 3.5). Such specific lipid-protein interactions might disrupt interac-
tions with residues located in other regions of the enzyme, for example interactions with
residues of the BC loop, which is in close proximity of helix G’, or interactions between
the β1 sheet and helix F’. While the globally low RMSD appears to suggest that CYP3A4
remains in a nearly-closed conformation in its membrane-bound form, side-chain fluctua-
tions due to the interaction with the lipids directly affect the opening and closing of access
tunnels leading to the active site of the enzyme.
A-anchor F’/G’ helices
Figure 3.5: Number of contacts between CYP3A4 and the membrane in its membrane-bound form.
Average number of contacts (within 5 A˚) between the heavy atoms of CYP3A4 and those of lipids and
DCLE molecules. The average was taken over the last 20 ns of the simulations and over the 5 HMMM
membrane binding simulations. After insertion, the residues located in A-anchor and in helices F’ and
G’ form the majority of hydrophobic contacts with the lipid tails and the DCLE molecules.
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3.3.4 Membrane-Induced Modulation of Access Tunnels
For other human CYP isoforms, it has been suggested that access of lipophilic substrates
to the active site is primarily through the membrane while egress of products occurs
through solvent-accessible tunnels [183, 202, 215]. In our simulations, the interaction of
CYP3A4 with the membrane induces local changes that promote the opening of access
tunnels leading to the active site of the enzyme (Fig. 3.6). These tunnels correspond to
the 2a, 2b, 2e, 3 and solvent (S) tunnels, named after their lining secondary structures
according to the nomenclature established in [181]. The tunnels were observed to start to
open to different degrees during the membrane binding simulations. Interestingly, tunnels
2a and 3 are delimited by regions of CYP3A4 that are in close contact with the membrane
(Table 3.3); for example, Tunnel 2a is located between β1 sheet and the F-F’ loop, close
to A-anchor, and tunnel 3 is located within the F-G loop, surrounded by helices F’ and
G’.
Table 3.3: Gate residues and lining secondary structures of the access tunnels.
Tunnel Lining Secondary Structures Gating residues
2a β1 sheet and F’ helix Ile-50, Leu-216, Leu-221
2b β1 sheet and B-C loop Gln-78, Phe-108, Pro-227
2e B-C loop Arg-106, Phe-108, Ser-119, Ile-120
3 F’-G’ helices Phe-213, Phe-220, Val-240
S F-F’ loop and I helix Arg-212, Phe-213, Gln-484
The identified access tunnels open to varying degrees in each simulation (Fig. 3.6).
The data was collected from the last 40 ns of each simulation (i.e., for membrane-bound
CYP3A4). Tunnels 2b and 2e are predominantly more open than other tunnels during the
simulations. Furthermore, the solution simulation of CYP3A4 reveals that these tunnels
are open to a lesser extent in the absence of the membrane. The interaction of CYP3A4
with the membrane not only promotes the opening of those tunnels already identified
based on the crystal structures [179,194], it also induces the opening of additional tunnels.
It should be noted that these opening events are not observed in the solution simulation
of the enzyme. We also note that although these openings are significant, we do not
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Figure 3.6: Membrane-induced rearrangement of the access tunnels. (Top) Access tunnels that were
observed to be opening during simulations. Two views, rotated by 120 ◦, are presented, showing the side
(left) and bottom (right) of the protein and the location of the access tunnels leading to the active site.
(Middle) Percentage of frames from the membrane binding (Mem-1 to Mem-5) and solution trajectories
in which the access tunnels to the active site were opening. (Bottom) Time evolution of the smallest
(bottleneck) radius along each access tunnel during the simulations. A tunnel is considered to be opening
when its bottleneck radius ≥ 1.2 A˚
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believe that we have been able to capture the complete process and the ultimate “open”
configuration of the tunnels, since they are still too small for accommodating such large
substrates as those metabolized by CYP3A4. Although the HMMM model allows for an
increased lateral diffusion of the lipids in our simulations, the internal degrees of freedom
of the protein governing the opening of the access tunnels still follow the unaccelerated,
and therefore slow protein dynamics. Therefore, it is highly likely that we have not been
able to capture the full opening of the access tunnels and the formation of their fully open
states.
The opening of the tunnels facing the membrane is of particular importance in the
recruitment of lipophilic substrates directly from the membrane into the active site [202,
206, 207]. In our simulations, access tunnels 2a, 3 and S are observed to open to varying
degrees and are found to be facing the lipid layer in the membrane-bound form of CYP3A4.
The lipophilic substrate transport hypothesis is particularly relevant for tunnel 3, since
it is formed only after membrane binding of the enzyme, with opening observed in at
least 20% of the snapshots in systems Mem-2 and Mem-3. In the membrane binding
simulations, tunnels 2b and 2e open after binding to the membrane, and they remain open
for most of the simulation time (Fig. 3.6), whereas in the aqueous simulation these tunnels
start to open only sporadically. Access tunnel 3 opens after binding to the membrane in
systems Mem-2 and Mem-3, where the opening occurs approximately at t = 25 ns and
t = 40 ns, respectively (Fig. 3.6). The opening of tunnel 3 is related to the motion of
the side-chain of Phe-219 located in helix F’, favoring the opening of this tunnel when
pointing towards the membrane.
The entrance of this tunnel is defined by residues Phe-213 and Phe-220, which together
with Phe-108, Phe-219, Phe-241, and Phe-304 form a Phe-cluster in the absence of the
membrane (Fig. 3.7), a distinctive region of CYP3A4 that has been suggested to serve
as a substrate recognition mechanism [179, 216] and that has been observed to serve as
a peripheral binding site for progesterone, through residues Phe-219 and Phe-220 [179].
Access tunnel S is observed to open to various degrees after membrane binding, except for
system Mem-5 (Fig. 3.6). The opening of this tunnel seems to be coupled to the motion
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Figure 3.7: Membrane-induced rearrangement of the Phe-cluster of CYP3A4. Side view of the Phe-
cluster of CYP3A4 in the crystal structure (left) and in the membrane-bound form (system Mem-2)
(right). The dashed line represents the approximate location of the membrane surface. The side-chains
of Phe-108, Phe-213 and Phe-220, involved in tunnel gating, are shown in red stick representation. The
side-chain of Phe-219 is shown in gray stick representation. During the process of membrane binding the
side-chain of Phe-219 is observed to change its orientation towards the membrane, and the Phe-cluster
starts to break.
of Arg-212, a residue that has been recently reported to assist the binding of ligands to
the active site [196, 197]. It has been suggested that tunnel S might function as a ligand
egress path in other CYPs [183, 215] as well as in CYP3A4 in water [202]. Available
crystal structures indicate that in order to accommodate large compounds in the active
site of CYP3A4, i.e., ritonavir [196], two ketoconazole molecules or erythromycin [191],
rearrangement of the F-G region, in particular between helices F and F’, is necessary,
suggesting that this is a very flexible region (Fig. 3.8). Although we do not observe a
dramatic backbone motion in this region in our simulations, the side-chain motion of the
residues located in this region, including the Phe-cluster, is promoted in the presence of
the membrane.
The radius of the observed access tunnels is small for the average size of the substrates
of the enzyme, indicating that further changes are needed in order for the substrates to
be able to gain access to the active site. The interaction with the membrane might
represent only the first step for the formation of substrate access pathways to the active
site. Although the binding of small ligands to the active site does not require major
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Figure 3.8: Rearrangement of the F-F’ coil of CYP3A4 induced by ligands in the active site. Super-
position of available crystal structures of CYP3A4 with ligands in the active site and a snapshot taken
from one of the HMMM simulations representing the membrane-bound form of the enzyme. The crystal
structures indicate that in order to accommodate large compounds in the active site, e.g., ritonavir (pdb:
3NXU), two ketoconazole molecules (pdb: 2V0M), and erythromycin (pdb: 2J0D), a significant rear-
rangement of the region between helices F and F’ (residues 211 to 218) is necessary (for 2J0D, residues
214 to 218 are missing in the crystal structure). Simulations reveal that the motion of the side-chains
in this region, in particular the phenylalanine side-chains (213, 215, 219, and 220), is promoted by the
membrane.
conformational changes over the enzyme [179,196], it has been observed that the binding
of larger compounds accompanies a significant effect in the conformation of the F-G region
of CYP3A4 [191,195,197], including helices F’ and G’ that are in direct contact with the
membrane in the membrane-bound CYP3A4. These conformational changes induced by
the ligand, together with the interaction between the enzyme and the lipids observed in
our simulations, suggest that the size of the tunnels leading to the active site could further
increase to allow a lipophilic substrate into the active site.
3.4 Summary
CYP3A4, a membrane-associated isoform of the cytochrome P450 family, is the most com-
mon metabolizing enzyme in the human body for biotransformation of a large number
of pharmaceutical compounds and toxic xenobiotics, and a major site for biosynthesis of
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various endogenous compounds. Given the fact that a large fraction of compounds metab-
olized by the enzyme primarily partition in the membrane, characterizing the membrane-
bound form of the enzyme is key to our understanding of its mechanism and spectrum,
yet proven an extremely challenging task given the difficulties associated with high reso-
lution structural determination of the membrane-associated state of peripheral membrane
proteins. In the present study, employing a concerted experimental and simulation ap-
proach, we have developed a structural model for the membrane-bound state of CYP3A4.
Spontaneous membrane binding and insertion of the globular domain of CYP3A4, inde-
pendent of the transmembrane helix of the protein, have been successfully captured in
multiple independent, unbiased simulations taking advantage of a novel membrane repre-
sentation (HMMM) with enhanced lipid diffusion that allows for more efficient description
and sampling of membrane-associated phenomena without compromising atomic details.
The simulations resulted in a convergent model for the membrane-bound state of
CYP3A4, characterized by the depth of insertion and orientation of the globular domain
on the surface of the membrane. These results indicate that CYP3A4 does not interact
with the membrane merely through non-specific contacts and adsorption to the surface,
but rather through specific lipid-protein interactions that closely control the pose of the
protein on the surface of the membrane. The protein is anchored into the membrane
primarily through a hydrophobic anchor located between helices A” and A, which inserts
deeply into the membrane, and helix G’ which partitions mainly within the head group
region. In parallel to the simulations, experimental linear dichroism measurements of
CYP3A4 bound to POPC Nanodiscs have been used to determine the orientation of the
globular domain of CYP3A4 with regard to the membrane. These measurements also
demonstrate a specific orientation of the globular domain of the enzyme in its membrane
bound form, as opposed to non-specific adhesion to the lipid bilayer. Remarkably, the
heme tilt angles obtained from the simulations and the experiments are in close agree-
ments, which further verifies the validity of the structural model resulting from the sim-
ulations. Moreover, the resulting model was further tested using simulations performed
in a full membrane environment during which the insertion depth and orientation of the
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protein on the membrane were largely preserved.
We show that membrane binding of CYP3A4 has significant structural and dynamical
impacts on its globular domain at the membrane interface. The presence of the membrane
induces local side-chain fluctuations that initiates the opening of access tunnels to the
active site that are not observed in the crystal structures or in solution simulations,
suggesting that binding to the membrane might play a role in efficient recruitment of
lipophilic ligands from the membrane to the active site. In particular, rearrangement
of a Phe-cluster induced by the membrane is found to be among the structural changes
that are directly coupled to modulation of the access tunnels leading to the active site.
These attributes are of direct relevance to the mechanism and pathway for recruitment
and binding of amphiphilic substrates, including both endogenous and drug molecules,
directly from the membrane into the active site of the enzyme.
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Chapter 4
Membrane-Mediated Drug
Recruitment by CYP3A4 ∗
4.1 Introduction
Accumulating experimental evidence has strongly indicated that the interaction of CYPs
with the cellular membrane contributes to the recruitment and access of liposoluble sub-
strates to the active site of the enzyme [182, 183, 187, 217, 218]. Therefore, in order to
understand the mechanism by which various molecular species gain access to the active
site of the enzyme, it is important to characterize its interaction with the membrane.
In the case of CYP3A4, the orientation and insertion depth that the catalytic domain
of the enzyme adopts in the membrane are expected to be the main determinants for
efficient substrate recruitment [164, 205, 219]. Several X-ray structures of CYP3A4, both
in the ligand-free form and bound to a variety of molecules [179, 191, 194–197, 220], pro-
vided valuable insight into the structural features of CYP3A4. However, the available
structures provide limited information on possible substrate access pathways [181], as a
complete description of the involved pathways relies on the characterization of the orienta-
tion and dynamics of the enzyme in the membrane, as well as the description of important
∗This chapter is in preparation as a research article.
Javier L. Baylon and Emad Tajkhorshid, “Probing Ligand Dynamics in Membrane-bound CYP3A4 to
Characterize Substrate Access and Product Egress Pathways”, in preparation.
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membrane–protein interactions at atomic resolution.
Recent computational studies employing molecular dynamics (MD) simulations have
aimed to characterize the membrane–bound form of a number of different human CYPs [205,
219, 221], including CYP2C9 [206, 207] and human aromatase CYP19 [222, 223]. In our
previous work [164], we were able to characterize the membrane-bound form of CYP3A4
with MD simulations, and we experimentally determined the orientation that the en-
zyme takes in the membrane employing linear dichroism, providing validation for our
membrane–bound model of the enzyme. Together, these atomic models of membrane–
associated CYPs reveal that the globular domain of the enzymes is partially inserted in
the lipid bilayer, while a significant portion of the catalytic domain remains exposed to
solvent [164, 207, 219]. MD simulations of membrane–bound CYPs have also shown that
membrane–protein interactions regulate the opening of access tunnels connecting the ac-
tive site of the enzyme with its surroundings, i.e. solvent and membrane. [164, 205–207,
219]. The location of the entrance of some of these access tunnels, close to the head group
region of the lipid bilayer, indicates that these tunnels could be involved in substrate
access pathways leading to the active site of membrane–bound CYPs [164, 206, 207, 219].
Additionally, the position that specific substrates of human CYPs adopt in the mem-
brane has been shown to match the entrance of deeply inserted and solvent exposed tun-
nel openings, suggesting that these tunnels may facilitate substrate recruitment and/or
product egress [206, 219]. One caveat of these observations, however, is that the iden-
tified access tunnels are too narrow (e.g., with bottleneck radii < 2.5 A˚ in CYP2C9 and
CYP3A4 [164,207]) compared the average size of the substrates of CYPs. Therefore, the
binding pathway of a ligand in the enzyme is not clearly evident from the opening of
access tunnels observed in the substrate-free simulations alone.
In order to further explore the mechanism of ligand binding in membrane-bound
CYP3A4, we have extended our previous membrane-bound model [164], by further relax-
ing the POPC membrane–protein complex in a microsecond simulation. The orientation
of CYP3A4 in this extended model shows a better agreement with the experimental
data that we have reported previously [164], suggesting a more realistic atomic model of
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membrane–associated CYP3A4. Moreover, to take into the account conformational sam-
pling and dynamics of the protein in the presence of the membrane that might be relevant
to substrate binding pathways, we performed molecular docking in about 830 snapshots
of the protein obtained from the microsecond simulation, using progesterone as a model
substrate of CYP3A4. This approach, based on the relaxed complex scheme [175, 176]
that combines MD information with docking algorithms, allows us to take into the ac-
count the dynamics of the protein in the presence of the membrane in order to get a
better sense of where a ligand can be located within the enzyme. This approach reveals
a putative access pathway from the membrane to the active site of CYP3A4 for proges-
terone, located in tunnel 2b (Fig. 3.6 in Chapter 3) according to the nomenclature for
access tunnels in CYPs [181]. In order to probe this pathway, we performed independent
MD simulations starting from several docked poses of progesterone along the putative
pathway. These simulations revealed a continuous pathway sampled by progesterone in
independent simulations, where the access to the active site appears to be controlled by
the conformation of Met-371, a residue located in the vicinity of the active site.
4.2 Methods
4.2.1 System Preparation
A membrane-bound model of the globular domain of CYP3A4 (PDB entry 1TQN [194]),
including the transmembrane helix, was adopted from the last frame of one of the mem-
brane binding simulations reported previously [164], consisting of CYP3A4 bound to a
POPC bilayer. The system was first energy minimized for 1000 steps and equilibrated
for 100 ps while constraining the heavy atoms of the protein (with a force constant k =
1 kcal mol-1 A˚-2), and then simulated without constraints for 20 ns. The resulting system
was then employed to perform a 1 microsecond simulation using Desmond on Anton [128]
(with frames stored every 120 ps).
To elucidate how a drug can bind to the enzyme and gain access the active site
of CYP3A4, we performed molecular docking with Autodock 4.2 [177, 178] on different
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snapshots from the microsecond simulation, following the approach described in Chap-
ter 2. Snapshots of the protein in the membrane were taken from the microsecond MD
trajectory every 1.2 ns (i.e. every 10 frames), resulting in 834 different snapshots of the
protein. Molecular docking was performed on each snapshot employing PGS as a model
substrate of CYP3A4. The resulting docked structures were then clustered according
to their location in potential access pathways using precomputed geometries of access
tunnels calculated with CAVER 3.0 [224] (Fig. ??).
4.2.2 Simulation Systems
To investigate the dynamics of PGS bound to CYP3A4, docked poses of the steroid with
the best docking score along the most populated pathway, termed the putative access
pathway, were selected to be employed as seeds to perform additional MD simulations.
Seven docked poses of PGS, termed PGS-1 to PGS-7 (Fig. 4.1), were picked in order
to ensure coverage of the putative access pathway without increasing the computational
effort (e.g, the number of simulations).
The resulting systems minimized for 1000 steps and equilibrated for 100 ps while har-
monically restraining (k = 1 kcal mol-1 A˚-2) the heavy atoms of the protein backbone and
the ligand. This step was then followed by unconstrained 100 ns simulations, with some
systems extended to 200 ns (Fig. 4.3).
4.2.3 Specific Analysis
To characterize the position of PGS along a putative pathway in independent simulatons,
trajectories were aligned to a reference structure of the globular domain of CYP3A4
(without including the first 27 residues) obtained from the last frame of the microsecond
trajectory. The reference structure was rotated and translated so that the center of mass
of the active site of the enzyme was located at the origin of the coordinate system.
To identify key CYP3A4 residues interacting with PGS along the binding pathway,
interaction energies were calculated for each simulation employing a generalized implicit
solvation approach [225].
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Figure 4.1: Molecular docking reveals putative access pathway for progesterone. (Left) Results from
molecular docking performed on multiple snapshots of CYP3A4 in the membrane obtained from the
microsecond simulation. The structure of progesterone, employed as model substrate of CYP3A4, is
also shown. Each bead represents the center of mass a docked pose of progesterone. The distribution
of docked poses in the putative access pathway is shown in blue. (Right) Seven docked poses located
in the putative access pathway were picked to perform independent MD simulations in order to probe
the pathway. Progesterone and the heme moeity are shown in stick representation in blue and red,
respectively.
To reconstruct binding pathway from PGS, the RMSD of the steroid was calculated
for each pair of simulations. First, an ensemble of protein–ligand complexes were obtained
(every 100 ps) from the simulations. For two given PGS simulations, the RMSD of PGS
for all the frames of simulation one was calculated using the frames of simulation two as
references, and the minimum RMSD value of the generated RMSD matrix was reported.
From these calculations, RMSD values < 0.8 A˚ suggest a ”stitching” point in which PGS
samples the same region of the protein in separate simulations. By obtaining multiple
stitchin points, it is possible to obtain an ensemble of structures in which the complete
translocation of PGS from the membrane and into the active site of CYP3A4 is observed.
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4.3 Results and Discussion
4.3.1 Refined Model of Membrane-Bound CYP3A4
We have expanded our previous membrane-bound model of the CYP3A4 [164] by ex-
tending the membrane representation from the short-tailed lipids of the HMMM [161]
model to a POPC membrane. To further refine the previously obtained membrane-bound
model of the enzyme, the system was simulated for 1 microsecond in the presence of the
membrane.
Figure 4.2: Orientation and insertion of CYP3A4 in the membrane. (top) Time series of the heme tilt
angle for the microsecond simulation. The heme plane was defined by fitting the position of the four
porphyrin nitrogen atoms to a plane. The tilt angle θ is defined as the angle between the membrane
normal (z-axis) and the heme plane. The box shows the average experimental angle measured with linear
dichroism reported in our previous work [164] and the average tilt angle in our extended simulation. The
dashed line indicates the average experimental value. (bottom) Time evolution of the average height
of the center of mass of A-anchor and helices F’ and G’, using the same color scheme as in Fig. 3.2 in
Chapter 3.
51
The transmembrane helix of CYP3A4 remains inserted in the lipid bilayer during
the simulation, while the globular domain of CYP3A4 remains partially inserted in the
membrane. The convergence of the extended simulation was assessed by monitoring the
orientation that the globular domain of CYP3A4 takes in the membrane. The orientation
was characterized by calculating the heme tilt angle with respect to the membrane nor-
mal (z-axis) (Fig. 4.2). The interaction of the enzyme with the POPC membrane results
in a slightly deeper insertion of the A-anchor and helices F’ and G’ into the hydropho-
bic core of the membrane compared to our previous model [164], resulting in a ∼10 ◦
change in the orientation of the globular domain of CYP3A4 with respect to our previ-
ous model. During the simulation, the orientation that the globular domain of CYP3A4
takes in the membrane fluctuates around 60 ◦, with an average of 57.8 ◦. This value is
in close agreement with the experimental value of 59.7 ◦ obtained in POPC nanodiscs by
linear dichroism that we have reported previously [164]. The close agreement between
the orientation of the membrane-bound enzyme obtained in the extended simulation and
in experiment indicates that the extended simulation results in a more accurate model of
the membrane-bound of CYP3A4.
4.3.2 Molecular Details of a Putative Ligand Binding Pathway
It has been suggested that the interaction of CYPs with the membrane mediates the
recruitment of lipophilic and amphiphilic substrates by these enzymes [182, 183]. Taking
advantage of the conformational sampling of CYP3A4 in the presence of the membrane
obtained from the microsecond simulation, we try to elucidate the mechanism by which
a substrate can bind to the enzyme and gain access the active site of CYP3A4.
Given that the access tunnels leading to the active site of membrane-bound CYPs are
narrow and transiently open [164,206,207,219], the location of a ligand in the enzyme is
not clearly identified from the simulation. To overcome this, we perform molecular docking
of PGS on ∼830 snapshots of CYP3A4 obtained from the microsecond simulation (see
Methods). This approach, inspired by the relaxed complex scheme [175, 176], provides a
better sense of where PGS can be located in the membrane-bound enzyme, by taking into
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account the dynamics of the protein in the presence of the membrane.
Figure 4.3: Summary of simulations for PGS. Seven initial positions were tested for PGS, labeled PGS-1
to PGS-7, in independent protein-ligand simulations. The distribution of the center of mass of PGS in
each simulation is shown. The simulation time for each case is shown in the bottom left corner. The heme
moeity is shown in magenta sticks. Representative residues, identified by their interaction energies with
PGS (Table 4.1) are shown in stick representation. The membrane interface (defined by the phosphorous
atoms of PO4) is shown in gray spheres.
The molecular docking results reveal that most of the docked poses of PGS are located
in the active site. Interestingly, a distribution of docking poses connecting the membrane
to the active site is observed from the molecular docking calculations (Fig. 4.1). These
docking poses are located in the 2b tunnel (Fig. 3.6 in Chapter 3), following the estab-
lished nomenclature for tunnels in CYPs [181]. We have previously reported that the
interaction of CYP3A4 with the lipid head groups of the membrane favors the opening
of this tunnel [164]. The location of the docked poses in access tunnel 2b suggests that
this tunnel could be a potential access pathway for lipophilic substrates into the active
site of CYP3A4. Molecular docking also reveals a distribution of docked poses located in
the vicinity of the F-G region of CYP3A4 and the membrane (Fig. 4.1). This peripheral
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region of CYP3A4 has been previously identified to bind progesterone [179] and it has
been proposed as a functionally important ligand binding site involved in the mechanism
of cooperativity of CYP3A4 [216], and was further explored as described in Chapter 5.
Table 4.1: Interaction energies calculated from MD simulations. Key residues and interacting energies
for each cluster calculated from simulations, as outlined in the Methods section.
PGS-1 PGS-2 PGS-3 PGS-3
Residue Interaction
Energy
(kcal/mol)
Residue Interaction
Energy
(kcal/mol)
Residue Interaction
Energy
(kcal/mol)
Residue Interaction
Energy
(kcal/mol)
Arg-106 -6.4± 1.2 Phe-57 -1.4± 0.5 Arg-105 -3.2± 1.9 Arg-105 -4.9± 0.9
Pro-107 -1.6± 0.8 Asp-76 2.1± 0.5 Arg-106 -5.0± 3.8 Arg-106 -3.5± 1.2
Phe-108 -1.8± 0.6 Arg-106 -7.9± 1.0 Phe-108 -3.3± 1.3 Phe-108 -3.3± 0.9
Gly-109 -2.6± 0.7 Phe-108 -3.3± 0.6 Ser-119 -2.5± 3.4 Ser-119 -1.0± 0.4
Phe-215 -2.3± 0.7 Gly-109 -1.2± 0.4 Arg-212 -1.2± 1.0 Arg-212 -1.4± 0.9
Phe-220 -1.8± 1.1 Phe-215 -3.5± 0.9 Phe-215 -2.0± 0.7 Phe-215 -1.6± 0.6
Ile-223 -2.6± 0.7 Phe-220 -2.4± 0.6 Arg-372 -2.8± 3.0 Ile-301 -1.2± 0.5
Thr-224 -1.8± 0.9 Ile-223 -2.1± 0.6 Phe-304 -1.4± 0.6
Ile-230 -1.3± 0.8 Thr-224 -1.3± 0.6 Met-371 -3.5± 0.9
Met-371 -1.0± 0.6 Met-371 -4.0± 1.1 Arg-372 -1.1± 0.7
Arg-372 -5.7± 1.6
Glu-374 -1.3± 1.0
PGS-5 PGS-6 PGS-7
Residue Interaction
Energy
(kcal/mol)
Residue Interaction
Energy
(kcal/mol)
Residue Interaction
Energy
(kcal/mol)
Arg-105 -4.7± 0.8 Arg-105 -3.4± 1.2 Arg-105 -3.8± 0.9
Arg-106 -3.6± 0.8 Arg-106 -1.0± 0.7 Arg-106 -1.4± 0.6
Pro-107 -1.3± 0.3 Pro-107 -1.7± 1.1 Pro-107 -2.3± 0.7
Phe-108 -3.9± 1.0 Phe-108 -3.4± 1.6 Phe-108 -4.3± 1.1
Phe-213 -1.2± 0.4 Ser-119 -1.3± 1.0 Ser-119 -1.4± 0.6
Phe-215 -2.0± 0.5 Arg-212 -6.8± 5.9 Arg-212 -4.9± 5.4
Phe-304 -1.1± 0.4 Phe-213 -1.1± 0.5 Phe-213 -1.0± 0.5
Met-371 -3.5± 0.6 Ile-301 -1.6± 0.6 Ile-301 -1.0± 0.4
Phe-304 -2.0± 0.7 Phe-304 -1.8± 0.4
Ala-370 -2.4± 0.7 Ala-370 -2.0± 0.7
Met-371 -2.7± 0.7 Met-371 -3.0± 0.7
The location of the docked poses of PGS inside the tunnel suggests that it could serve
as an access pathway for lipophilic substrates into the active site of CYP3A4. In order to
probe the relevance of this putative pathway, we performed MD simulations employing
different docked poses along this putative access pathway as initial seeds (Fig. 4.1), re-
sulting with labeled PGS-1 to PGS-7 (Fig. 4.3). During these simulations, PGS samples
different regions of the enzyme along the putative pathway, including the active site in
PGS-6 and PGS-7, and the F’-G’ region close to the membrane with the remaining sys-
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tems (Fig. 4.3). The putative pathway contains mainly nonpolar side chains that make
contacts with PGS. Close to the membrane and along the putative pathway, the rings of
PGS establish hydrophobic contacts mainly with Phe-108, located in the B-C loop, Met-
371 in the vicinity of the active site, and Phe-215 and Phe-220, located in the F-F’ region,
among other hydrophobic residues (Table 4.1). These phenylalanine residues, together
with Phe-219, Phe-240 and Phe-304, form the characteristic ’Phe-cluster’ of CYP3A4,
which as been suggsted to be involved in substrate recruitment and recognition [179,216],
and, we have previously shown [164], undergoes significant rearrangement in the presence
of the membrane (Fig. 3.7 of Chapter 3).
4.3.3 M371 Regulates Access to Active Site Through Identified
Binding Pathway
Table 4.2: Smallest pairwise RMSD between the PGS molecules in independent simulations. The RMSD
was calculated employing the heavy atoms of PGS, after aligning all the frames of the 7 simulations to
a reference CYP3A4 structure. RMSD< 0.8 A˚ indicates substantial spatial overlap of PGS in different
simulation.
PGS-1 PGS-2 PGS-3 PGS-4 PGS-5 PGS-6 PGS-7
PGS-1 0.44 1.29 5.05 4.84 7.99 7.76
PGS-2 0.44 0.79 3.23 3.42 6.43 6.34
PGS-3 1.29 0.79 0.28 2.02 1.86 2.04
PGS-4 5.05 3.23 0.28 2.05 1.43 1.41
PGS-5 4.84 3.42 2.02 2.05 1.72 3.28
PGS-6 7.99 6.43 1.86 1.43 1.72 0.28
PGS-7 7.76 6.34 2.04 1.41 3.28 0.28
Conformation ensembles of the CYP3A4-PGS complex obtained from MD simulations
were used to reconstruct an access pathway for PGS going from the membrane into the
active site (Fig. 4.5). This was done first by quantifying the RMSD of the heavy atoms
of PGS in different simulations, in order to identify simulations were PGS samples the
portion of the binding pathway (Table 4.2). A small RMSD value (< 0.8 A˚) obtained
from the analysis indicates that PGS ensentially samples the same region of the protein
in different simulations during a certain portion of the trajectories. From this analysis,
we observed that there is transient overlap between systems PGS-1, PGS-2, PGS-3 and
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PGS-4, as well as between PGS-6 and PGS-7 (Fig 4.4).
Indeed, we observe that there is significant spatial overlap of the rings of PGS (termed
A, B, C and D) between PGS-1, PGS-2, PGS-3 and PGS-4 systems (Fig. 4.5). Over-
lap in the xy, yz and zx planes indicates that the space is sampled continuously by
each ring. while PGS preserves its overall orientation and direction in the overlapping
regions (Fig. 4.5). This suggests that PGS samples different portions of a continuous
pathway connecting the membrane to the active site in the 4 independent simulations,
as shown in Fig. 4.4. Interestingly, the space sampled by these 4 simulations is observed
to be occupied by ritonavir analogues in recent crystal structures of CYP3A4 bound to
these drugs [220], supporting the relevance of this putative pathway in substrate access
into the active site.
Figure 4.4: Spatial overlap of PGS in independent simulations. (Left) Conformation and position of PGS
at the points of intersection (smallest RMSD) between different simulations. Progesterone is observed
to preserve is orientation and directionality at these points, which suggests that the molecule samples
a continuous pathway in the presented systems. The different conformation that Met-371 presents in
each simulation is shown in stick representation. (Right) Reconstructed binding pathway for PGS from
the membrane surface to the active site of CYP3A4, obtained by piecing together the conformations
generated in systems PGS-1, PGS-2, PGS-3 and PGS-4.
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Figure 4.5: Spatial overlap of PGS in independent simulations. Projection of the position of rings A,
B, C and D of PGS onto the xy, yz and zx planes for systems PGS-1, PGS-2, PGS-3 and PGS-4. The
origin of the planes is located at the position of the heme (magenta circle). Overlap in the three planes
indicates that the space is sampled continuously by each ring. The dashed line represents the average
z-position of the membrane surface.
The largest spatial overlap in the three simulations is observed between PGS-1 and
PGS-2, as seen in Fig. 4.5, where PGS samples the region between the membrane and
what appears to be the bottleneck of the access pathway, consisting of residues Phe-108
and Phe-215 (Fig. 4.3). Similary, there is significant spatial overlap in systems PGS-3
and PGS-4, as indicated by the plane projections. However, between these two pairs of
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systems there is spatial overlap only in a small region of the planes, particularly for ring A
and B (Fig. 4.5). The lack of sufficient spatial overlap is related to the orientation of the
Met-371 side chain: in systems PGS-1 and PGS-2 this side chain is pointing towards the
heme moiety, essentially occluding access to the active site, whereas in PGS-3 and PGS-
4 it is pointing away from the active site (Fig. 4.4). This observation suggests that the
conformation of Met-371 can affect substrate access to the active site. Analysis of Met-371
in the microsecond simulation reveals that this residue can take certain conformations that
result in the transient occlusion of the access to the active site (Fig. 4.6). This suggests
that the access tunnels are not necessarily open in a continuous manner (i.e., connecting
the membrane and the active site at once), and instead consist of smaller, contiguous
segments, which openings are controlled by transient sidechain fluctuations.
Figure 4.6: Conformations of Met-371 in microsecond simulations. (Left) Conformations adopted by
Met-371, shown in sitck representation, results in the transient occlusion the access to the active site
through the putative access pathway. A representative geometry of the access pathway is shown in wired
surface representation. (Right) Time evolution of the distance of heavy atoms in the Met-371 side chain
to the heme iron during the microsecond simulation.
Although, to our knowledge, the role of Met-371 in the activity of CYP3A4 has not
been explored experimentally, it has been recently observed in crystal structures that the
loop containing this side chain (residues 369 to 371) is always occupied when ligands are
present in the active site of CYP3A4 [220], indicating that this could be an important
binding site of the enzyme, which is in agreement with our simulations. Given its flexi-
bility, Met-371 could block the access to the active site once it has been occupied by one
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or more substrates [191].
4.3.4 Partition of PGS Into the Membrane
The reconstructed binding pathway from progesterone shown in Fig. 4.4 suggests that
PGS can be recruited from the surface of the membrane by CYP3A4. To assess this
mechanism, we performed a simulation (termed PGS-MEM) in which the spontanous
partition of PGS into a POPC membrane was captured. After partitioning into the
membrane, PGS is positioned at the region between headgroups and lipid tails, below the
phosphate group (Fig. 4.7, consistent with observations from MD simulations for other
steroid hormones [226].
Figure 4.7: Positioning of PGS in the membrane. (Top left) Distribution of the position along the
membrane normal (z-axis) of PGS in the POPC simulation (PGS-MEM), and in system PGS-1, in access
pathway, bound to CYP3A4. (Top right) Representative snapshots of both systems PGS-MEM and
PGS-1 depicting similar position and orientation of PGS in the membrane. (Bottom) Distribution of the
orientation of PGS in the membrane (PGS-MEM) and bound to CYP3A4 in system PGS-1.
From the position and orienation PGS adopts in the membrane, the ligand could
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be recruited by CYP3A4 through the identified access pathway. The location of the
entrance of the reconstructed binding pathway in system PGS-1 agrees with the position
that PGS adopts in the membrane. In the membrane, PGS is able to adopt a wide
range of orientations, including the orientation observed in PGS-1 at the entrance of
the binding pathway (∼ 120 ◦) (Fig. 4.7). The apparent mobility of the steroid in the
membrane would facilitate the encounter with CYP3A4, initiating the binding process,
through the identified pathway identified, into the active site. The interaction energies
shown in Table 4.1 provide a hint of what residues might be involved in the recruitment
mechanism. Several hydrophobic residues, including Phe-108, Phe-215 and Phe-220 that
interact with PGS in system PGS-1 are near the membrane surface. The location of these
Phe side chains relative to the membrane suggests that they could be involved in the
substrate recognition mechanism of CYP3A4.
Although the access pathway identified in our simulations might facilitate the access
of planar (i.e., PGS) [179] or long substrates (i.e., ritonavir) [195, 197, 220] from the
membrane surface, it is still not evident how larger substrates, such as erythromicin [191],
bind to the active site. The recruitment of such large compounds might require a larger
conformational change of the enzyme, similar to what has been observed for P450cam in
solution in recent double electron resonance experiments [227].
4.4 Summary
Recently, we developed a model for the membrane-bound form of CYP3A4, employing
a concerted simulation/experimental approach. From the simulations, we observed that
the interaction of CYP3A4 with the membrane favors the opening of pathways leading to
the active site, which might play a role in the recruitment of lipophilic ligands from the
membrane. Using this membrane-bound model, we performed a microsecond-long MD
simulation, providing extended conformational sampling for the protein in the presence of
the membrane. To take advantage of the conformational sampling of membrane–bound
CYP3A4 in the microsecond–level simulation, we adopted an alternative approach to
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Figure 4.8: Membrane-mediated drug binding mechanism of CYP3A4. The binding pathway of pro-
gesterone was reconstructed by combining independent equilibrium simulations of progesterone along the
putative access tunnel (shown in green-to-blue colorscale, stick representation), and membrane-partition
simulations (shown in dark red-to-gold colosrcale). Heme cofactor, located in the active site of the enzyme,
is shown in magenta stick representation.
study drug–binding, in which we combined MD simulations with ensemble molecular
docking [175, 176] employing progesterone, a prototypical steroid substrate of CYP3A4.
The proposed approach consisted in performing molecular docking of progesterone on
multiple snapshots (e.g., ∼ 8500) of the protein obtained from the microsecond simulation,
allowing to account for transient conformational changes captured during the simulation
that would facilitate accommodating progesterone along a putative access pathway leading
to the active site of the enzyme. The analysis of the resulting docked poses revealed a
continuous distribution of progesterone docked poses in the membrane-bound CYP3A4,
61
connecting the active site of the enzyme to the membrane, suggesting a putative binding
pathway for progesterone (Fig. 4.4). Interestingly, these results suggest that the access
tunnels are not necessarily open in a continuous manner (i.e., connecting the membrane
and the active site at once), and instead consist of smaller, contiguous segments, which
openings are controlled by transient sidechain fluctuations.
The relevance of the putative progesterone binding pathway identified with molecular
docking was further explored with additional MD simulations, starting from a selection
of progesterone docked poses, consisting of structures with the best docking score. The
simulations started with progesterone located at different positions along its putative bind-
ing pathway, in order to increase the sampling of important protein–ligand interactions.
Remarkably, we were able to reconstruct an access pathway for progesterone from the
protein–ligand conformations generated from multiple independent unbiased simulation
from the membrane (Fig. 4.8).
Clustering analysis of the resulting simulations revealed significant spatial overlap of
progesterone along different simulations in which the molecule preserves its overall ori-
entation and direction through the overlapping regions, indicating that progesterone is
able to sample a continuous pathway connecting the membrane to the active site in the
ensemble generated by combining independent simulations.Thus, the combined molecular
docking/MD approach revealed the presence of a complete binding pathway that could
facilitate the binding of amphipathic molecules partitioning into the membrane into the
active site of CYP3A4. Indeed, our simulation of progesterone binding to a POPC mem-
brane revealed that this steroid remains at the phosphate level of the lipid bilayer, where
it could be recruited by CYP3A4, as shown in our fully reconstructed binding path-
way (Fig. ??). Given the propensity of many CYP substrates to partition into this same
region of the lipid bilayer, our findings provide insights into a general mechanism for drug
binding to peripheral membrane proteins, including other CYP enzymes, in which the
membrane plays a major role in facilitating drug recruitment by serving as an intermedi-
ate binding partner for small molecules.
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Chapter 5
Molecular Mechanism of Drug-Drug
Interactions in CYP3A4 ∗
5.1 Introduction
Cytochromes P450 make up a key class of enzymes involved in the metabolism of xeno-
biotics, with the CYP3A4 isoform in human liver being responsible for many critical
biotransformations. Given their involvement in the metabolism of numerous drugs, these
enzymes constitute a major site of drugdrug interactions. CYP3A4 can bind multiple
copies of many compounds, and the enzyme often exhibits cooperativity with multiple
substrates. Very often, these interactions are detected as inhibition of CYP3A4-mediated
metabolism of test substrates by the presence of an effector or another compound, [229]
which can result in a dangerously high concentration of an administered therapeutic. Some
compounds can accelerate CYP3A4-mediated metabolism in vitro, e.g., α-naphthoflavone
(ANF), [230] quinidine, [231] steroids, [232] and a number of potential drug candidate
molecules. [233] This metabolic interaction between two different compounds is termed
heterotropic and, like the homotropic case, is manifested through the simultaneous bind-
∗This chapter appeared as a research article in Biochemistry [228].
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ing of multiple molecules to the enzyme. Despite the importance of CYP3A4 to human
pharmacology, the detailed mechanisms of such heterotropic effects are not completely
understood. Given different systems and protocols employed by various research groups,
it has been difficult to directly compare the reported results, leading to confusion and
conflicting claims. For instance, ANF was stated to be both an inhibitor [234, 235] and
an activator of CYP3A4. [236–238] Further complications arise when one considers the
possibility of oligomeric complexes of multiple P450s. [238]
The anticonvulsant drug carbamazepine (CBZ) has been reported to increase the rate
of clearance of warfarin, [239] and this positive heterotropic effect has been attributed
to induction of CYP3A4. [240] Direct interaction of CBZ with the sedative drug mida-
zolam inside the substrate binding pocket has been suggested to be the molecular basis
underlying the observed changes in stereospecificity of midazolam hydroxylation. [241]
The accelerated metabolism of steroids (including oral contraceptives) during CBZ ad-
ministration has also been attributed to the induction of CYP3A4. [242–244] On the other
hand, CBZ has been reported to act as an inhibitor of hydroxylation of both steroids and
midazolam in vitro, [241,245] while 10,11-epoxidation of CBZ by CYP3A4 is activated in
the presence of various endogenous steroids [232, 245, 246] as well as other effectors, e.g.,
ANF, artemisinin, and quinidine. [247]
To understand the mechanism of heterotropic cooperativity in monomeric CYP3A4,
we initiated a series of experimental studies using a pair of substrates with substantially
different physical properties, namely, the clinically relevant steroid progesterone (PGS)
and the anti-epileptic drug CBZ. Both drugs are known CYP3A4 substrates, and their
mutual metabolic effects have been reported in several previous studies, although no mech-
anistic interpretation was provided for the observed heterotropic interactions. [245, 247]
In addition, both drugs can act as allosteric effectors, activating the metabolism of other
substrates (PGS and other steroids activate CBZ epoxidation [247]) or changing the re-
gioselectivity of hydroxylation for other substrates catalyzed by CYP3A4. [241] However,
their relative affinities with respect to the productive binding site inside the substrate
binding pocket near the heme iron (P-site) and to the nonproductive allosteric binding
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site (A-site) are anticipated to be distinct because of the differences in their molecular
shape and solubility. Importantly, heterotropic effects could be most pronounced in the
mixture of two substrates with preferential affinities for the productive site (P-type sub-
strate) for one and the allosteric site (A-type substrate) for the other. In such a case,
preferential binding of the A-type substrate to the allosteric site is expected to favor bind-
ing and metabolism of the P-type substrate inside the binding pocket, if its affinity for
the latter is higher.
In addition to the experimental investigations focused on determining the fundamental
catalytic properties of CYP3A4 in its multiple substrate-bound states, we also performed
a series of molecular dynamics (MD) simulations of the CYP3A4 monomer in a membrane
environment, with CBZ and PGS bound to the enzyme. The allosteric site of CYP3A4
located near the membrane interface was probed with PGS and CBZ in independent
simulations to study the dynamics of the two substrates at this nonproductive binding
site. The dynamics of CBZ near the productive site of CYP3A4 were probed using both
one and two copies of this substrate in the active site and provided critical structural
insight into the mechanism of heterotropic cooperativity of CYP3A4.
5.2 Methods
5.2.1 System Preparation
CYP3A4 Model and Initial Configurations. A membrane-bound model of the glob-
ular domain of CYP3A4 (Protein Data Bank entry 1TQN [194]), including the trans-
membrane helix formed by residues 1-27, was adopted from the last frame of one of
the membrane binding simulations reported previously. [164] The system is composed of
CYP3A4 bound to a solvated POPC membrane. This system was then minimized for 1000
steps and equilibrated for 100 ps while restraining the heavy atoms of the protein and the
lipids within 3.5 A˚ of the protein with a force constant k of 1 kcal mol-1 A˚-2. Following this
step, the system was simulated without restraints for 100 ns.
Molecular Docking and Ligand-Bound Simulations. To study the binding mode
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and dynamics of PGS and CBZ bound to CYP3A4, we first employed molecular docking
using Autodock 4.2 [177, 178] to probe potential binding sites for these drugs in the
enzyme. Taking advantage of the MD simulation of membrane-bound CYP3A4 described
above, we included a large number of snapshots taken from the 100 ns trajectory (in
contrast to a single structure used in most docking studies) in our docking as described
below. This approach allows us to take into the account the dynamics of the protein in the
presence of the membrane and probe in our docking cavities and putative binding sites
that only transiently arise during the simulations. The snapshots of membrane-bound
CYP3A4 were taken from the MD trajectory at 1 ns intervals, resulting in 100 different
snapshots, which were then used for docking of either PGS or CBZ.
5.2.2 Simulation Systems
Protein-ligand interactions were modeled with the Lamarckian genetic algorithm [177]
with a grid box spanning the allosteric binding site region (near the F-F’ and G-G’ loops
in CYP3A4) for both PGS and CBZ, and around the active site for CBZ. The top 10
docking poses for each snapshot and for each ligand (1000 poses for PGS and 1000 poses
for CBZ) were collected for further analysis. The resulting docked structures were then
clustered on the basis of their root-mean-square deviation (RMSD), using an RMSD cutoff
of 2 A˚, resulting in a total of five clusters for each ligand. For PGS in the allosteric binding
site, the docked poses in which the substrate adopts an orientation similar to that of the
crystal structure of substrate-bound CYP3A4 [179] were chosen as starting positions for
the MD simulations of ligand-bound systems. For CBZ in the allosteric site, the docking
poses with the highest docking scores from the pool of the first four clusters were selected
as starting positions for ligand-bound MD simulations. In the case of CBZ in the active
site, the best docked pose (highest docking score) in each cluster was selected as initial
positions for MD simulations. Two of the initial positions of CBZ were discarded on the
basis of the distance between the sites of metabolism of the substrate (C10 and C11) and
the heme iron (> 6 A˚), resulting in only three initial orientations for a single CBZ molecule
in the active site. The resulting systems were minimized for 1000 steps and equilibrated
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for 100 ps while the heavy atoms of the protein backbone and the ligand were harmonically
restrained (k = 1 kcal mol-1 A˚-2). This step was then followed by unrestrained, production
simulations. Simulations of substrates in the allosteric site were run each for 30-100 ns for
CBZ and 100 ns for PGS. For a single CBZ in the active site, the production simulations
were each 10-20 ns in duration.
To generate models for two CBZ molecules bound to CYP3A4, the general molecular
docking approach was repeated employing snapshots from the single CBZ simulations
where the distance between CBZ C10/C11 and the heme iron was < 6 A˚, resulting in 30
frames. In this case, each snapshot also included the first CBZ molecule, in addition to
the protein. The resulting docked poses of the two CBZ molecules were clustered on the
basis of the RMSD, with an RMSD cutoff of 2 A˚. The best docked pose for each cluster
was then selected as the initial configuration for additional MD simulations, resulting in
four independent systems each with two CBZ molecules bound.
MD simulations were performed using NAMD2, [127] utilizing the CHARMM36 force
field with cMAP [119] corrections for the protein and CHARMM36 [113] for lipids. Pa-
rameters for PGS were derived from available testosterone and cholesterol CHARMM
parameters. [202, 248] Parameters for CBZ were obtained by analogy [121, 122] from the
CHARMM General Force Field [113] and further optimized employing the Force Field
Toolkit [249] implemented in VMD. [117] The TIP3P model was used for water. [120]
All simulations were performed as an NPT ensemble at 1.0 atm and 310 K, with a time
step of 2 fs. Constant pressure was maintained using the Nose´-Hoover Langevin piston
method, [250,251] and constant temperature was maintained by Langevin dynamics with
a damping coefficient γ of 0.5 ps-1 applied to all atoms. Nonbonded interactions were
cut off after 12 A˚ with a smoothing function applied after 10 A˚. Bond distances involving
hydrogen atoms were constrained using the SHAKE algorithm. [252] The particle mesh
Ewald (PME) method [126] was used for long-range electrostatic calculations with a grid
density of > 1 A˚-3.
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5.2.3 Summary of Experimental Methods
Our experimental collaborators at the Sligar Lab (UIUC) expressed CYP3A4 proteins,
purified, and reconstructed them into the Nanodiscs. They also performed UV-Vis spec-
troscopy, NAPDH oxidation and product formation measurements using CYP3A4-incorporated
Nanodiscs. Finally, our collaborators also performed a global analysis to deconvolute co-
operative effects in P450. For details of the experimental methods, see reference [228].
5.3 Results and Discussion
5.3.1 Asymmetric Heterotropic Effect in PGS/CBZ Mixtures
To understand the mechanism of activation of CYP3A4-mediated metabolism of one or
both substrates in the mixture, spin shift titration data and steady-state kinetics of sub-
strate turnover were collected, as described elsewhere [253, 254]. All experiments were
performed under identical conditions, allowing us to use the same set of binding con-
stants in the analysis of multiple experiments.
The results of experiments with the mixture of CBZ and PGS are shown in Fig-
ure 5.1. The absolute rate of NADPH consumption at maximum, and the shape of its
dependence on the substrate concentration, are very similar to those observed with pure
CBZ. However, the maximal rate is reached already at 10µM PGS and 120µM CBZ,
i.e., at significantly lower concentrations compared to those when only a single substrate
is present. In addition, significantly different values of the product formation rates are
observed for both PGS and CBZ. For PGS, the maximal product formation rate (5 min -1)
is reached at 18-20µM PGS, with the subsequent decrease to 4 min-1 at 60µM and higher
PGS concentrations. This is 4 times slower than the maximal rate observed with pure
PGS, indicating substantial inhibition of PGS hydroxylation in the presence of CBZ. At
the same time, the rate of CBZ epoxidation reaches a maximal value of 6 min-1 at 240 µM
CBZ and then remains approximately the same up to 800µM CBZ. This rate is 2 times
higher than the rate of 3 min-1 observed with pure CBZ, meaning significant activation of
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Figure 5.1: NADPH consumption rate and product forming rates (top) for PGS and CBZ observed
using the mixture of PGS and CBZ at a 1:12 molar ratio. PGS concentrations are shown at the bottom
and corresponding CBZ concentrations at the top. Rates (min -1) of product formation (bottom image)
for all 10 binding intermediates with results for PGS hydroxylation colored blue and those for CBZ
epoxidation green.
CBZ metabolism in the presence of PGS. Note that all rate values are calculated per total
CYP3A4, which metabolizes both substrates in the mixture, so the actual activation for
CBZ and inhibition for PGS are even more pronounced. Importantly, this activation is
seen with monomeric CYP3A4.
Global analysis does not show any measurable product formation for PGS in the pres-
ence of CBZ, indicating predominant positioning of CBZ at the productive site near the
heme iron in these intermediates. The product formation rates for CBZ obtained are
significantly higher than for CBZ alone, revealing these faster rates as the main source
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of activation of CBZ epoxidation in the presence of PGS. As a result, CBZ epoxidation
is significantly accelerated in the presence of PGS, while PGS hydroxylation is strongly
inhibited. This asymmetric heterotropic effect can be explained only by an uneven distri-
bution of two substrates between the productive binding site close to the heme iron and
the unproductive peripheral binding sites.
5.3.2 Dynamics of PGS and CBZ in the Allosteric Site of CYP3A4
To explore the effects of multiple-ligand binding and gain insight into the structural basis
of heterotropic cooperativity in CYP3A4, we performed several MD simulations of the
enzyme in the presence of PGS or CBZ at different binding sites. It has been suggested
that the mechanism of cooperativity of CYP3A4 is regulated by the binding of a ligand to a
peripheral binding site [179,205,216,238,255]. The binding of a substrate in the periphery
of CYP3A4 might trigger a conformational change necessary to facilitate the cooperative
behavior of the enzyme. In this regard, experimental structural studies have identified
a peripheral binding site in the proximity of the F–G region of the enzyme [179, 216],
with X-ray crystal structures revealing PGS binding at this site. In the membrane-bound
form of CYP3A4, the peripheral binding site is located in a region that interacts with
the membrane [164, 219]. Given the partitioning of steroids in the membrane [226] in a
region located between the headgroup and lipid tails, it is likely that a substrate can be
recruited by the enzyme and bind to this peripheral site, resulting in allosteric modulation
of CYP3A4 function.
To study the dynamics of PGS in the allosteric binding site of CYP3A4 in the presence
of a lipid bilayer, we performed three independent MD simulations starting from docked
poses where the ligand has a conformation similar to that of the available crystal structure
of PGS-bound CYP3A4 [179] (Fig. 5.2).
Similarly, we executed four independent simulations with CBZ docked in the allosteric
binding site. Because there is no structural information about binding of CBZ to this
allosteric site, we tested four different docked poses for CBZ, one in each simulation
(Fig. 5.3). In the resulting docked poses, PGS and CBZ are packed in the vicinity of
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Figure 5.2: Dynamics of PGS in the allosteric binding site of CYP3A4. Representative snapshots (top
right) of the conformation of the F–G region of CYP3A4 for both substrate-free (green) and PGS-bound
simulations (red). Side chains of residues interacting with PGS are shown as sticks in their respective
colors. PGS is shown as gray sticks. Time series (bottom right) of the center of mass (COM) distance
between the Phe-213 side chain and the heme. The average distance for the substrate-free simulation
over 100 ns is 14.7 A˚. Change in the active site volume (left) resulting from the displacement of Phe-213
from the active site. The Phe-213 side chain and the heme moiety are shown as red sticks. The volume
was calculated using the program ”mdpocket”. [?]
the hydrophobic side chains in the allosteric binding site. During the simulations, PGS
maintains its contacts with hydrophobic side chains located in this region, particularly
with Phe-219 and Phe-220, while forming additional transient contacts with Leu-211,
Asp-217, and Arg-243. In the case of CBZ, the substrate detached from the enzyme in
three of the four simulations, as quantified by its RMSD evolution (Fig. 5.3). In the single
simulation in which CBZ remains bound to the enzyme, it is stabilized by interactions
between its carbonyl oxygen and the backbone amide group of Leu-211 and between its
amine nitrogen and backbone carbonyl oxygen atoms of Leu-211 and Val-240 (Fig. 5.3).
Interestingly, the presence of PGS in the allosteric binding site induces a change in
the orientation of the Phe-213 side chain, located in the F–F’ loop (Fig. 5.2). In the
absence of the substrate, Phe-213 is located closer to the productive binding site (active
site), with its side chain pointing toward the heme and away from the membrane. In
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Figure 5.3: Dynamics of CBZ in the allosteric binding site of CBZ. Snapshots (top left) of the four
different orientations of CBZ in the peripheral binding site probed with MD simulations. Time series
(top right) of the RMSD of CBZ and the COM distance between the Phe-213 side chain and the heme
for each simulation. The average distance for the 100 ns substrate-free simulation is 14.7 A˚ (dashed line).
Snapshot (bottom left) of interactions of CBZ with residues Leu-211 and Val-240, obtained from system
CBZ-4. CBZ and residues Leu-211 and Val-240 are shown as sticks. Time series (bottom right) of the
distance between interacting elements of CBZ and Leu-211 and Val-240.
this orientation, the average distance between Phe-213 and the heme is 14.7 A˚. In the
simulations in which PGS is bound to CYP3A4, a transient change in the orientation
of Phe-213 is observed. In these cases, the Phe-213 side chain flips out of the active
site and packs against PGS, resulting in an increase of ∼4 A˚ in the distance between its
side chain and the heme. In contrast, in the CBZ simulations, Phe-213 remains pointing
toward the active site, with the distances between the side chain and heme being ∼14 A˚,
similar to that of the substrate-free simulation, even in the simulation where CBZ remains
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bound to CYP3A4 (Fig. 5.3). This local conformational change induced by PGS favors
an increase in the volume of the CYP3A4 active site, from 675 A˚3 in the absence of the
substrate to 990 A˚3 when PGS is present in the allosteric binding site. The relevance of
Phe-213 in cooperativity has been observed experimentally, where mutation of this residue
results in the reduced cooperativity of CYP3A4 [256], and decreased level of stimulation
by α-naphthoflavone [236]. In the context of the membrane, our simulations suggest that
Phe-213 is important for modulating cooperativity by allowing an increase in the volume
of the active site, therefore facilitating the binding of other substrates in the productive
site of CYP3A4.
5.3.3 Dynamics of CBZ in the Active Site
Figure 5.4: Dynamics of a single CBZ in the active site of CYP3A4. Snapshots (right) of the three
different orientations of CBZ in the active site probed with MD simulations. The structure of CBZ is
also shown, indicating its sites of metabolism, C10 and C11. CBZ is shown as sticks. The heme moiety
is shown as a red stick. Time series (left) of the distance between C10 and C11 of CBZ and the heme
iron atom.
The active site of CYP3A4 is capable of accommodating more than one substrate
molecule, as suggested by X-ray structures in which two ketoconazole [191] or riton-
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avir [220, 257] molecules were found in the active site. To study the dynamics of CBZ in
the active site, we have performed several independent simulations in which one or two
CBZ molecules are located in the active site. Although several binding modes of CBZ
based on molecular docking have been previously proposed [258], none of the previous
studies took into account the dynamics of the binding site and the substrate. Therefore,
to take into account different potential orientations of the substrate in the active site,
we performed three independent simulations, each starting from one of the three most
representative docked poses of a single CBZ molecule in the active site (Fig. 5.3). During
these simulations, CBZ is significantly displaced from its initial position in the active site,
as shown by the distances between the heme iron and C10 and C11 of CBZ (Fig. 5.3). For
example, in system CBZ-3, the molecule transiently approaches the heme (heme iron–C10
or C11 distances of < 5 A˚), while in systems CBZ-1 and CBZ-3, the molecule gradually
drifts away from its initial position and from the heme. Together, these simulations
suggest that it may be difficult for a single CBZ molecule to find a stable position and
orientation that would facilitate its oxidation.
Starting from the snapshots obtained from single-CBZ simulations, and employing
molecular docking, we also generated membrane-bound models of CYP3A4 with two
CBZ molecules in the active site. For this condition, we tested four different initial
configurations. In these systems, the CBZ molecule that is closer to the heme remains
in its position during the simulations, with C10– and C11–heme iron distances of ∼5 A˚
(Fig. 5.5). This observation suggests that the presence of a second CBZ molecule could
favor the epoxidation of the first molecule by keeping it in the proximity of the heme.
Moreover, the simulations reveal that some of the tested two-CBZ configurations favor
the transient motion of Phe-213 out of the active site (Fig. 5.5). This is particularly
evident in system CBZ-2, where the distance between the Phe-213 side chain and the
heme remains above the average of 14.7 A˚ observed in the substrate-free simulation. In
this case, the Phe-213 side chain is displaced from the active site, allowing the second
CBZ molecule to occupy its position and contact Phe-241 and Phe-304. The observed
displacement of Phe-213 in this case suggests that the binding of two or more substrates
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Figure 5.5: Two CBZ molecules in active site of CYP3A4. Snapshots (top right) of the four different
configurations of two CBZ molecules in the active site probed with MD simulations. CBZ molecules
are shown as sticks colored cyan (first molecule) and pink (second molecule). Time series (top left) of
the distance between C10 and C11 of the first CBZ and the heme iron atom. Time series (bottom) of
the COM distance between the Phe-213 side chain and the heme. The average distance for the 100 ns
substrate-free simulation is 14.7 A˚ (dashed line).
in the active site of CYP3A4 might be facilitated by the binding of another substrate,
such as PGS in our case, to the peripheral binding site. Therefore, these simulations
provide some structural insight into the role of the different substrates in the mechanism
of cooperativity of CYP3A4.
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5.4 Summary
Different properties of PGS and CBZ with respect to their binding affinity for productive
and nonproductive allosteric sites give rise to strongly asymmetric mutual perturbation
of their metabolic turnover catalyzed by monomeric CYP3A4, with strong activation of
CBZ epoxidation and simultaneous inhibition of PGS hydroxylation in the mixed titration
experiments. Using a global analysis, we have deconvoluted the partial contributions of
the mixed binding intermediates into the overall observed rates of product formation
and found a 1.5-3.5-fold acceleration of CBZ metabolism upon binding of one or two
PGS molecules to the same CYP3A4 monomer. Importantly, our results obtained using
CYP3A4 monomer in Nanodiscs are in very good agreement with the earlier results of
Houston et al. [232,259] obtained with the same substrates using human liver microsomes
and human hepatocytes, despite a recent claim that such heterotropic activation will not
be reproducible in monomeric systems [238].
Figure 5.6: Two CBZ molecules in active site of CYP3A4. (left) Snapshot showing a representative
configuration from system CBZ-2 in Fig. 5.5, in which Phe-213 is displaced from the active site. Phe-213,
Phe-241, and Phe-304 are shown as magenta sticks. (right) Schematic representation of the mechanism
of cooperativity elucidated from MD simulations.
The MD simulations reported in this study suggest a structural mechanism explaining
the experimentally observed synergy between PGS, found to bind between F–F’ and G–G’
helices, and activation of CBZ metabolism. As seen in Figure 5.2, PGS binding at this
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peripheral site results in the movement of the Phe-213 side chain out of the binding pocket
and a concomitant increase in the volume of the substrate binding cavity. Moreover, MD
simulation of two CBZ molecules inside the substrate binding pocket (Fig. 5.6) reveals the
same outward movement of Phe-213 to provide the necessary space for the second CBZ
molecule to bind. This striking similarity of conformational changes involving Phe-213
and its neighboring residues in response to PGS binding at the allosteric site and those
involved in accommodating two CBZ molecules inside the substrate binding cavity in a
productive position provides a possible molecular mechanism of allosteric communication
between the remote and productive binding sites in CYP3A4.
Results of MD simulations of PGS bound in the suggested allosteric remote site and
one or two CBZ molecules bound inside the substrate binding cavity of CYP3A4 provide
detailed insight into the possible conformational changes caused by these binding events.
These conformational changes involving the side chains of several phenylalanine residues
at the F–F’ and G–G’ loops are likely to give rise to the allosteric interactions between
PGS binding outside of the binding cavity and CBZ binding inside the substrate binding
pocket and explain the positive heterotropic cooperativity observed experimentally. Such
a mechanism is expected to manifest itself with other substrates metabolized by CYP3A4,
especially if their relative binding affinities with respect to the allosteric and productive
sites are significantly different. Moreover, a similar mechanism may also apply to other
membrane-bound eukaryotic cytochromes P450s, especially those with broad substrate
specificities, because of the general similarity of their protein folds [205, 260] and/or of
their positioning in the membrane [219], so that the F–F’ and G–G’ region is contacting
the membrane surface and forms a pocket potentially suitable for accommodation of
medium-sized hydrophobic molecules, such as endogenous steroids.
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Chapter 6
Membrane Interactions of
Cytochrome P450 2J2 (CYP2J2) ∗
6.1 Introduction
The cytochrome P450 (CYP) superfamily is a class of heme-containing enzymes that
are widespread throughout all kingdoms of life [262]. In humans, CYPs mediate the
biotransformation of both xenobiotics and endogenous substrates for homeostasis [263].
Eukaryotic CYPs interact with membrane bilayers through an N-terminal anchor as well
as various non-contiguous hydrophobic residues that constitute the monofacial membrane-
binding domain [187,264].
The CYP interaction with the membrane bilayer is a complex phenomenon that is
an active area of both experimental and computational research. While seminal stud-
ies correctly identified the general nature of the protein-membrane binding and topol-
ogy [185], more recent examples have elucidated the interactions at the molecular and
atomistic levels [164, 205, 219]. Notably, P450 interactions with membranes have been
shown to regulate ligand binding mechanisms [265], membrane depth of insertion [266],
∗This chapter appeared as a research article in Biochimica et Biophysica Acta – Biomembranes [261].
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redox potentials [267], enzyme stability [268], structure and orientation [164]. Addition-
ally, advanced computational approaches have revealed the dynamic nature of CYPs and
how their hydrophobic motifs interact with the membrane bilayer [164,219]. Both exper-
imental and computational approaches have revealed that CYPs are inserted within the
membrane, with a partially imbedded active site and deeply immersed N-terminus and
F-G loop [206,269].
CYP2J2 is an extrahepatic human CYP that catalyzes the epoxidation of both omega-
3 and omega-6 polyunsaturated fatty acids into a number of biologically active metabo-
lites [270]. Importantly, CYP2J2 is highly expressed in the myocardium and surrounding
aortic epithelium where it has been shown to be a key regulator of cardiovascular home-
ostasis [271]. The metabolism of arachidonic acid, an omega-6 polyunsaturated fatty acid,
by CYP2J2 produces 8 unique regio- and stereoisomers known as epoxyeicostrienoic acids
(EETs) that are collectively characterized as anti-inflammatory and vasodilatory lipid
mediators [272].
CYP2J2 is anchored within the endoplasmic reticulum [263]. The presence of the hy-
drophobic membrane binding domains of CYP2J2 complicates its use in many biochemical
assays due to its inherent tendency to aggregate outside of the membrane environment.
The disruption of the protein-membrane interactions affords solubility and enables struc-
tural elucidation through methods such as nuclear magnetic resonance (NMR) and high
resolution X-ray crystallography. Currently, there are no reports of the successful solu-
bilization and subsequent crystallization of any member of the CYP2J subfamily. How-
ever, this was achieved for other CYP2 family members including CYP2C5, CYP2A6,
CYP2C8, CYP2C9 and CYP2D6 [187, 273–276]. Specifically, soluble isozymes were en-
gineered through a combination of deletions and hydrophilic substitutions of targeted
membrane binding regions that resulted in increased expression yields and protein ho-
mogeneity. For example, the solubility of CYP2C5 was increased by substituting the
N-terminus (∆21) with MAKTSK, adding a four-residue histidine tag at the C-terminus
and incorporating five substitutions at the membrane binding interface with the muta-
tions N202H, R206E, I207L, S209G, and S210T [187]. Similarly, CYP2C9 N-terminal
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(∆29) residues were replaced by MAKKTSSKGR, a four-histidine carboxy-tag and the
seven amino acid mutations (K206E, I215V, C216Y, S220P, P221A, I222L and I223L)
in the F-G loop [273]. Soon after, CYP2D6 was successfully crystallized by truncating
the N-terminus, adding a four-histidine tag at the C-terminus and mutating the F-G loop
Leu-230 and Lue-231 with a combination of hydrophilic residues (Asn, Lys, His, Gln, Arg,
and Ser) [276]. Importantly, these changes afforded some of the first structural insights
of mammalian P450s through high resolution X-ray crystallography. However, membrane
dissociation while maintaining the native functional characteristics is an essential, yet
difficult step, in the field of CYP protein engineering.
Figure 6.1: Structure of CYP2J2. Representation
of the CYP2J2 ∆34 homology model. The stick
backbone of the heme is colored red, the F- and G-
helices are dark blue with the remaining P450 protein
fold and helices colored light blue. The two residues
selected for mutation (I236 and F239) in this study
are colored red on the F-G loop represented by cyan.
The truncation of the membrane-
spanning CYP N-terminus is the most
widely used strategy to disrupt protein-
membrane interactions [179, 274–277]. In-
deed, we previously demonstrated that the
complete truncation of the CYP2J2 N-
terminus results in a construct with signif-
icantly increased solubility. Importantly,
this truncated construct (∆34-CYP2J2)
exhibited similar substrate turnover rates
as the full length CYP2J2 construct in
model membranes [278]. Notably, ∆34
maintained its membrane insertion despite
the N-terminal truncation [278]. Accumu-
lating evidence suggests that the F-G loop
of CYPs (Fig. 6.1) is an essential mediator
of membrane binding [279]. Additionally, the F-G loop is positioned at the mouth of the
substrate access tunnels and is thought to control the rate of substrate access to the buried
active site [280]. Unlike the N-terminal motif, the non-conservative mutations within the
F-G loop region often results in significantly altered enzymatic activity [281]. Thus far,
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strategies have typically included random mutagenesis and substitution of alternative
CYP chimeras which are typically an exercise of trial-and-error [282].
In this study, we used molecular dynamics (MD) simulations in conjunction with ex-
perimental studies to evaluate the role of the F-G loop of CYP2J2 in membrane binding
and insertion. Previously, MD simulations have been used to study protein-membrane
interactions of membrane-bound CYPs [164,205–207,219,221]. Herein, we first employ a
highly mobile membrane-mimetic (HMMM) model [161] to capture spontaneous binding
of CYP2J2 to the membrane. The HMMM model employs short-tailed lipids while an
organic solvent replaces the hydrophobic core of the membrane, resulting in increased
lipid mobility. Due to the enhanced lipid mobility, the model accelerates the association
of proteins with the lipid bilayer, and has been successfully employed to capture mem-
brane binding of a variety of peripheral and membrane proteins including the GLA do-
main [161], cytochrome P450 3A4 [164], talin [73], α-synuclein [165], synaptotagmin [283],
and synaptobrevin [166]. This approach enabled us to capture atomic level interactions
between CYP2J2 and the membrane. Importantly, these interactions were preserved
when the short-tailed lipids were extended to a full POPC membrane. Secondly, after a
membrane-bound model of CYP2J2 was obtained, we studied the effect of F-G loop mu-
tations on membrane-binding and insertion depth, by taking advantage of the enhanced
lipid dynamics of the HMMM model.
To experimentally support the MD findings, hydrophilic residues were engineered in
the CYP2J2 F-G loop. Subsequent studies revealed the effects of the mutations on en-
zyme functionality, subcellular distribution and membrane binding characteristics. The
details of the relative depth of insertion were explored by measuring the mutants’ intrinsic
tryptophan fluorescence and energy transfer to pyrene phospholipids incorporated in lipid
bilayers.
Determining the degree of the Trp-pyrene fluorescence resonance energy transfer (FRET)
is a widely used method to probe the interaction of both peripheral and membrane pro-
teins with membrane bilayers. Previously, liposomal systems were used to measure the
Trp insertion of membrane proteins such as CYP3A4 [266] and CYP1A2 [284] as well as
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peripherally binding proteins such as cytochrome C [285] and 14-3-3 [286]. The use of
nanodiscs in this application offers several advantages over traditional liposomal systems.
Specifically, nanodiscs are nanoscale discoidal lipid bilayers that exhibit significantly en-
hanced stability and homogeneity relative to liposomal systems. Additionally, nanodiscs
are more easily concentrated without aggregation and lack the typical scattering effects
observed with liposomal systems [269,278,287].
Overall this work provides novel insights on the role of key residues in the CYP2J2 F-G
loop and their effects on membrane binding and functional metabolism. The use of MD
simulations provides high resolution interactions between the membrane and CYP2J2 F-
G loop. Experimentally, the introduction of hydrophilic residues in the F-G loop provides
essential functional data as well as an assay for membrane depth of insertion. Under-
standing the nuances of these interactions will enable new applications with CYP2J2 and
other membrane bound CYPs.
6.2 Methods
6.2.1 System Preparation
Preparation of HMMM Membrane. The HMMM membrane was constructed start-
ing from a solvated POPC membrane by shortening the lipid tails to only 5 carbons [161],
while the remaining carbon atoms were converted to 1,1-dichloroethane (DCLE). This
resulted in an HMMM membrane patch with two leaflets of short-tailed PC lipids at the
interface of water and DCLE, as described in detail elsewhere [161]. The solvated HMMM
membrane contained 137 short-tailed PC lipids in each leaflet and 1268 DCLE molecules,
yielding a system with ∼41,000 atoms. The solvated membrane mimetic system was en-
ergy minimized for 2000 steps and simulated for 1 ns using an NPnAT ensemble with
constant area, and with a target normal pressure and temperature of 1.0 atm and 310
K, respectively. A constant area of 10,281 A˚2 (101.4×101.4 A˚2) was employed, yielding
an area of 75 A˚2 per lipid (AL), about 8% higher than the experimental AL for POPC
membranes [211]. Based on our experience with other peripheral proteins, a mild increase
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in AL (5-8%) can significantly accelerate membrane binding [161, 165]. The resulting
membrane was employed in all subsequent binding simulations of wild-type CYP2J2 and
its mutants. To mimic the atomic distributions of a full lipid bilayer in the HMMM sim-
ulations more closely, a harmonic constraint along the z-axis (membrane normal) with a
force constant k = 0.05 kcal mol-1 A˚-2 was applied to the carbonyl carbon atoms of the
short-tailed PC lipids.
Initial Model of CYP2J2. A homology model of the catalytic domain of CYP2J2,
generously provided by Dr. D. Mansuy (Universite´ Rene´ Descartes, Paris France), was
employed as the starting structure of CYP2J2 for this study. The homology model was
derived using the available crystal structures of CYP2A6 (PDB: 1Z11), CYP2B4 (PDB:
2BDM), CYP2C5 (PDB: 1NR6), CYP2C8 (PDB: 1PQ2), and CYP2D6 (PDB: 2F9Q) as
templates, as previously described [288]. The sequence identity of the template structures
with CYP2J2 ranged from 41% to 45%. The individual sequence identity of each template
with CYP2J2 is as follows: CYP2A6: 42%; CYP2B4: 45%; CYP2C5: 41%; CYP2C8:
42%; CYP2D6: 42%. Initially, the CYP2J2 structure was relaxed by placing the enzyme
in a water box with dimensions of 90×90×90 A˚3, containing 20,000 water molecules,
generated with the SOLVATE plugin of VMD [289], and neutralized with 100 mM NaCl
ions using the AUTOIONIZE plugin. The system was then energy minimized for 2000
steps and simulated for 100 ps with the Cα atoms of the protein harmonically restrained
(k = 1 kcal mol-1 A˚-2), and followed by 100 ns run with no constraints. The resulting
structure of CYP2J2 was used as the initial structure for simulations.
Pyrene Phospholipid Partitioning in the Membrane. In order to gain a more
detailed description of the partitioning and orientation of pyrene molecules in a lipid
bilayer, we performed another set of MD simulations. A solvated POPC membrane con-
taining one pyrene phospholipid in each leaflet was constructed to study the dynamics
of pyrene in the membrane. A POPC molecule was employed as a template to generate
the pyrene-attached phospholipid, by removing carbons from the acyl tail and replacing
them by a pyrene moiety. The resulting system was then minimized for 1000 step and
simulated for 1 ns with the heavy atoms of the lipid head groups harmonically restrained
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(k = 1 kcal mol-1 A˚-2), except for the pyrene phospholipids. The step was then followed
by a 50 ns production simulation.
6.2.2 Simulation Systems
For the membrane-binding simulations, wild-type CYP2J2 was placed 10 A˚ above the
surface of the HMMM membrane with different initial orientations (50 ◦ and 80 ◦ with
respect to the z-axis). Three initial systems were prepared for simulation, two of which
started from the same initial orientation (80 ◦). The resulting structure was further sol-
vated using the SOLVATE plugin, and neutralized with 100 mM NaCl using the AU-
TOIONIZE plugin of VMD [290]. Each of the three resulting initial systems consisted
of a box with dimensions of 101.4×101.4×122.0 A˚3 and containing ∼120,000 atoms. The
systems were energy minimized for 2000 steps and relaxed further for 100 ps with the Cα
atoms of the protein harmonically restrained (k = 1 kcal mol-1 A˚-2), followed by 40 to 60 ns
of production simulation.
To study the effect of F-G loop mutations on membrane binding of CYP2J2, the
mutations I236D, F239H, and I236D/F239H were introduced in the last frame of each
membrane-binding simulation of the wild-type CYP2J2. This approach allowed us to
take advantage of the accelerated lipid dynamics to monitor changes in the membrane
insertion of CYP2J2 induced by the mutations. The Asp residue in the mutants was
modeled in its deprotonated (charged) form, while the His residue was modeled in its
neutral form, to match the expected charge of these side chains at pH 7.4. The resulting
systems were energy minimized for 1000 steps and relaxed further for 100 ps with the
Cα atoms of the protein, except for the mutated residues, harmonically restrained (k =
1 kcal mol-1 A˚-2), followed by 40 to 50 ns of production simulation.
The resulting models of membrane-bound CYP2J2 and its mutants in the HMMM
membrane were extended to a full POPC membrane, to perform additional simulations.
A membrane-bound model of the CYP2J2 for each case (wild-type and mutants) was
adopted from the last frames of one of the HMMM membrane-binding simulations de-
scribed above. The short-tailed lipid bilayer was transformed into a POPC bilayer by
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removing the DCLE molecules and adding the missing carbons of the lipid tails. The
positions of the added lipid tail atoms were refined based on the coordinates of randomly
selected lipid molecules obtained from a POPC bilayer equilibrated separately. During
these steps, the positions of the lipid atoms already present in the HMMM membrane
(headgroups and the initial five carbons of the lipid tails) were preserved, maintaining the
original contacts established between the lipids and CYP2J2 during the HMMM simula-
tions. The resulting POPC-bound CYP2J2 systems were then minimized for 2000 steps
and equilibrated for 100 ps while restraining all the protein and short-tailed lipids atoms
with a force constant k = 1 kcal mol-1 A˚-2 to allow relaxation of the newly added lipid tail
atoms. Following this step, the resulting wild-type and mutants systems were simulated
without restraints for 70 to 100 ns.
All simulations were performed with NAMD2 [127] using the CHARMM27 [119] force
field with cMAP corrections for the protein and CHARMM36 [113] for lipids. Parameters
of the pyrene-attached phospholipid were derived by analogy from the CHARMM General
Force Field [121,122]. The TIP3P model was used for water [120]. The NPnAT ensemble
at 1.0 atm and 310 K, with a constant area of 10,281 A˚2 (101.4×101.4 A˚2), was employed
for all HMMM simulations. The POPC systems were simulated as an NPT ensemble
at the same pressure and temperature. All simulations were performed with a time
step of 2 fs. Constant pressure was maintained by the Nose´-Hoover Langevin piston
method [250,251] and constant temperature was maintained by Langevin dynamics with
a damping coefficient γ of 0.5 ps-1 applied to all atoms. A cutoff of 12 A˚ was used for
nonbonded interactions, with a smoothing function applied after 10 A˚. The particle mesh
Ewald (PME) method [126] was used for long-range electrostatic calculations with a grid
density greater than 1 A˚−3.
6.2.3 Summary of Experimental Methods
Our experimental collaborators, the Aditi Das Lab (UIUC), expressed wild-type and mu-
tant CYP2J2 proteins, purified, and reconstructed them into the Nanodiscs. They also
performed substrate metabolism assays, and steady state fluorescence titration experi-
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ments, using quenching of CYP2J2 intrinsic tryptophan fluorescence. For details of the
experimental methods, see reference [261].
6.3 Results and Discussion
6.3.1 Membrane-Bound Form of CYP2J2
Figure 6.2: Membrane–bound form of CYP2J2. (Top) Membrane binding of CYP2J2 captured with
the HMMM membrane in 40 ns. The membrane-bound model of CYP2J2 was extended to a POPC
membrane and simulated for another 100 ns. The stick backbone of the heme is colored red, the F- and
G-helices are blue with the remaining P450 colored light blue. Lipids are shown in stick representation.
(Bottom) Residues Trp-48, Trp-235, Ile-236 and Phe-239, identified to interact with the membrane upon
binding, are shown in stick representation.
In order to generate a membrane-bound model of CYP2J2 which would allow us to
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better understand the key lipidprotein interactions involved in membrane binding of the
protein, we performed three independent MD simulations between 40 and 60 ns, starting
with the ∆34-CYP2J2 placed above a phosphatidyl choline (PC) HMMM lipid bilayer.
The aim was to capture the spontaneous membrane binding and insertion of the protein
into lipid bilayer in unbiased simulations. Owing to the enhanced lipid dynamics of the
membrane model, spontaneous membrane binding of the catalytic domain of CYP2J2 was
consistently observed during these simulations (Fig. 6.2). The analysis of the three result-
ing simulations reveals a similar behavior in terms of depth of insertion and orientation
in the membrane of CYP2J2 (Fig. 6.3). The resulting binding pose of CYP2J2 suggests
that the enzyme can interact with the membrane through hydrophobic residues located
in the F-G loop region, in particular residues Trp-235, Ille-236 and Phe-239. During
the simulations, these side chains were observed to insert in the membrane (i.e., posi-
tioning below the reference plane defined by the PO4 level) (Fig. 6.3). The N-terminal
loop formed containing residue Trp-48 is also observed to insert into the membrane after
binding (Fig. 6.3).
Starting from the HMMM membrane-bound models of CYP2J2, the short-tailed lipids
(with five carbons in each tail) were extended to full POPC lipids, resulting in a model
of CYP2J2 bound to a POPC membrane as shown in Fig. 6.2. The extended model
simulation shows that the main interactions observed in the HMMM model are preserved,
and Trp-48, as well as residues Trp-235, Ile-236 and Phe-239 located in the F-G loop
remain inserted in the membrane (inserted below the PO4 level). In order to test the
convergence of the membrane-bound models of CYP2J2, we characterized the orientation
that the enzyme with respect to the lipid bilayer by calculating the heme tilt angle, defined
as the angle between the heme plane (defined as the plane containing the four porphyrin
nitrogen atoms) and membrane normal (z-axis). In the three extended POPC simulations,
the heme tilt angle converges to values ∼ 50◦, suggesting a convergent membrane-bound
pose for CYP2J2. The orientation that CYP2J2 adopts in the membrane is similar to
that reported for other membrane-bound CYPs, measured both from experiments and
from simulations, which are reported to be around 60 to 70◦ [6] and [57].
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Figure 6.3: Insertion of CYP2J2 into membrane. Time series of the center of mass (COM) z-coordinate
of the side chains Trp-48, Trp-235, Ile-236 and Phe-239, and of the heme tilt angle of CYP2J2 for the
HMMM and POPC membranes. Data was collected from the three independent simulations performed.
A side chain is assumed to insert into the membrane when its COM z-position is below the reference
plane defined by the COM z-position of the PO4. The black dashed lines indicate the time allowed for
the grown POPC membrane to relax. The positions of the phosphorous (PO4) and nitrogen (choline)
atoms of the lipids are show in brown and gray, respectively. The red dashed line indicates the average
for the heme tilt angle in the POPC membrane.
6.3.2 Pyrene Partitioning in the Membrane
We performed experiments to evaluate the interaction of the mutated CYP2J2 proteins
with membranes by measuring the Trp quenching by pyrene phospholipids inserted into
the homogeneous lipid bilayer. Therefore, in order to identify potential interactions be-
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Figure 6.4: Membrane insertion of pyrene–incorporated POPC lipids.. Distribution of the z-coordinate
of pyrene molecules attached to phospholipids and of the Trp-48 and Trp-235 side chains, obtained from
separate simulations. The dashed brown lines indicate the distribution of the z-coordinate PO4 group of
each leaflet. The location of pyrene and Trp side chains in the simulation is also shown.
tween a pyrene molecule attached to a phospholipid and the membrane-bound CYP2J2,
we performed a separate simulation of a POPC membrane containing a single pyrene
phospholipid in each leaflet for 50 ns in the absence of CYP2J2. The goal was to charac-
terize the distribution of the pyrene molecules within the lipid bilayer and use it to infer
information on the potential interaction of the side chains of CYP2J2 with pyrene upon
membrane binding based on the location of this moiety in the membrane. The distribu-
tion of the z-position for each molecule revealed that the pyrene moiety is located mainly
in the hydrophobic core of the membrane, below the phosphate groups (Fig. 6.4). Despite
being attached to their respective phospholipid tail, pyrene molecules are able to sample a
wide range of insertion depth within the hydrophobic core of the membrane, as indicated
by their wide z-position distributions. Interestingly, the insertion depth of CYP2J2 in the
POPC membrane would allow for the side chains of Trp-48 and Trp-235 to interact with
the pyrene moiety located in the PYR-ND, as indicated by their z-position distributions
(Fig. 6.4). The distribution of the z-position of each side chain shows that they both
insert to a similar level around the PO4 level, with Trp-235 slightly more inserted than
Trp-48. Therefore using PYR-ND one can delineate the membrane interactions of the
CYP2J2 mutants with the lipid bilayer using experimental approaches as described later.
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6.3.3 CYP2J2 Construct Design
The initial structural analysis and MD simulations suggested two hydrophobic residues
in the F-G loop, Ile-236 and Phe-239, as putative membrane anchors (Figs. 6.2 and 6.3).
These sites were mutated to hydrophilic residues with the aim of altering membrane-
binding characteristics by decreasing the overall hydrophobicity of this region. To this
end, two single mutations, I236D (∆34-I236D) and F239H (∆34-F239H), as well as a con-
struct containing both I236D and F239H (∆34-double) were designed. Apart from the N-
terminal anchor, the CYP F-G loop has been hypothesized to be the primary membrane-
binding motif. This assumption is further supported by the observation that the greatest
structural differences between the soluble prokaryotic CYPs and the membrane bound
mammalian CYPs are found in the F and G helices and the F-G loop [?]. Notably,
CYP2D6 was successfully solubilized and crystallized by truncating the N-terminus and
mutating the F-G loop Leu-230 and Leu-231 with a combination of hydrophilic residues
that included I230D and I231R [276]. Following a similar design strategy we mutated
Ile-236 and Phe-239 to hydrophilic residues to examine the effects on solubility and func-
tionality. Additionally, the close proximity of the naturally occurring Trp-235 to the
mutated sites enabled membrane-binding studies using fluorescence spectroscopy.
6.3.4 Membrane Binding Modes of the F-G Loop Mutants
We studied the effect of these specific F-G loop mutations on membrane binding of
CYP2J2 by introducing the mutations in the membrane-bound models obtained from
MD simulations. To achieve this, we used the final snapshot of each of the three HMMM
membrane-binding simulations, introduced the mutations and performed production sim-
ulations on the system. This approach allowed us to monitor changes in the membrane
insertion depth of the protein due to mutations in the F-G loop. Single mutations ∆34-
I236D and ∆34-F239H, as well as double mutation ∆34-double were introduced in the
membrane-bound CYP2J2, resulting in 3 models for each mutant, which were simulated
individually between 40 and 50 ns.
The results of these simulations show that the mutations affect the insertion of the
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Figure 6.5: Effect of F-G loop mutations in membrane-binding of CYP2J2. (Top) Time series of
the COM z-position of side chains Trp-48, Trp-235, Ile-236 and Phe-239 for the HMMM and POPC
membranes shown for I236D/F239H, I236D, and F239H mutants. For each case, the HMMM simulations
were extended to a POPC membrane and simulated 80 ns. The black dashed lines indicate the time
allowed for the extended POPC membrane to relax after conversion from HMMM. The positions of the
phosphorous (PO4) and nitrogen (choline) atoms of the lipids are show in brown and gray, respectively.
(Bottom) Average relative position of the COM z-coordinate of the side chains forming the F-G loop
(residues 225 to 240) with respect to the reference plane defined by the COM z-position of the PO4. The
average was taken from the last 20 ns of simulations for each case. The error bars represent one standard
deviation
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F-G loop to various degrees (Fig. 6.5). The I236D mutation promotes the detachment of
Trp-235 from the membrane. In the cases were this mutation is introduced (I236D and
1236D/F239H), Trp-235 moves from a fully inserted position to an average position that
is above the PO4 and choline levels, with occasional detachment of the residue from the
membrane (Fig. 6.5, Double and I236D). In both cases, the position of Trp-235 side chain
(above the phosphate level) is maintained upon the conversion of the HMMM membrane
with short-tail lipids to a full POPC membrane (Fig. 6.5, Double and I236D). In the POPC
membrane, the average position of Trp-235 resulting from the I236D mutation is between
5 and 10 A˚ above the reference PO4 plane (Fig 6.5, bottom). The F239H mutation, on
the other hand, seems to have a smaller effect on Trp-235 insertion, causing only transient
detachment of Trp-235 both in the short-tail lipid membrane and in the POPC membrane
(Fig. 6.5, F239H), resulting on an average relative position that is close to the Trp-235
insertion in the wild type case (Fig 6.5, bottom). Taken together, the simulations indicate
that introducing mutations in the F-G loop results in a shallower membrane insertion of
Trp-235 in the F-G loop when compared to the wild-type simulations. As discussed later,
this was corroborated by an increased percentage of the mutants in the cytosolic fraction
and fluorescence experiments where we measured CYP2J2 Trp quenching by membranes
containing pyrene lipids.
6.3.5 Membrane Insertion of CYP2J2 Into Pyrene Nanodiscs
To investigate the CYP2J2 constructs’ insertion in the membrane bilayer, the relative
Trp quenching energy transfer between the protein monofacial Trp residues and pyrene
phospholipids was measured. To this end, nanodiscs with pyrene phospholipids (PYR-
ND) were prepared. As shown in Fig. 6.4, the Trp residues of the CYP2J2 membrane
binding region are predicted to interact with pyrene phospholipids incorporated in the
membrane bilayer. Using a POPC/PYR-PC molar ratio of 64:1 the expected PYR-PC
was 1 pyrene molecule per nanodisc leaflet. Previously, pyrene-containing liposomes have
been successfully employed to characterize membrane insertion properties of peripheral
and integral CYP proteins [266,285,291]. Here the use of PYR-ND as a new iteration of
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Figure 6.6: Effect of F-G loop mutations in membrane-binding of CYP2J2. (Left) Trp fluorescence
signals of CYP2J2 constructs were monitored in the presence of empty nanodiscs (Fo) and presence of
PYR-ND (F) to calculate F/Fo. The F/Fo was measured using PYR-ND containing POPS/POPC molar
ratios of 0:100, 30:70 and 60:40. (Right) The effect of 0.5 M NaCl on F/Fo ratio was measured for each
CYP2J2 F-G loop mutant using 60 mol% POPS PYR-ND.
this method is demonstrated.
As previously discussed, MD simulations revealed that the pyrene moiety can sam-
ple a wide range of orientations just under the phospholipid heads in the membrane
core (Fig. 6.4). Upon insertion into the membrane bilayer the two residues, Trp48 and
Trp235, were shown to interact with pyrene. Thus, in the presence of saturating con-
centrations of PYR-ND, the experiment is a measure of membrane depth of insertion of
these fluorophores. Using the PYR-ND system we examined the relative quenching of
Trp fluorescence (F/Fo) as a function of both the mol% of anionic phospholipids (POPS)
and the absence/presence of 0.5 M NaCl. The rationale of these two conditions used is
explained below.
The presence of anionic lipids is known to induce both CYP conformational shifts as
well as increased penetration into membrane bilayers [266,292]. Thus, we further examined
the membrane insertion properties (relative F/Fo changes) of CYP2J2 when anionic lipids
(POPS) were incorporated into the bilayers of nanodiscs (Fig. 4D). In the absence of
anionic lipids, the differences among the CYP2J2 mutants F/Fo are subtle (Fig. 6.6).
Specifically, ∆34, ∆34-I236D, ∆34-F239H and ∆34-double exhibited average F/Fo ratios
of 0.82± 0.02, 0.848± 0.01, 0.845± 0.04 and 0.89± 0.01, respectively. These results suggest
that the F-G loop mutants are oriented in a way that the Trp residues are not as deeply
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imbedded, consistent with the MD results. When mol% of POPS was substituted at the
expense of POPC (from 30 to 60 mol%), greatly enhanced differences among the F-G loop
mutants and the ∆34 construct were observed. Thus, using a high percentage of anionic
lipids we were able to affect the greatest changes between the ∆34 construct and the F-G
loop mutants. The different membrane binding interactions induced by the presence of
anionic lipids suggest that the hydrophobicity and charge of the F-G loop is important for
POPS mediated depth of insertion. Specifically, these differences support the assumption
that the enzyme topology is altered when the F-G loop is mutated with these hydrophilic
residues. This conclusion is supported by the MD data that demonstrate these residues
are putative membrane anchors and hydrophilic mutations detach this region from the
leaflet.
To further explore the nature of the membrane depth of insertion, we examined the
effect of a high concentration of NaCl on the F/Fo ratio when the 60 mol% POPS PYR-
ND was employed to achieve the maximum membrane interaction of CYP2J2 (Fig. 6.6).
Importantly, high salt concentrations effectively solubilize membrane proteins, altering
their nature from an irreversibly membrane bound protein to a state of protein that can
bind and dissociate in a peripheral manner [187]. This effect was observed when the ∆34G
construct was examined, with a decrease in the Trp quenching (F/Fo) from 0.52 to 0.71,
for the no salt buffer to 0.5 M NaCl buffer, respectively. Surprisingly, the presence of a
high concentration of NaCl had little effect on the extent of Trp quenching for the F-G
loop mutants which demonstrates the membrane insertion depth is maintained despite
the high salt concentration.
6.4 Summary
In this work, we demonstrate that the CYP2J2 F-G loop region is an important protein-
membrane interface that controls membrane insertion and substrate metabolism char-
acteristics. The HMMM model simulations revealed that CYP2J2 interacts at the F-G
loop through the Trp-235, Ille-236 and Phe-239 residues. Importantly, these binding in-
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teractions and the protein orientation were preserved in the MD simulations when the
short-tailed lipids were extended to POPC lipids. The effects of mutating the putative
membrane anchors Ile-236 and Phe-239 with hydrophilic residues were also examined.
These mutations significantly decrease the F-G loop depth of insertion when used in MD
simulations. To experimentally corroborate these findings, four CYP2J2 constructs (∆34,
∆34-I236D, ∆34-F239H and ∆34-double) were expressed in E. coli. Notably, the F-G
loop mutant expression yields derived from the membrane fraction were substantially de-
creased and the protein was localized to the cytosolic fraction to a greater extent. While
all constructs demonstrated sufficient P450 content and stability we observed significant
differences in their functional metabolism. Wild-type activity was restored through the in-
troduction of a double mutation F239H and I236D. Thus, we experimentally demonstrate
that the insertion of CYP2J2 into the membrane bilayers of PYR-ND is influenced by the
overall hydrophobicity of the F-G loop. The relative membrane binding characteristics
were experimentally derived by monitoring CYP2J2 Trp quenching after insertion into
the membrane bilayers of PYR-ND. The N-terminal truncated construct ∆34-CYP2J2
exhibited membrane binding to a greater extent than the F-G loop mutants (∆34-I236D
and ∆34-F239H) suggesting a different enzyme topology in agreement with the MD sim-
ulations.
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Chapter 7
Characterizing Fatty Acid Binding
in Membrane-Bound CYP2J2 ∗
7.1 Introduction
The omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) are converted to lipid
metabolites that are involved in various signaling processes mediating cardiovascular dis-
eases, cancer, and inflammation. [293, 294] These fatty acids (FAs) are metabolized by
three principle enzyme classes, namely the cyclooxygenase (COX), lipoxygenase (LOX),
and cytochrome P450 (CYP) epoxygenase classes. For instance, arachidonic acid (AA)
is the primary omega-6 PUFA that is metabolized by COX or LOX enzymes into gen-
erally pro-inflammatory prostaglandins and leukotrienes, respectively, which part of the
20-carbon lipid metabolite class known as eicosanoids. [272, 295] AA eicosanoids are im-
plicated in many diseases, including inflammation [296–298] and cancer. [296,299,300]
CYP epoxygenases belong to the hemoprotein superfamily of CYPs that have long
been studied for their monooxidative mechanisms regarding xenobiotic metabolisms and
steroid biosynthesis. Recently, some of these enzymes have been recognized in compris-
∗This chapter has been submitted as a research article to Biochemistry. William R. Arnold, Javier
L. Baylon, Emad Tajkhorshid, and Aditi Das, “Docosahexaenoic Acid (DHA) Preferentially Binds to
Cardiovascular CYP2J2 and Inhibits Arachidonic Acid (AA) Metabolism”. Submitted to Biochemistry,
2016.
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ing the third branch of PUFA metabolisms. Moreover, the CYP-mediated metabolism
of omega-3 and omega-6 PUFAs have gained scientific interest due their implications
in cardiovascular health. [293, 301–306] It was demonstrated that dietary omega-3 and
omega-6 fatty acids modulate the eicosanoid profile in humans primarily via the CYP-
epoxygenase pathway. [307] These enzymes metabolize PUFAs to generate mostly epox-
ides [270,307–312] (Fig. 7.1) that, in contrast to the pro-inflammatory prostaglandins and
leukotrienes, are generally anti-inflammatory in nature. The primary CYP epoxygenase
in the human cardiomyocytes is CYP2J2. [313] CYP2J2 epoxidizes AA into four anti-
inflammatory epoxyeicosatrienoic acids (EETs) [270,309,313] and hydroxylates it to two
hydroxyeicosatetraenoic acids (HETEs) [270,272,314] (Fig. 7.2).
Figure 7.1: Structures and names of fatty acids used in this study. [carbon lenght : degree of unsat-
uration (omega-3 or -6)]. Abbreviations given at the end. Metabolite structures and names also given.
Numbering refers to the positions of the other regioisomers of epoxide and hydroxides.
In addition to demonstrating anti-inflammatory activity, EETs are pro-angiogenic,
pro-fibrylogenic, mediate cellular proliferation and vascular tone, and have been impli-
cated in cancer tumorigenesis. [295, 296, 308, 310, 315–319] CYP2J2 has also been shown
to epoxidize another omega-6 PUFA, linoleic acid (LA), into two epoxyoctadecenoic acids
(EpOMEs) [320] It also metabolizes the omega-3 fatty acids eicosapentaenoic acid (EPA)
into epoxyeicosatetraenoic acids (EEQs) and hydroxyeicosapentaenoic acids (HEPEs) and
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Figure 7.2: Metabolism of AA by CYP2J2 in the presence of other lipids. Schematic showing CYP2J2
and its redox partner CPR incorporated into Nanodiscs metabolizing AA into epoxyeicosatrienoic acids
(EETs) and hydroxyeicosatetraenoic acids (HETEs).
docosahexaenoic acid (DHA) into epoxydocosapentaenoic acids (EDPs) and hydroxydo-
cosahexaenoic acids (HDHEs) [270, 321] These omega-3 epoxide metabolites have been
shown to be more potently anti-inflammatory and cardioprotective as compared to their
AA-derived counterparts, EETs [307, 322, 323] They have also been shown to be anti-
tumorigenic, in contrast to EETs. [296, 324, 325] Therefore, the EPA and DHA epoxides
have different and generally more beneficial physiological properties as compared to AA
epoxides.
Of interest is how these PUFAs interact and influence each others metabolisms, consid-
ering their opposing roles regarding inflammation. It has been shown that the metabolism
of omega-6 fatty acids by COX and LOX is often inhibited by the presence of omega-3
fatty acids, [326–328] owing to their structural similarity and subsequent similar binding
of these two classes of PUFAs. [329,330] Despite numerous physiological studies establish-
ing their biological importance, the biochemistry of CYP-epoxygenases interacting with
omega-3 and omega-6 fatty acids is largely unknown. CYPs offer a unique platform by
which substrate-substrate interactions may arise, insofar as they generally possess a large
and promiscuous active site leading to drug-drug interactions. [188, 331–333] In the case
of CYP2J2, therefore, it becomes imperative to establish the kinetics of PUFA-PUFA
interactions at the biochemical level, which can potentially be complex. The difficulty in
measuring CYP kinetics is compounded, partly, by the inherent difficulties of studying the
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molecular-structural interactions due to a lack of crystallographic data. [334] Furthermore,
this difficulty is increased with the inherent difficulty in measuring PUFA kinetics in an
aqueous environment. Whereas certain soluble CYPs, such as the bacterial CYP102A1
(BM3), can metabolize PUFAs with high turnover rates, [335–337] AA metabolism by
mammalian CYPs and especially CYP2J2 is rather slow. [270,338,339]
Herein, we have performed detailed kinetic analyses to determine what effect various
fatty acids have on AA metabolism by CYP2J2. We use the nanodisc (ND) system to sta-
bilize CYP2J2 and its redox partner cytochrome P450 reductase (CPR). [340] Nanodiscs
are nanoscale lipid bilayers that have been used extensively to stabilize various types of
membrane proteins in aqueous solutions. [261, 278, 287, 341–344] Furthermore, we utilize
a combined approach of molecular dynamic (MD) simulations and molecular docking to
predict key residues that mediate the tight binding of the PUFAs to the active site of
CYP2J2. By monitoring the dynamics of PUFA binding to the active site of CYP2J2,
we are given insights into the conformational fluidity and constraints of the PUFAs in
the active site that may affect enzymatic activity. [334, 345, 346] Combining these two
computational methodologies allows us to account for transient changes in the active site
captured in our previous CYP2J2 simulation that might affect substrate binding. [261]
Using CYP2J2-NDs, we firstly determined the metabolism of AA in the presence of DHA,
LA, and EPA. We found that DHA is strongly inhibitory towards AA metabolism and LA
and EPA are moderately inhibitory. Using global fit analyses, we determine that these
PUFAs competitively inhibit each others metabolism. The competitive model signifies
that high amounts of AA can override our measured fourfold greater inhibition by DHA
and promote AA metabolism over the more beneficial DHA or EPA metabolism. Using
titration binding experiments, competitive binding assays, and stopped-flow cyanide bind-
ing kinetics, we determined that the inhibition is most likely due to differential binding
of these PUFAs to the active site of membrane-bound CYP2J2. Our combined dock-
ing and MD simulations approach reveals distinct binding conformations adopted by the
PUFAs. Although PUFAs present similar conformations and binding interactions in the
active site, the MD simulations show that DHA preferentially interacts with a triad of
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residues located in the vicinity of the active site. As a result, DHA is locked in a con-
formation that would increase productive heme interactions, which can help to explain
the observed experimental data. Overall, our studies report that not only which omega-3
class of PUFAs we consume but also the individual PUFAs, such EPA and DHA, will
have differential preference for metabolism by CYP2J2. We also show that the active site
of CYP2J2 has selectivity towards DHA which is supported both by experimental data
and MD simulations.
7.2 Methods
7.2.1 System Preparation
Molecular docking of AA, DHA and EPA using AutoDock Vina [347] was employed to
probe its binding to CYP2J2. We employed our previously obtained 100 ns MD simulation
of POPC membrane-bound CYP2J2 [261] to include a large number of snapshots in the
docking. This allows taking into the account the dynamics of the protein in the presence
of the membrane and probing putative binding sites that are only transiently present
during the simulation. Snapshots of membrane-bound CYP2J2 were taken from the MD
trajectory at 100 ps intervals, resulting in 1000 different snapshots used for AA, EPA
and DHA docking. A grid box with dimensions 22.5 A˚ in the x, y and z directions and
with center in the active site of CYP2J2 was employed. For each ligand (AA, EPA or
DHA), the top 10 docking poses for each snapshot were collected for further analysis,
resulting in 10000 docked poses for each fatty acid. The resulting docked structures were
then clustered by RMSD of the heavy atoms, with a maximal value distance between two
poses of 4.0 A˚. This approach identified four main conformations of the fatty acids in the
active site. For each cluster, further filtering was performed on the basis of the distance of
the carbons involved in the in the formation of the major epoxide experimentally observed
(i.e., carbons 14,15 in AA; 17,18 in EPA and 19,20 in DHA, as shown in Fig. ??) and the
heme iron, with a cutoff distance of 6 A˚, as well as docking score.
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7.2.2 Simulation Systems
For each cluster, the docked pose within the cutoff distance with the best docking score
was selected as the initial structure for simulations, resulting in four initial conforma-
tions for each ligand. The resulting membrane-bound protein-ligand systems were min-
imized for 1000 steps and equilibrated for 100 ps while the heavy atoms of the protein
backbone and the ligand were harmonically restrained (k = 1 kcal mol-1 A˚-2), then fol-
lowed by unrestrained, production simulations for 100 ns for clusters 1,2 and 3, and 200 ns
for cluster 4 for each fatty acid. MD simulations were performed using NAMD2, [127]
utilizing the CHARMM36 force field with cMAP [119] corrections for the protein and
CHARMM36 [113] for lipids. Parameters for AA. EPA and DHA were derived by anal-
ogy from the CHARMM General Force Field [113], employing DHA parameters previously
derived [348]. The TIP3P model was used for water. [120] All simulations were performed
as an NPT ensemble at 1.0 atm and 310 K, with a time step of 2 fs. Constant pressure was
maintained using the Nose´-Hoover Langevin piston method, [250,251] and constant tem-
perature was maintained by Langevin dynamics with a damping coefficient γ of 0.5 ps-1
applied to all atoms. Nonbonded interactions were cut off after 12 A˚ with a smoothing
function applied after 10 A˚. Bond distances involving hydrogen atoms were constrained
using the SHAKE algorithm. [252] The particle mesh Ewald (PME) method [126] was
used for long-range electrostatic calculations with a grid density of > 1 A˚-3.
7.2.3 Specific Analysis
To identify key CYP2J2 residues interacting with the fatty acids (AA, EPA or DHA),
interaction energies were calculated for each simulation employing a generalized implicit
solvation approach [225].
7.2.4 Summary of Experimental Methods
Our collaborators at the Das Lab (UIUC) performed titration binding experiments, com-
petitive binding assays, and stopped-flow cyanide binding kinetics of CYP2J2 incorpo-
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rated to nanodiscs, employing AA, LA, DHA and EPA as substrates of CYP2J2.
7.3 Results and Discussion
7.3.1 Inhibition Model to Describe the Metabolism of AA by
CYP2J2 in the Presence of DHA
To determine PUFA-PUFA interactions, mixed-substrate kinetics were performed where
the metabolism of AA was measured in the presence of low concentrations (15 µM) and
high concentrations (50 µM) of either DHA or EPA. Since the metabolites of AA with
DHA, EPA, or LA were analyzed, the inhibition of each PUFA within the pair can be
analyzed, depending on which PUFA we treat as the inhibitor. When looking at the
metabolism of AA in the presence of DHA, we are therefore treating DHA as the inhibitor
and AA as the substrate.
In order to accurately determine the mode of inhibition of these PUFAs on AA
metabolism, the data were fitted to the mixed inhibition equation,
v =
Vmax[S]
Km(1 +
[I]
Kii
) + [S](1 + [I]
Kii′
(7.1)
where v is the rate of product formation, Vmax is the maximum rate, [S] is the sub-
strate concentration, Km is the Michaelis-Menten steady-state equilibrium constant, [I]
is the concentration of the inhibitor and Kii and Kii′ are the binding affinities of the in-
hibitor to the substrate-free and substrate-bound states of the enzyme, respectively [349].
This formula can collapse onto competitive, uncompetitive, and noncompetitive models
depending on the values for Kii and Kii′ . If Kii and Kii′ return definite values, then the
inhibition is mixed. Noncompetitive inhibition is a special case of mixed, in which Kii =
Kii′ . If either Kii or Kii′ return infinitely high values, then the inhibitor essentially has
no affinity for the substrate-free and bound forms, respectively.
Figure 7.3 shows the fitting of the data with the concentration of AA in the presence
of DHA. The data can be analyzed individually for each amount of inhibitor. Analyzing
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Figure 7.3: AA and DHA mixed kinetics. (Left) 3D plot of AA metabolism in the presence of DHA. Here,
DHA is treated as the inhibitor and its effects on AA calculated. (Right) 3D plot of DHA metabolism in
the presence of AA. Here, AA is treated as the inhibitor in the calculations. Total metabolite formation
and was fitted to the mixed inhibition equation (Eq. 7.1) taken as a concentration of all species. Rates
are in units of pmolproducts min
-1 nmolCYP2J2
-1. Error bars represent ± SEM.
the data as a function of both the concentrations of AA and DHA provides a global (3D)
analysis of all the data. This determines the effect of DHA over a concentration range
and provides a better fit of the data, utilizing all 15 data points. For the 3D analysis,
the concentration of AA is plotted on the x-axis, the concentration of DHA on the z-axis,
and the rate of AA metabolism on the y-axis. The 3D analysis returned an inhibitor
binding affinity Kii of 16.5± 2.2µM, with an infinitely high value for Kii′ , indicating a
competitive model (Table 7.1).
Similar analyses were performed to determine the inhibition of DHA by AA under the
same conditions (Fig. 7.3 and Table 7.1). Here, AA is treated as the inhibitor and the
rate of DHA metabolism plotted on the y-axis. The 3D fit for the inhibition of DHA by
AA returned a binding affinity 65.2± 15.8µM, a value fourfold higher than the binding
affinity for inhibition of AA by DHA. This indicates that AA is a weaker competitive
inhibitor of DHA.
Similar analyses were also performed on AA/LA and AA/EPA (Table 7.1). The 3D
analysis gives binding affinities of 260± 157µM and 46.4± 9.9µM for EPA and LA, re-
spectively, indicatting that these PUFAs are also competitive inhibitors of AA, albeit
much weaker thatn DHA. Overall from these detailed kinetic analysis, we infer that al-
though DHA, LA, EPA and AA are structurally similar, DHA bears the strongest inhibi-
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Table 7.1: 3D mixed-inhibition fits of AA/DHA, AA/EPA, and AA/LA. Kinetic experiments were
performed in varying concentration of each substrate, and the metabolites of AA, DHA, EPA, and LA
were analyzed. Each analyte was treated as either a substrate or inhibitor for each fit and Kii and Kii′
represent the binding affinity of the inhibitor for the substrate-free and substrate-bound state of CYP2J2,
respectively. The inhibition model was determined from the value of each parameter. Error represents
the error of the fits.
AA as a Substrate
Inhibitor Kii Kii′ Inhbition Model
DHA 16.5± 2.2 ∞ Competitive
EPA 260.5± 157 ∞ Competitive
LA 46.4± 9.9 ∞ Competitive
AA as a Inhibitor
Inhibitor Kii Kii′ Inhbition Model
DHA 65.2± 15.8 ∞ Competitive
EPA ∞ ∞ None
LA 78.4± 31.9 ∞ Competitive
tion towards AA metabolism while LA and EPA moderately inhibit AA metabolism by
CYP2J2.
7.3.2 Binding of Fatty Acids to CYP2J2
To understand the atomistic details of fatty acid binding to CYP2J2, we employed a
combined approach of molecular docking and MD simulations, as described in Methods.
Since the bound form of the fatty acids is not known, we employed different initial con-
formations of AA, EPA and DHA in the active site of CYP2J2 in POPC membranes,
obtained from molecular docking, as initial seeds to perform MD simulations. The ini-
tial conformations were selected from four identified clusters of conformations of docked
poses resulting from ensemble molecular docking (Fig. 7.4). For each cluster, a starting
conformation was selected based on the minimum distance of the carbons involved in the
formation of the major epoxidation product as shown in Figure 7.1 (carbons 14,15 in AA;
17,18 in EPA and 19,20 in DHA) to the heme and the best docking score.
Cluster analysis of the resulting docking poses revealed that AA, EPA and DHA
similarly adopt two major orientations in the active site of CYP2J2 (Fig. 7.4). The main
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Figure 7.4: Conformation of AA, EPA, and DHA in the active site of CYP2J2. (Top) Representative
conformations of the four identified clusters identified from molecular docking of AA, DHA and EPA.
These conformations were employed as starting points for subsequent MD simulations. In each case, the
ligand and the heme are shown in stick representation. The side-chain of residues interacting with the
fatty acid during the simulations based on the interaction energies (Tables 7.2 and 7.3) are also shown in
stick representation. (Bottom) Distribution of distances between epoxidation sites of AA, DHA and EPA
to the iron atom of the heme, obtained from MD simulations. For each fatty acid, data was obtained
from 100 ns simulations for cluster 1,2 and 3, and 200 ns simulations for cluster 4.
difference between the two orientations is the location of the fatty acid carboxyl group
within the active site. For clusters 1, 2 and 3, the fatty acids are extended along the
active site cavity, and the carboxyl group is pointing towards the F-G loop of the protein,
formed by residues 224 to 240. In the simulations that started from these positions,
the fatty acids adopt similar conformations, maintaining their overall orientation during
the simulations. In contrast, in cluster 4 the carboxyl group is located close to helix I,
composed of residues 297 to 330 (Fig. 7.4), adopting a significantly different orientation
and position compared to the three other clusters during simulation.
For DHA and EPA, the MD simulations showed that the alkene moieties of the fatty
acid are close to heme for all starting conformations (i.e., carbon-to-heme distance < 6 A˚
in Fig. 7.5), suggesting that either of the simulated orientations could lead to formation
of metabolites shown in Figure 7.1. For AA, the carbon-to-heme distance distributions
show an increase of about 4 A˚ compared to DHA and EPA, suggesting that this fatty acid
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Figure 7.5: Positioning of fatty acids in the active site of CYP2J2. Distribution of carbon-to-heme
distances between epoxidation/hydroxylation sites of AA, DHA and EPA to the iron atom of the heme,
obtained from MD simulations. For each fatty acid, data was obtained from 100 ns simulations for cluster
1,2 and 3, and 200 ns simulations for cluster 4.
is less restrained in active site than the other two. CYP2J2-substrate interaction energies
(Tables 7.2 and 7.3) revealed that fatty acids are stabilized mostly by establishing contacts
with residues located in the active site of CYP2J2, mainly Ile-127, Phe-310 and Ile-489
(Fig. 7.4). In addition to these contacts, some important electrostatic interactions were
identified for cluster 4.
7.3.3 DHA Binding is Stabilized by Helix I Interactions
For the three tested fatty acids, the conformation adopted in cluster 4 (Fig. ??) positions
the carboxyl group close to Arg-321 located in helix I. Simulations revealed that fatty
acids establish favorable interactions with the Arg-321 side-chain (Fig. ??), and these
interactions in turn facilitate formation of additional electrostatic interactions. AA, DHA
and EPA can transiently form h-bonds with Thr-318 and Ser-493. As shown in Figure ??,
these interactions facilitate the accommodation of the epoxidation sites close to the heme
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Table 7.2: Interaction energies calculated from MD simulations. Key residues and interacting energies
for each cluster calculated from simulations, as outlined in the Methods section. Clusters 1 and 2 are
100 ns simulations.
AA EPA EPA
Residue Interaction
Energy
(kcal/mol)
Residue Interaction
Energy
(kcal/mol)
Residue Interaction
Energy
(kcal/mol)
Cluster 1
Arg-111 -1.4± 0.4 Ile-127 -1.7± 0.6 Arg-111 -1.1± 1.0
Pro-112 -2.9± 1.1 Thr-219 -2.4± 0.9 Thr-114 -1.4± 2.6
Val-113 -2.1± 0.9 Glu-222 -1.4± 0.7 Ile-127 -2.1± 0.7
Thr-114 -2.8± 1.0 Ala-223 -1.0± 0.4 Thr-219 -1.4± 1.2
Arg-117 -1.7± 0.6 Gln-228 -2.6± 2.5 Glu-222 -1.2± 1.4
Ile-127 -1.9± 0.6 Phe-310 -2.3± 0.6 Gln-228 -1.5± 2.0
Met-128 -1.3± 0.6 Ala-311 -1.7± 0.5 Phe-310 -2.4± 0.7
Asn-231 -2.1± 0.7 Glu-314 -1.9± 0.7 Ala-311 -1.6± 0.6
Phe-310 -1.3± 0.4 Thr-315 -2.0± 0.7 Glu-314 -1.4± 0.5
Ala-311 -1.1± 0.4 Thr-318 -1.0± 0.5 Thr-315 -1.7± 0.7
Val-380 -2.4± 0.5 Ile-376 -1.2± 0.6 Ile-376 -1.2± 0.5
Pro-381 -1.4± 0.7 Val-380 -1.1± 0.4 Val-380 -2.0± 0.8
Met-400 -1.3± 0.5 Thr-488 -1.2± 0.7 Thr-488 -1.0± 0.6
Ile-489 -2.4± 0.7 Ile-489 -4.3± 0.9 Ile-489 -3.7± 0.9
Ser-490 -3.6± 0.9 Ser-490 -1.7± 1.3
Cluster 2
Ile-127 -1.6± 0.6 Arg-117 -1.1± 0.7 Thr-114 -1.3± 0.6
Thr-219 -2.7± 0.7 Ile-127 -1.6± 0.6 Arg-117 -1.3± 0.6
Ala-223 -1.3± 0.5 Thr-219 -1.9± 0.6 Ile-127 -2.1± 0.7
Gln-228 -2.7± 2.5 Glu-222 -1.7± 0.7 Met-128 -1.1± 0.6
Phe-310 -2.4± 0.7 Ala-223 -1.3± 0.6 Gln-228 -1.6± 2.4
Ala-311 -1.6± 0.5 Gln-228 -2.5± 2.6 Asn-231 -1.3± 1.6
Glu-314 -1.3± 0.6 Phe-310 -2.9± 0.8 Phe-310 -2.1± 0.7
Thr-315 -1.2± 0.6 Ala-311 -1.7± 0.5 Ala-311 -1.5± 0.5
Gly-486 -2.8± 2.2 Glu-314 -1.2± 0.6 Glu-314 -1.7± 0.7
Ile-487 -3.3± 3.6 Thr-315 -1.8± 0.8 Thr-315 -1.9± 0.7
Thr-488 -1.8± 1.8 Val-380 -1.3± 0.5 Thr-318 -1.1± 0.5
Ile-489 -3.8± 0.8 Gly-486 -3.0± 2.3 Ile-375 -1.0± 0.4
Ser-490 -3.3± 0.8 Ile-487 -3.5± 4.1 Ile-376 -1.2± 0.5
Thr-488 -4.0± 4.8 Val-380 -1.9± 0.7
Ile-489 -6.0± 3.3 Thr-488 -1.2± 0.7
Ser-490 -3.2± 1.1 Ile-489 -3.6± 0.9
Ser-490 -1.2± 0.9
(with a carbon-to-heme distance < 6 A˚) for DHA and EPA, and < 8 A˚ for AA. Of the
three fatty acids, DHA showed the highest degree of interactions during the simulations,
suggesting a tighter binding mode when compared to AA or EPA for this particular
orientation of the fatty acid in the active site (Fig. 7.6). The observed intreactions can
be due to the presence of one additional alkene moiety closer to carboxyl head in DHA
(between carbons 4 and 5), not present in either AA or EPA. It has been shown that
the polyunsaturation in DHA increases its flexibility, particularly by lowering rotational
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Table 7.3: Interaction energies calculated from MD simulations. Key residues and interacting energies
for each cluster calculated from simulations, as outlined in the Methods section. Clusters 3 is 100 ns
simulations and Cluster 4 is 200 ns. For Cluster 4, Thr 318, Arg 321, and Ser 493 are highlighted.
AA EPA EPA
Residue Interaction
Energy
(kcal/mol)
Residue Interaction
Energy
(kcal/mol)
Residue Interaction
Energy
(kcal/mol)
Cluster 3
Thr-114 -1.8± 1.4 Arg-111 -1.2± 0.8 Arg-111 -1.9± 0.9
Ile-127 -1.8± 0.6 Thr-114 -3.6± 4.1 Pro-112 -1.2± 0.8
Met-128 -1.2± 0.6 Arg-117 -4.4± 8.0 Thr-114 -3.9± 4.2
Gln-228 -1.2± 2.5 Ile-127 -2.4± 0.6 Arg-117 -3.3± 2.8
Asn-231 -3.2± 2.8 Met-128 -1.3± 0.6 Ile-127 -2.3± 0.7
Phe-310 -1.6± 0.6 Phe-310 -2.4± 1.0 Met-128 -1.1± 0.6
Ala-311 -1.3± 0.6 Ala-311 -2.0± 0.7 Asn-231 -1.8± 1.8
Ile-376 -1.6± 0.8 Glu-314 -1.1± 0.6 Phe-310 -2.2± 0.9
Val-380 -2.8± 0.6 Thr-315 -1.1± 0.5 Ala-311 -1.6± 0.6
Pro-381 -1.2± 0.6 Val-380 -2.3± 0.6 Glu-314 -1.4± 0.6
Thr-488 -2.1± 0.9 Pro-381 -1.1± 0.6 Thr-315 -1.7± 0.8
Ile-489 -2.8± 1.0 Thr-488 -1.0± 0.7 Ile-376 -1.2± 0.5
Ser-490 -1.3± 0.8 Ile-489 -2.8± 0.8 Val-380 -2.6± 0.9
Pro-381 -1.1± 0.7
Ile-487 -1.1± 2.5
Thr-488 -2.4± 4.3
Ile-489 -3.7± 2.2
Cluster 4
Ile-127 -1.5± 0.5 Ile-127 -1.3± 0.6 Ile-127 -1.7± 0.6
Thr-219 -1.5± 0.4 Thr-219 -1.7± 0.8 Thr-219 -1.3± 0.6
Phe-310 -2.5± 0.6 Phe-310 -2.4± 0.9 Phe-310 -2.9± 0.7
Ala-311 -2.4± 0.7 Ala-311 -2.0± 0.6 Ala-311 -1.4± 0.5
Thr-315 -2.0± 0.7 Thr-315 -1.7± 0.8 Thr-315 -1.5± 0.7
Thr-318 -5.3± 5.2 Thr-318 -6.0± 5.8 Thr-318 -11.0± 5.2
Arg-321 -19.0± 4.1 Arg-321 -20.4± 7.0 Arg-321 -17.9± 6.5
Trp-322 -1.4± 2.3 Trp-322 -1.0± 2.8 Ile-375 -1.8± 0.6
Ile-375 -1.7± 0.5 Ile-375 -1.8± 0.6 Ile-376 -1.9± 0.6
Ile-376 -1.5± 0.5 Ile-376 -1.3± 0.5 Val-380 -1.6± 0.6
Arg-484 -1.2± 1.7 Val-380 -1.2± 0.6 Arg-484 -6.8± 5.8
Ile-489 -3.2± 0.8 Arg-484 -10.7± 10.6 Ile-489 -1.5± 0.9
Ser-490 -5.6± 1.5 Ile-489 -1.8± 0.7 Ser-490 -3.5± 0.9
Pro-491 -1.8± 0.7 Ser-490 -3.3± 1.3 Val-492 -6.5± 1.4
Val-492 -5.2± 1.8 Pro-491 -1.0± 1.0 Ser-493 -12.3± 5.9
Ser-493 -4.6± 2.7 Val-492 -3.5± 2.1 Arg-495 -1.6± 5.3
Arg-495 -1.0± 2.0 Ser-493 -4.8± 6.5
Arg-495 -1.4± 2.3
barriers about methylene bridges [348]. Therefore, DHA has increased flexibility closer to
carboxyl group due to the additional double bond, which can facilitate interactions with
surrounding residues, such as Thr-318 and Ser-493, in addition to Arg-321. In contrast,
AA and EPA are less flexible around their carboxyl head due to the close saturated
carbons. The interaction energy for AA and EPA with Arg-321 and Thr-318 in this
108
Figure 7.6: Interaction of fatty acids with helix I of CYP2J2. (Left) Time series of the interaction energy
of AA, DHA and EPA with residues Thr-318, Arg-321, and Ser-493 (Right) Representative conformations
of AA, DHA and EPA in the active site, observed in the simulations. Residues Thr-318 and Arg-321 are
located in helix I, shown in cartoon representation with purple color. The fatty acids are shown in stick
representation, AA in green, DHA in black, and EPA in magenta. Side chains and heme are also shown
in stick representation.
conformation is similar (Fig. 7.6), suggesting a similar binding mode for the two molecules,
which can explain why there is no significant difference seen in our inhibition studies and
subsequent binding analyses. DHA binding establishes a key residue triad that could
explain why the binding of DHA is stronger than AA or EPA. Although all the tested
fatty acids form similar hydrophobic contacts in the active site, only DHA clearly interacts
with Arg-321, Thr-318 and Ser-493 at the same time.
7.4 Summary
The enzyme pathways involved in PUFA metabolisms are complex. Therefore, there is a
need to gain fundamental understanding of enzyme mechanisms with respect to PUFA-
PUFA interactions. One of the major pathways of PUFA metabolism is via the CYP
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epoxygenases, which generate anti-inflammatory PUFA epoxides. While many physio-
logical studies on the metabolism of PUFA by CYP epoxygenases have been reported, a
detailed molecular level of understanding by measuring the kinetic and thermodynamics
is absent.
We performed experimental and computational analyses of the major cardiac CYP
epoxygenase, CYP2J2, with several major omega-3 and omega-6 PUFAs. Doing a global
inhibition analysis at varying concentrations of AA and DHA revealed that DHA is a
strong competitive inhibitor of AA metabolism. The inhibition of DHA metabolism
by AA is weaker, as determined by an almost fourfold higher binding affinity for the
AA inhibition of DHA. This indicates that DHA exhibits preferential metabolism by
CYP2J2 as compared to AA. Additional experimental data revealed that DHA inhibits
AA metabolism by CYP2J2 while EPA and LA does not. However, the data could not
explain how structurally similar lipid substrates can have differential interactions with
the active site of CYP2J2. Therefore, in the absence of a crystal structure of lipid bound
CYP2J2, we use MD simulations to reveal key residues that could lend support to our
experimental observations.
MD simulations revealed that PUFA binding is mainly governed by hydrophobic in-
teractions with non-polar side chains including Ile-127, Phe-310 and Ile-489, located in
the active site. In addition to these contacts, some additional electrostatic interactions
appear to stabilize binding. We identified that the fatty acids in the binding site adopt
two main orientations (Fig. 7.4). In the main orientation (cluster 1, 2 and 3), the fatty
acids are extended along the cavity connecting the active site and surface of the protein,
In the second orientation (cluster 4), the carboxyl head of the molecule is located in the
vicinity of Arg-321 of helix I. The three acids can interact with Arg-321; however only
DHA can form multiple additional electrostatic interactions with Thr-318 and Ser-493 at
the same time, as observed in the calculated interaction energies (Table 7.3).
Our data also indicates that PUFA metabolism and inhibition by CYP2J2 is governed
by the binding of the substrates as a result of restricted conformation and length. Having
more alkenes in certain positions can restrict which amino acid residues the FAs can in-
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teract with. Therefore, it cannot be said that omega-3 FAs are more favorable, since EPA
and AA showed similar flexibilities when interaction the Arg-321 triad. DHA, however,
is an omega-3 PUFA that has the right combination of conformational restriction and
length to favorably interact with this triad and bind tighter.
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Chapter 8
Membrane Insertion of the Influenza
Virus Hemagglutinin Fusion Peptide
(HAfp) ∗
8.1 Introduction
Viral infection starts with the fusion of the viral and host membranes [350], process
mediated by hemagglutinin (HA), a homotrimeric glycoprotein located on the surface of
the virus [351]. HA monomers are each composed of two major domains: HA1, a globular
domain anchored in the viral membrane, and HA2, the domain that mediates attachment
to the host membrane. During the fusion process, the N-terminal 23 residues of HA2,
known as the HA fusion peptide (HAfp), are the only part of the virus in direct contact
with the host membrane [352]. At high or normal pH HAfp is buried within the core of
HA [353], but lowering the pH, e.g. in the endosomes, induces a significant conformational
change in HA that results in the exposure of HAfp [354, 355], so that it can target and
insert into the host cellular membrane, thereby initiating the fusion of the viral and host
membranes. Although the detailed mechanism by which HA mediates membrane fusion
∗This chapter appeared as a research article in Journal of Physical Chemistry B [167].
Javier L. Baylon and Emad Tajkhorshid, “Capturing Spontaneous Membrane Insertion of the Influenza
Virus Hemagglutinin Fusion Peptide”. Journal of Physical Chemistry B, 119(25):7882-7893, 2015.
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remains elusive, it is well established that the role of HAfp in this process hinges on its
direct interaction with and insertion into the host membrane [356, 357]. In addition to
its anchoring role, it has been proposed that upon membrane insertion, HAfp promotes
significant changes in the lipid bilayer structure, including membrane curvature [358,359]
and lipid protrusion [360], that can further facilitate membrane fusion.
Figure 8.1: Structure of HAfp. Cartoon represen-
tation of important structural details of HAfp. Helix
A (red) is composed of residues 3 to 12, and Helix
B (blue) is composed of residues 14 to 22, brought
together by a small linker region (Gly-13).
Due to its importance in the fusion pro-
cess, and aiming at providing a detailed
picture of the underlying molecular events
for its function, a large number of biophys-
ical studies have investigated HAfp in its
isolated form, i.e., in the absence of the re-
mainder of HA2. At low or neutral pH,
binding experiments have shown that dif-
ferent variants of HAfp are able to insert
into lipid bilayers, thus promoting mem-
brane fusion [171, 361, 362]. The most recent structure of HAfp is the NMR structure of
full length HAfp (subtype H1) in micelles, consisting of 23 residues. [363]. This struc-
ture contains three additional C-terminal residues (Trp-21, Tyr-22 and Gly-23) which are
strictly conserved among all the known serotypes of HA, but were not resolved in the
previous HAfp structures [171]. The structure of HAfp in micelles [363] is characterized
by two alpha helices tightly packed in a hairpin-like arrangement, with the hydrophobic
side chains facing the same side in both helices while the polar residues are mostly located
at the interhelical interface (Fig. 8.1). Subsequent NMR studies aimed at characterizing
the interaction of HAfp with micelles revealed the pH- and length-dependence of both
the conformation and fusogenic activity of the peptide [364,365], suggesting an important
role for Trp-21, Tyr-22 and Gly-23 in interaction with the membrane.
Because of the highly dynamic nature of the peptide–membrane interactions, the de-
tails of the membrane binding mechanism of HAfp are difficult to elucidate experimentally.
To overcome this, computational approaches employing molecular dynamics (MD) simula-
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tions have been employed to elucidate the role of HAfp in membrane fusion by characteriz-
ing its interactions with artificial lipid bilayers [358,360,366–373]. These studies have em-
ployed a variety of models, including all-atom representations [358,360,366–370,372,373],
and coarse-grained models [371]. Simulations in membranes of different lipid composi-
tions have suggested that wild-type HAfp induces significant structural changes in the
lipids, resulting in thinning of the bilayer [358, 366–369], lipid protrusion [360, 372], and
in positive curvature of the membrane [369, 371], while mutations of HAfp (e.g., E11A
and W14A) greatly reduce thinning and curvature-inducing effects [369]. The induced
disruption of the membrane by HAfp is suggested to promote the formation of a fusion
stalk where lipids in the outer leaflets of both the host and viral membranes make con-
tacts [360], which could eventually lead to pore formation and irreversible fusion between
the viral and host cell membranes [356,357].
Understanding the interaction of the HAfp with the membrane is a crucial step towards
elucidating the role of the peptide in membrane fusion. The majority of the previous com-
putational studies have employed a model peptide containing only the first 20 N-terminal
residues of HAfp [171], with only one using on the recently resolved full-length, 23-residue
HAfp [373]. Although the first 20 residues of HAfp are sufficient to maintain fusogenic
activity [361,362,364], the full length sequence of the peptide has been suggested to reg-
ulate conformational changes of HAfp which might be relevant to membrane fusion [364].
More importantly, previous MD studies have employed a predefined placement of HAfp
in the membrane, based on EPR spectroscopy [171]. Since membrane relaxation is a slow
process, placing the peptide in a predefined position could potentially bias the results of
the simulations, specifically the resulting insertion depth and the orientation of peptide in
the membrane. On the other hand, capturing the spontaneous association and insertion of
proteins with membranes is challenging as the process is primarily hampered by the slow
dynamics of membrane lipids and their insufficient sampling on the timescales currently
accessible by atomistic MD simulations. Recently, an alternative approach to study pe-
ripheral membrane proteins based on a highly mobile membrane-mimetic (HMMM) model
has been developed [161]. This membrane model employs a biphasic solvent system [160]
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together with short-tailed lipids located at the solvent/water interface. The design of
the HMMM model allows for an increase of 1-2 orders in the lipid diffusion, accelerating
the spontaneous association of proteins with the bilayer [161]. The HMMM model has
been successfully employed to capture the membrane binding and insertion of a variety of
proteins, such as the GLA domain of the human coagulation factor VII [161], cytochrome
P450 [164], talin [73], α–synuclein [165], synaptotagmin [283], and synaptobrevin [166],
while preserving the atomistic detail of the interactions between the protein and lipid
head groups [163].
In this study, we employed the HMMM model to study the process of spontaneous
membrane binding of the full-length HAfp. The HMMM model is particularly suitable
to study HAfp–membrane interactions, given the expected partitioning of the peptide at
the interfacial region as suggested by the micelle-derived structure and subsequent NMR
studies [363, 374], since the short-tailed lipids accurately reproduce relevant interactions
and free energies of amino acid insertion into this region of the membrane with great
detail [163]. The size of the system together with the accelerated lipid dynamics of the
HMMM membrane allow for an increased sampling of membrane binding events. Spon-
taneous binding and insertion of the peptide into the membrane were captured in 18
independent simulations, resulting in a convergent model of the membrane-bound HAfp,
despite the designed scatter of the initial configurations in different simulations. The
insertion depth and the orientation of the membrane-bound HAfp are preserved after
converting the HMMM model to a full lipid bilayer. These simulations provide a conver-
gent membrane-bound model for influenza HAfp resulting from spontaneous binding of
the peptide, that is not biased by initial placement of the peptide in the membrane.
8.2 Methods
8.2.1 System Preparation
Membrane Preparation. The HMMM membrane was constructed by placing two
leaflets of divaleryl-phosphatidylcholine (DVPC) at the interface of water and 1,1-dichloroethane
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(DCLE), as described in detail elsewhere [161]. The DVPC molecules were generated by
shortening the lipid tails of a palmitoyl-oleoyl-phosphatidylcholine (POPC) molecule to
only 5 carbons [161]. The HMMM membrane was assembled with the Packmol soft-
ware [170], employing a DCLE box with dimensions of 65×65×10 A˚3 and containing 308
molecules of the organic solvent, and placing 128 short-tailed lipids at each water/DCLE
interface, with 64 lipids on each side. The resulting structure was then solvated using
the solvate plugin of VMD [117], resulting in a system with ∼23,000 atoms. The sol-
vated membrane system was energy minimized for 10,000 steps and simulated for 2 ns,
using an NPnAT ensemble with constant area, with a target pressure and temperature of
1.0 atm and 310 K, respectively. A constant area of 4,356 A˚2 (66×66 A˚2) was employed,
yielding an area per lipid (AL) of ∼68 A˚2, which closely matches the experimental AL for
POPC [211, 375]. The resulting membrane was employed in the subsequent membrane-
binding simulations.
Modeling of the Fusion Peptide. The NMR structure of subtype H1 HAfp was
obtained from the RCSB Protein Data Bank [376] (PDB entry 2KXA) [363]. This PDB
entry contains 10 conformations of HAfp obtained in DPC micelles at pH 7.4, all present-
ing very similar structures. Given the high structural similarity, only one conformer (the
first one) was used for the simulations. Glu and Asp residues of the peptide were modeled
in their unprotonated (charged) forms, in order to model the charge of the peptide at
neutral pH. HAfp was placed in a box with dimensions of 60×60×60 A˚3 and containing
∼20,000 water molecules, generated with the solvate plugin of VMD [117], and neutral-
ized with 100 mM NaCl ions using the autoionize plugin. The solvated peptide system
was then energy minimized for 10,000 steps and simulated for 50 ps with the Cα atoms
of the peptide harmonically restrained (k = 5 kcal mol-1 A˚-2), and a 20 ns run with no
restraints followed. The resulting equilibrated structure of HAfp in solution was used as
the initial structure for the membrane-binding simulations with the HMMM membrane
model.
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Figure 8.2: Initial configurations of HAfp in membrane-binding simulations. Seven different initial
positions were used for membrane-binding simulations. Different orientations and heights of the peptide
with respect to the membrane plane (z-axis) were employed in order to test the convergence of the
membrane-bound form of HAfp. A set of 3 independent 100–ns simulations were performed for each
initial configuration. The peptide is shown in cartoon representation, with polar residues shown in green,
hydrophobic residues in white, and acidic residues in red. Different configurations were labeled according
to their orientation with respect to the membrane normal (z-axis) and the part of the peptide initially
facing the membrane: (a) Helix A and (b) Helix B are placed closer to the membrane surface, respectively;
and the linker region between Helices A and B placed at a (r) reclined, (i) inclined, (n) nosedive, (p)
parallel, and (s) standing positions with respect to the membrane.
8.2.2 Simulation Systems
The equilibrated HAfp structure was added to the membrane model by placing its center-
of-mass (COM) at a position 7-10 A˚ above the PO4 plane of the cis leaflet, without
contacting the membrane. In order to test the convergence of the membrane-binding
simulations, seven different starting orientations of HAfp were employed (Fig. 8.2). An
additional layer (10 A˚) of water was added using the solvate plugin to the resulting struc-
tures to ensure sufficient hydration. To neutralize the systems, 100 mM NaCl was added
using the autoionize plugin of VMD [117]. These initial peptide-membrane systems
consisted of a box with dimensions of 65×65×72 A˚3 containing 29,622 atoms.
The systems were energy minimized for 10,000 steps and simulated for 50 ps with the
Cα atoms of the peptide harmonically restrained (k = 5 kcal mol-1 A˚-2), followed by a pro-
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duction run of 100 ns. Three independent runs for each starting position were performed,
resulting in a total of 21 independent membrane–binding simulations, from which a set of
18 yielded membrane insertion of HAfp within 100 ns (Table 8.1). A harmonic restraint
along the z-axis, with a force constant k = 0.05 kcal mol-1 A˚-2, was applied to the car-
bonyl carbon atoms of the DVPC lipids to mimic the atomic distributions of a full lipid
bilayer more closely, and to prevent the occasional lipid diffusion into the aqueous phase,
expected for these surfactant-like molecules [161].
In addition to the HMMM systems, and to further examine the stability of the
resulting membrane-bound HAfp, simulations employing a full POPC lipid bilayer were
also performed. Three membrane-bound models of HAfp were adopted from the last
frames of simulations r3, i2, and s1 (Table 8.1). For these systems, the DVPC bilayer was
transformed into a POPC bilayer by removing the DCLE molecules and adding the missing
carbons of the lipid tails, while preserving the positions of the lipid atoms already present
in the HMMM model (head groups and initial few carbons of the lipid tails). The positions
of the newly added lipid tail atoms were then optimized by adopting the coordinates of the
corresponding atoms obtained from randomly selected POPC molecules from a membrane
previously equilibrated. During these steps, the original contacts established between
the lipids and HAfp in the HMMM membrane-binding simulations were preserved. The
resulting POPC-membrane systems, hereby referred to as r3f, i2f and s1f, were then
minimized and equilibrated for 100 ps while restraining (k = 1 kcal mol-1 A˚-2) the heavy
atoms of the peptide and the short-tailed lipids already present before extending the
tails to allow for the newly added atoms to relax. Following this step, the systems were
equilibrated without restraints for 30 ns, with the last 20 ns used for structural analysis.
Simulations were performed using NAMD2 [118], utilizing the CHARMM27 force field
with CMAP [119] corrections for proteins and CHARMM36 [113] parameters for lipids.
The TIP3P model was used for water [120]. All the HMMM simulations were performed
in NPnAT ensembles at 1.0 atm and 310 K, and with a time step of 2 fs. The POPC
systems were simulated as an NPT ensemble with similar parameters. Constant pressure
was maintained using the Nose´-Hoover Langevin piston method [124, 125], and constant
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Table 8.1: Summary of the simulations. The systems are labeled according to the initial orientation a, b,
r, i, n, p, s of HAfp (see Fig. 8.2). The suffix (1, 2 or 3 ) indicates the replicate number for the respective
system. A letter f at the end of the system name indicates the extension of the membrane-bound system
fo a full POPC membrane. The simulations in which insertion of the peptide was observed (18 out of 21)
are indicated in the left column.
System Name Simulation Time Membrane Insertion
Helix A
a1 100 ns -
a2 100 ns +
a3 100 ns +
Helix B
b1 100 ns +
b2 100 ns +
b3 100 ns +
Reclined
r1 100 ns -
r2 100 ns -
r3 100 ns +
r3f 30 ns already
membrane-bound
Inclined
i1 100 ns +
i2 100 ns +
i3 100 ns +
i2f 30 ns already
membrane-bound
Nosedive
n1 100 ns +
n2 100 ns +
n3 100 ns +
Parallel
n1 100 ns +
n2 100 ns +
n3 100 ns +
Standing
s1 100 ns +
s2 100 ns +
s3 100 ns +
s1f 30 ns already
membrane-bound
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temperature was maintained by Langevin dynamics with a damping coefficient γ of 0.5 ps-1
applied to all atoms. Nonbonded interactions were cut off after 12 A˚ with a smoothing
function applied after 10 A˚. The particle mesh Ewald (PME) method [126] was used for
long-range electrostatic calculations with a grid density of > 1 A˚-3.
8.2.3 Specific Analysis
The position of HAfp with respect to the membrane was characterized by the height
(depth of insertion) along the membrane normal (z-axis) of the center of mass (COM) of
the heavy atoms of the hydrophobic side chains of HAfp (Leu-2, Phe-3, Ile-6, Phe-9, Ile-10,
Trp-14, Met-17, Ile-18, and Trp-21), in order to monitor the insertion of the peptide during
the simulations. Membrane insertion was assumed when the COM of the hydrophobic
side chains of the peptide was located around or below the PO4 level (see Fig. 8.3). After
insertion, the profile of HAfp in the membrane was characterized by the average distance
along the z-axis between a selected set of the side chains without the backbone (e.g., Helix
A and Helix B) and the PO4 plane of the cis leaflet. The average was taken over the last
10 ns of the simulation (i.e., after insertion was completed). The effect of the membrane on
the structure of the peptide was quantified by measuring the backbone root mean square
deviation (RMSD) with respect to the NMR structure [363]. In addition, to quantify
the structural variability of the peptide among different simulations, for each pair of the
simulation systems, backbone RMSD was also calculated. For each pair this was done by
generating an ensemble of 100 peptide backbone structures from the last 1 ns of the first
simulation (10 ps interval), calculating RMSDs of all 100 frames to those obtained from
the second simulation, and reporting the average of all the 100 × 100 RMSD values.
During the simulations, the orientation of the peptide was characterized by the orien-
tation of its two helices (Helices A and B) individually. The helix axis was defined by the
average backbone N-H bond vector of residues 3 to 12 for Helix A, and residues 14 to 22
for Helix B. The orientation of each helix was then characterized by the tilt angle between
its main axis and the membrane normal (the z-axis). The tilt angle for each helix was
averaged over the last 10 ns of each simulation. Rotation of the peptide around the heli-
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cal hairpin principal axes was calculated for the last 10 ns of simulation for each system,
employing the angles defined by Chen et al. [377] to characterize protein orientation.
The interaction of HAfp with the membrane was also characterized by the number of
hydrogen bonds. The criteria used to determine the presence of a hydrogen bond was a
distance less than 3 A˚ between donor and acceptor heavy atoms, and a donor-H-acceptor
angle of at least 150 ◦.
8.3 Results and Discussion
Membrane binding and insertion of HAfp were captured in multiple independent simu-
lations, permitting detailed characterization of the binding steps of the peptide for the
first time. The peptide was modeled at neutral pH), with charged Glu-11 and Asp-19
side chains. This condition was chosen to preserve the helical structure of the peptide,
which has been shown to be disrupted at low pH [365]. The resulting membrane-bound
form of the peptide also allowed for the characterization of important structural features
of the peptide, such as depth of insertion and membrane orientation. Although the in-
teraction of HAfp with a membrane has been studied previously with MD simulations
using a wide variety of approaches [358,366–372,378–382], the process leading to peptide
insertion has not been described at an atomic level. Previous MD studies have used a
predefined placement of HAfp in the membrane, e.g., based on EPR measurements [171].
To our knowledge, this is the first study reporting spontaneous insertion of HAfp to a
membrane.
8.3.1 Spontaneous Membrane Binding and Insertion of HAfp
In order to study the binding of HAfp to the membrane, seven completely different initial
configurations (i.e., positions and orientations of the peptide above the membrane) were
tested (Fig. 8.2), with each configuration simulated in 3 independent 100–ns runs. In all
cases the peptide was initially at least 7 A˚ away from the surface of the membrane, en-
suring that the process of binding is not biased by initial placement of the peptide inside
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Figure 8.3: Spontaneous membrane binding and insertion of HAfp. (Top) Snapshots taken at different
times from System i1, representing a typical example of spontaneous membrane insertion observed in
HMMM simulations. Helix A and Helix B are shown in red and blue, respectively; hydrophobic side
chains are shown in white. (Bottom) Time evolution of the position along the membrane normal (z-axis)
of the center of mass (COM) of the heavy atoms of hydrophobic side chains of HAfp (Leu-2, Phe-3, Ile-6,
Phe-9, Ile-10, Trp-14, Met-17, Ile-18 and Trp-21) for all the 21 simulation systems. Membrane insertion
was assumed when the COM of the hydrophobic side chains was located at or below the PO4 level. The
average positions of the phosphorus (PO4) and the nitrogen (choline) atoms of the lipid head groups are
shown using brown and gray dotted lines, respectively.
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the membrane, which is a common practice when employing conventional atomistic mem-
branes in simulation studies. Spontaneous binding of the HAfp to the membrane within
100 ns was observed in a total of 18 out of 21 systems (1–3 for each initial configuration).
Membrane insertion was assumed when the COM of the hydrophobic side chains of the
peptide was located at or below the PO4 level (Fig. 8.3). In the cases where membrane
insertion was not observed in 100 ns, the peptide either interacted with the membrane
through some of its side chains (Phe-9 and Trp-14) without completing insertion or it
simply diffused into the aqueous phase without encountering the membrane (Fig. 8.3).
The first step of insertion occurs when bulky aromatic side chains (Phe-9, Trp-14,
or Trp-21) encounter the membrane and start to insert (Fig. 8.3). After this initial en-
counter, the rest of the hydrophobic and aromatic side chains begin to penetrate the head
group region of the membrane, while the polar residues remain exposed to the aqueous
solution, achieving a partitioning at the lipid-water interface, also reported as the peptide
configuration in micelles based on NMR measurements [363]. After binding, insertion
and stabilization of HAfp over the lipid layer is achieved during the remainder of the sim-
ulation, as characterized by the peptide insertion depth measured along the membrane
normal (Fig. 8.3). The time required for the peptide to encounter the membrane varies
greatly as it diffuses freely in water and does not depend on the initial configuration; for
example, in the i1 and i2 cases binding occurs around 5 and 22 ns, respectively.
In general, the structure of the peptide is largely unaffected by the membrane af-
ter insertion, as measured by the backbone RMSD with respect to the NMR structure
(Fig. 8.4). Stabilization of the overall structure of HAfp after membrane binding is ex-
pected since the NMR structure was obtained in DPC micelles [363]. For the majority
of the systems, the helical hairpin structure of the peptide is preserved upon membrane
binding (backbone RMSD < 2 A˚ with respect to the NMR structure), as observed in the
final structures of the peptide obtained from each simulation (Fig. 8.5). This is also sup-
ported by the low mutual RMSD (< 2 A˚) obtained between all the membrane-binding
simulations (Table 8.2). However, in some systems (p1, a2 and a3 ) the hairpin conforma-
tion is distorted. The RMSD of the individual helices reveals that the major disruption to
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Figure 8.4: Structural stability of HAfp during membrane-binding simulations. Time evolution of the
backbone RMSD of HAfp (top), Helix A (middle) and Helix B (bottom) of HAfp.
the hairpin conformation in these systems occurs in Helix A (Fig. 8.5). The RMSD of the
helices in each case decreases after membrane binding is completed, e.g., Helix A in sys-
tem n2, indicating that the membrane stabilizes the structure of the peptide, an expected
outcome which has also been observed in MD simulations of subtype H3 HAfp [368].
8.3.2 Membrane-Bound Configuration of HAfp
To further characterize the membrane-bound form of HAfp, the average insertion depth
of each side chain was calculated (see Methods). For all membrane-bound systems, the
peptide adopts a profile in which Helix A is more inserted than Helix B (Fig. 8.6). After
insertion, hydrophobic residues Leu-2, Phe-3, Ile-6, Phe-9 and Ile-10 in Helix A are buried
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Figure 8.5: Membrane-bound structures of HAfp. Final structures of the membrane-bound HAfp
obtained from each simulation. The top (top) and side (bottom) views of the peptide are shown for each
system.
(i.e., below the PO4 groups, with a COM side chain z-position < 0 in Fig. 8.6) for most of
the simulations. NMR measurements of the interactions of HAfp with a DPC micelle [363]
have suggested that Ile-6, Phe-9 and Ile-10 are buried in the hydrophobic region of the
micelle, consistent with the observed insertion of these side chains in our membrane-
binding simulations. In Helix B, amphipathic side chain Trp-14 and Met-17 are buried
for most simulations (relative z-position < 0 in Fig. 8.6), whereas Trp-21 is mostly located
at the head group region (relative z-position > 0 in Fig. 8.6). The insertion profile reveals
that the insertion of Helix A is deeper than Helix B, indicating that Helix A establishes
core hydrophobic interactions, through residues Leu-2, Phe-3, Ile-6, Phe-9 and Ile-10 with
the membrane. The insertion depth of Helix A is in close agreement with the EPR data of
membrane insertion at pH 7.4 reported for the first 11 residues of HAfp subtype H3 (i.e.,
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Table 8.2: Pairwsie backbone RMSD between the final states of the 18 membrane–binding simulations
(see Methods). The average RMSD is presented along with the standard deviation in parentheses.
b1 i1 n1 p1 s1 a2 b2 i2 n2
b1 0.8 (0.1) 0.8 (0.2) 3.1 (0.2) 1.3 (0.2) 2.5 (0.2) 0.6 (0.1) 0.7 (0.1) 0.7 (0.1)
i1 0.8 (0.1) 0.8 (0.1) 3.1 (0.2) 1.4 (0.2) 2.5 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1)
n1 0.8 (0.2) 0.8 (0.1) 3.0 (0.2) 1.4 (0.2) 2.5 (0.1) 0.7 (0.1) 0.7 (0.1) 0.7 (0.1)
p1 3.1 (0.2) 3.1 (0.2) 3.0 (0.2) 3.3 (0.2) 3.5 (0.2) 3.0 (0.2) 3.0 (0.2) 3.0 (0.2)
s1 1.3 (0.2) 1.4 (0.2) 1.4 (0.2) 3.3 (0.2) 2.3 (0.2) 1.3 (0.2) 1.3 (0.2) 1.3 (0.2)
a2 2.5 (0.2) 2.5 (0.1) 2.5 (0.1) 3.5 (0.2) 2.3 (0.2) 2.4 (0.1) 2.5 (0.2) 2.4 (0.2)
b2 0.6 (0.1) 0.8 (0.1) 0.7 (0.1) 3.0 (0.2) 1.3 (0.2) 2.4 (0.1) 0.6 (0.1) 0.6 (0.1)
i2 0.7 (0.1) 0.8 (0.1) 0.7 (0.1) 3.0 (0.2) 1.3 (0.2) 2.5 (0.2) 0.6 (0.1) 0.7 (0.1)
n2 0.7 (0.1) 0.8 (0.1) 0.7 (0.1) 3.0 (0.2) 1.3 (0.2) 2.4 (0.2) 0.6 (0.1) 0.7 (0.1)
p2 0.6 (0.1) 0.8 (0.1) 0.7 (0.1) 3.0 (0.2) 1.3 (0.2) 2.5 (0.2) 0.6 (0.1) 0.6 (0.1) 0.6 (0.1)
s2 0.7 (0.2) 0.9 (0.2) 0.8 (0.2) 3.1 (0.2) 1.3 (0.2) 2.5 (0.2) 0.7 (0.2) 0.7 (0.2) 0.7 (0.2)
a3 5.9 (0.3) 5.8 (0.3) 5.7 (0.3) 6.2 (0.3) 5.6 (0.2) 5.3 (0.2) 5.8 (0.2) 5.8 (0.3) 5.8 (0.3)
b3 1.5 (0.2) 1.6 (0.1) 1.6 (0.1) 3.4 (0.2) 1.0 (0.3) 2.3 (0.1) 1.5 (0.2) 1.5 (0.1) 1.5 (0.2)
d3 0.7 (0.1) 0.8 (0.1) 0.7 (0.1) 3.0 (0.2) 1.3 (0.2) 2.5 (0.1) 0.6 (0.1) 0.6 (0.1) 0.7 (0.1)
i3 0.6 (0.1) 0.8 (0.1) 0.7 (0.1) 3.0 (0.2) 1.3 (0.2) 2.4 (0.2) 0.6 (0.1) 0.6 (0.1) 0.6 (0.1)
n3 1.5 (0.2) 1.6 (0.1) 1.5 (0.1) 3.3 (0.2) 1.0 (0.3) 2.3 (0.1) 1.5 (0.1) 1.4 (0.1) 1.4 (0.1)
p3 1.0 (0.2) 1.2 (0.2) 1.1 (0.2) 3.2 (0.2) 1.2 (0.3) 2.5 (0.2) 1.0 (0.2) 1.0 (0.2) 1.0 (0.2)
s3 1.0 (0.1) 1.2 (0.1) 1.1 (0.2) 3.3 (0.2) 1.1 (0.2) 2.5 (0.2) 1.0 (0.1) 1.0 (0.1) 1.1 (0.1)
p2 s2 a3 b3 r3 i3 n3 p3 s3
b1 0.6 (0.1) 0.7 (0.2) 5.9 (0.3) 1.5 (0.2) 0.7 (0.1) 0.6 (0.1) 1.5 (0.2) 1.0 (0.2) 1.0 (0.1)
i1 0.8 (0.1) 0.9 (0.2) 5.8 (0.3) 1.6 (0.1) 0.8 (0.1) 0.8 (0.1) 1.6 (0.1) 1.2 (0.2) 1.2 (0.1)
n1 0.7 (0.1) 0.8 (0.2) 5.7 (0.3) 1.6 (0.1) 0.7 (0.1) 0.7 (0.1) 1.5 (0.1) 1.1 (0.2) 1.1 (0.2)
p1 3.0 (0.2) 3.1 (0.2) 6.2 (0.3) 3.4 (0.2) 3.0 (0.2) 3.0 (0.2) 3.3 (0.2) 3.2 (0.2) 3.3 (0.2)
s1 1.3 (0.2) 1.3 (0.2) 5.6 (0.2) 1.0 (0.3) 1.3 (0.2) 1.3 (0.2) 1.0 (0.3) 1.2 (0.3) 1.1 (0.2)
a2 2.5 (0.2) 2.5 (0.2) 5.3 (0.2) 2.3 (0.1) 2.5 (0.1) 2.4 (0.2) 2.3 (0.1) 2.5 (0.2) 2.5 (0.2)
b2 0.6 (0.1) 0.7 (0.2) 5.8 (0.2) 1.5 (0.2) 0.6 (0.1) 0.6 (0.1) 1.5 (0.1) 1.0 (0.2) 1.0 (0.1)
i2 0.6 (0.1) 0.7 (0.2) 5.8 (0.3) 1.5 (0.1) 0.6 (0.1) 0.6 (0.1) 1.4 (0.1) 1.0 (0.2) 1.0 (0.1)
n2 0.6 (0.1) 0.7 (0.2) 5.8 (0.3) 1.5 (0.2) 0.7 (0.1) 0.6 (0.1) 1.4 (0.1) 1.0 (0.2) 1.1 (0.1)
p2 0.7 (0.2) 5.8 (0.2) 1.5 (0.1) 0.7 (0.1) 0.6 (0.1) 1.5 (0.1) 1.0 (0.2) 1.1 (0.1)
s2 0.7 (0.2) 5.9 (0.3) 1.5 (0.2) 0.7 (0.2) 0.7 (0.2) 1.5 (0.2) 1.0 (0.2) 1.0 (0.1)
a3 5.8 (0.2) 5.9 (0.3) 5.5 (0.2) 5.8 (0.3) 5.8 (0.2) 5.4 (0.3) 5.8 (0.3) 5.8 (0.2)
b3 1.5 (0.1) 1.5 (0.2) 5.5 (0.2) 1.5 (0.1) 1.5 (0.1) 0.9 (0.2) 1.4 (0.2) 1.3 (0.2)
d3 0.7 (0.1) 0.7 (0.2) 5.8 (0.3) 1.5 (0.1) 0.6 (0.1) 1.5 (0.1) 1.0 (0.2) 1.1 (0.1)
i3 0.6 (0.1) 0.7 (0.2) 5.8 (0.2) 1.5 (0.1) 0.6 (0.1) 1.5 (0.1) 1.0 (0.2) 1.1 (0.1)
n3 1.5 (0.1) 1.5 (0.2) 5.4 (0.3) 0.9 (0.2) 1.5 (0.1) 1.5 (0.1) 1.3 (0.2) 1.2 (0.2)
p3 1.0 (0.2) 1.0 (0.2) 5.8 (0.3) 1.4 (0.2) 1.0 (0.2) 1.0 (0.2) 1.3 (0.2) 0.8 (0.2)
s3 1.1 (0.1) 1.0 (0.1) 5.8 (0.2) 1.3 (0.2) 1.1 (0.1) 1.1 (0.1) 1.2 (0.2) 0.8 (0.2)
GLFGAIAGFIE) [171], which are shared with the peptide studied here (HAfp subtype 1).
We observed that by increasing the realism of the membrane (i.e., extending the short-
tailed lipids to POPC lipids, see Methods) the insertion profile is preserved, as shown
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in Systems r3f, i2f and s1f (Fig. 8.6). This indicates that the HMMM simulations have
been able to achieve a stable configuration (in terms of insertion depth and orientation)
of the membrane-bound form of the peptide, while capturing the process of spontaneous
binding without any initial bias, such as the placement of the peptide in the membrane.
The resulting membrane–bound HAfp indicates that the peptide interaction with the cis
leaflet (i.e., head groups and first few carbons of tails) has been captured by the HMMM
model.
Figure 8.6: Membrane insertion profile of HAfp. (Top) Average distance along the z-axis of the side
chains of the inserted HAfp to the phosphorous (PO4) level of the lipids. The average was taken over the
last 10 ns of each simulation. (Bottom) Representative membrane-bound structure of HAfp, taken from
the final snapshot of System i1. Helices A and B are shown in red and blue, respectively, and Gly-13
(linker) is shown in gray. Side chains of hydrophobic residues Leu-2, Phe-3, Ile-6, Phe-9, Ile-10, Trp-14,
Met-17 and Trp-21 (white), acidic residues Glu-11 and Asp-19 (red), and the lipids interacting with the
peptide (heavy atom distance < 2.5 A˚) are shown in stick representation. The rest of the membrane is
shown in surface representation.
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Figure 8.7: Orientation of HAfp during membrane binding. Time series of the tilt angle of individual
helices of HAfp with respect to the membrane normal (z-axis). Each tilt angle is defined as the angle
between the average N-H bond vectors (shown in stick representation) of Helix A (residues 3-12) or Helix
B (residues 14-22) and the z-axis, respectively (see Methods). Dashed lines show the section of the
simulations (last 10 ns) that was used to calculated the average tilt angles, reported in Table 2.
To characterize the orientation of the peptide after insertion, the tilt angle between
individual helices of the fusion peptide and the membrane normal was calculated (see
Methods). Despite the wildly different initial orientations of the peptide (Table 8.3),
a convergent orientation is achieved during the simulations for all the membrane-bound
systems (Fig. 8.7). The tilt angle calculated for Helix A for membrane-bound HAfp ranges
from 76.0 ◦ to 126.0 ◦, with an average of 102.8 ◦ over the 18 simulations. The tilt angle
for helix B ranges from 66.0 ◦ to 126.4 ◦, with an average of 97.9 ◦. The range of tilt angles
that are sampled in these simulations are in close agreement with the recent NMR data
showing that the HAfp is able to undergo rocking motions when bound to a bicelle, with
128
Table 8.3: Initial (solution) and membrane-bound (averaged over the last 10 ns) tilt angles of Helices A
and B of HAfp in membrane-binding simulations. The average over all the membrane-bound systems is
also presented. The standard deviations are in parentheses.
Helix A Helix B
System Initial Tilt Angle
(Solution) (◦)
Membrane-
Bound Tilt Angle
(◦)
Initial Tilt Angle
(Solution) (◦)
Membrane-
Bound Tilt Angle
(◦)
b1 78.3 76.0 (4.4) 100.5 75.7 (3.7)
i1 143.9 126.0 (6.5) 38.1 90.4 (8.1)
n1 20.7 112.8 (4.7) 171.5 91.8 (4.6)
p1 102.8 83.4 (6.5) 86.3 122.7 (6.7)
s1 51.1 106.0 (6.0) 140.1 93.9 (7.6)
a2 99.1 116.3 (5.3) 63.7 86.7 (5.8)
b2 78.7 101.5 (6.1) 110.0 105.0 (5.9)
i2 30.5 102.8 (3.9) 129.5 101.7 (4.9)
n2 22.9 96.7 (7.1) 168.0 104.4 (7.1)
p2 88.0 106.7 (9.9) 72.1 102.2 (9.7)
s2 27.1 105.4 (5.9) 162.9 97.6 (7.3)
a3 98.3 113.1 (7.7) 64.2 126.4 (6.2)
b3 89.3 112.3 (5.7) 87.2 88.6 (7.4)
r3 65.0 89.6 (5.1) 139.7 109.6 (5.1)
i3 161.2 106.5 (4.8) 56.0 97.0 (4.9)
n3 13.8 105.6 (5.9) 170.5 94.0 (5.6)
p3 82.5 92.2 (5.5) 87.8 66.0 (5.6)
s3 14.9 97.6 (4.4) 170.7 107.7 (3.1)
Average 102.8 (12.2) 97.9 (14.6)
an amplitude of about 20 ◦ around the helix axes in the range of tens of nanoseconds [374].
Moreover, these tilt angles indicate that the peptide adopts an almost parallel orientation
with respect to the membrane plane after insertion, which is in agreement with what has
been suggested in NMR studies [363, 374]. The orientation of the peptide was further
characterized by the rotation around the helical hairpin axis (Fig. 8.7), following the
scheme proposed by Chen et al. to characterize protein orientations [377]. This rotation
ranges between 50◦ to 80◦, resulting from a deeper insertion of Helix A compared to Helix
B, consistent with the observed insertion profile of the peptide (Fig. 8.6).
The orientation of HAfp after insertion is preserved when the short-tailed lipids are
extended to full POPC lipids in Systems r3f, i2f and s1f (Table 8.4), with average angles
of 105.1 ◦ and 97.9 ◦ for Helices A and B, respectively.
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Table 8.4: Tilt angles of Helices A and B of
membrane-bound HAfp in a full POPC membrane.
The angles are averaged for each system over the last
10 ns of simulation. The average over all the systems
is also presented. The standard deviations are in
parentheses.
System Helix A (◦) Helix B (◦)
s1f 98.2 (5.2) 106.8 (5.3)
i2f 108.3 (5.7) 96.6 (6.5)
r3f 108.9 (5.5) 90.9 (5.6)
Average 105.1 (6.0) 97.9 (8.1)
This suggests that the peptide–lipid
interactions that determine the insertion
depth and orientation of the peptide upon
membrane binding are successfully sam-
pled with the HMMM model. It is impor-
tant to note however that the membrane
curvature and lipid protrusion-based mech-
anisms in which HAfp binding has been
suggested to directly contribute to the pro-
cess of membrane fusion [358,372] can not
be captured with the HMMM model mem-
brane, due to the short-tailed lipid representation, and decoupling of the two lipid leaflets.
The full POPC membrane simulations performed here are likely too short to capture any
associated membrane curvature.
8.3.3 Interaction of HAfp With the Membrane
In order to characterize the interaction of the peptide and the membrane, the pattern
of H–bonds between the two was calculated for all membrane-bound systems (Fig. 8.8).
These calculations were done by taking into account the H-bond contribution of both the
backbone and the side chain of each residue of HAfp. Overall, Helix B contributes to
the majority of the H-bonds formed with the phospholipid head groups. Because Helix
B contains five H–bond forming side chains, namely Trp-14, Thr-15, Asp-19, Trp-21, and
Tyr-22, a larger contribution to the H–bond formation from this helix is expected. In
contrast, Helix A only contains one H–bond forming side-chain (Glu-11), therefore its
overall contribution is significantly smaller than Helix B. In the membrane–bound form
of HAfp at pH 7.4 modeled in this work, charged residues Glu-11 and Asp-19 do not
contribute to any charge interactions between the peptide and the membrane, and due to
the helicity of the peptide the side chains point away from the membrane (Fig. 8.6).
Since the helical structure of the peptide remains largely unaltered during the course
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Figure 8.8: Hydrogen bonds between HAfp helices and the membrane. (Left) Time series of the number
of hydrogen bonds formed between HAfp and the membrane in the systems where membrane insertion
was observed (18 out of 21 simulations). In each plot the dashed line indicates the time at which peptide
insertion occurred. (Right) HAfp residues contributing to hydrogen bonding with the membrane. Time
series for the last 10 ns (90–100 ns) of simulation (i.e., after the peptide is inserted) of the hydrogen
bonds formed by residues Trp-14, Thr-15, Trp-21, and Tyr-22 with the membrane in the systems where
membrane insertion was observed. Both contributions from the backbone and side chains to H–bonds
were accounted for in the calculation.
of membrane-binding, it is expected that most of the H–bonds between the peptide and
the membrane involve the side chains. This suggests that H-bond donor side-chains sta-
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bilize the peptide after binding with the membrane (Fig. 8.8, right). Trp-14, Thr-15,
Trp-21 and Tyr-22 account for approximately 99% of all the H–bonds formed between
Helix B and the lipid head groups, while the side chains of Thr-15 and Tyr-22 account
for the majority of the total contribution (Fig. 8.8, right). The observation that trypto-
phan and tyrosine residues contribute to the H–bonding of the peptide within the lipid
head groups is in line with the well-known role of these residues in anchoring membrane
proteins to the interfacial region of the membrane [383, 384]. Moreover, this observation
suggests the importance of residues Trp-21 and Tyr-22 in the stabilization of the peptide
at the membrane–water interface after spontaneous binding occurs, something that, to
our best knowledge, has not been reported before, since the previously available struc-
tures of HAfp did not include these highly conserved residues [171,359,385]. Recent NMR
experiments have shown that these residues are important to stabilize the helical-hairpin
structure of the peptide [364]. Moreover, the larger contribution of Helix B to membrane–
biding observed in out simulations is supported by experimental evidence showing that
the truncated sequence of HAfp, containing only the first 14 residues, is void of fusogenic
activity [364]. This result, taken together with the observed deeper insertion of Helix A
in our simulations, suggests that Helix A contributes to peptide insertion by establishing
the majority of hydrophobic interactions after binding to the membrane, while Helix B
increases the affinity by providing amphipathic interactions at the membrane interface.
8.4 Summary
In this study, we have employed the HMMM membrane model to investigate the binding
and insertion of the hemagglutinin fusion peptide of the influenza virus. The HMMM
membrane model provides an enhanced lipid mobility, allowing to capture the sponta-
neous insertion of the peptide in atomistic simulations. The HMMM membrane model,
together with the small size of the system, allowed a greater sampling of the peptide-
membrane systems. The spontaneous binding and insertion of the peptide into the mem-
brane were captured consistently in 18 out of the 21 independent simulations performed.
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Despite employing broadly different initial configurations for the simulations, a repro-
ducible membrane-bound state of the peptide was observed in the simulations. The
insertion profile and the orientation of the membrane-bound HAfp are preserved after
converting the HMMM model to a full lipid bilayer. To our knowledge, this is the first
study reporting spontaneous insertion of HAfp to a membrane.
It was observed that the helical hairpin structure of the peptide is preserved upon
membrane binding. In the membrane–bound form, Helix A is inserted in the membrane
deeper than Helix B. The observed deeper insertion of Helix A in our simulations, suggests
that Helix A contributes to peptide insertion by establishing the majority of hydrophobic
interactions after binding to the membrane, while Helix B increases the affinity by pro-
viding amphipathic interactions at the interfacial region. The membrane-bound model
of HAfp, as well as the details of membrane-binding captured in the simulations could
be expanded in a subsequent work to study the mechanism of pore formation induced by
HAfp. It has been suggested that multiple copies of the peptide are necessary for pore for-
mation [386,387], while the peptide undergoes a pH-induced conformational change [365].
This mechanism could be further explored by employing our membrane-bound model as
well as the enhanced lipid dynamics of the HMMM membrane to study the peptide–
peptide interactions that preclude pore formation.
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Chapter 9
Molecular Mechanisms of
Phosphatidylserine (PS) Membrane
Recognition by T-cell
Immunoglobulin and Mucin Domain
(Tim) ∗
9.1 Introduction
Membrane associating proteins perform a diverse array of cellular functions including,
but not limited to, cytoskeletal remodeling, modulating membrane trafficking, and fa-
cilitating cell/cell signaling [30, 388]. These varied cellular functions in turn help to or-
chestrate an equally diverse assortment of biological responses including everything from
regulating immune response to mediating neurological signaling [10]. As such, membrane-
∗This chapter has been submitted as a research article to Biophysical Journal. Gregory T. Tiet-
jen*, Javier L. Baylon*, Daniel Kerr, Zhiliang Gong, J. Michael Henderson, Charles T. R. Heffern,
Mati Meron, Binhua Lin, Mark L. Schlossman, Erin J. Adams, Emad Tajkhorshid, and Ka Yee C. Lee,
“Molecular Mechanisms of Phosphatidylserine (PS) Membrane Recognition by Tim1”. Submitted to
Biophysical Journal, 2016.
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associating proteins represent an important class of molecules with broad importance in
nearly every area of biology. Unfortunately, the dynamic nature of lipid membranes
and membrane/protein interactions poses an extreme challenge with respect to under-
standing molecular mechanisms of action [7,389]. X-ray crystallography, the stalwart for
characterization of protein-protein interactions, is typically not amenable to the study
of protein/membrane interactions. Consequently, in spite of the biological importance
of membrane/protein interactions, there is disproportionately more known about pro-
tein/protein interactions. Of the more than one hundred thousand structures currently
available at the Protein Data Bank (PDB), only 15% correspond to transmembrane and
peripheral membrane-binding proteins [390,391]. While recent years have seen the devel-
opment of a number of new approaches focused on circumventing the challenges associated
with revealing the molecular details of membrane protein recognition [10], there remains
a significant gap between the level and reliability of atomic details in these methods when
compared to that provided by traditional X-ray crystallography.
In the absence of such atomic details, it is exceedingly difficult to distinguish subtle
differences between membrane binding proteins, particularly within a class of related re-
ceptors. Phosphatidylserine (PS) receptors, of which 15 and counting have been identified
over the past 10 years, exemplify this issue. Recognition of extracellularly exposed PS
lipids is most typically associated with recognition and removal of apoptotic cells, which
upon undergoing apoptosis actively expose PS lipids that are normally sequestered to the
inner leaflet of the plasma membrane in resting healthy cells [392]. However, it is now
appreciated that cellular apoptosis is not the only circumstance for which PS becomes
exposed extracellularly. Many types of immune cells appear to also expose PS upon ac-
tivation, albeit with significantly different characteristics (e.g. lower PS surface density
and transient PS exposure) than that of apoptotic cells. This alternative instance of PS
exposure, which also happens to coincide with the plethora of active signaling processes
that occur during immune cell activation, suggests that recognition of exposed PS may
have broader significance beyond simply facilitating the elimination of apoptotic cells.
Indeed there is now evidence to suggest that PS recognition by receptors expressed
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predominately on immune cells can lead to a variety of outcomes. The Tim (T cell
immunoglobulin and mucin) family of proteinswhich includes Tim1, Tim3, and Tim4 in
humans is largely restricted to immune cells where these proteins mediate starkly different
immunological functions [393, 394] (Fig. 9.1). Tim1, for example, has been shown to
mediate T cell proliferation upon receptor crosslinking, whereas Tim3 appears to mediate
the opposite effect of suppressing the immunological function of the Tim3 expressing cell
upon ligand engagement. In contrast to both Tim1 and Tim3, Tim4 appears to mediate
no changes in the Tim4 expressing cell (typically macrophages), but instead facilitates
the phagocytic engulfment of PS-exposing cells. Such distinct functional responses to the
recognition of PS between the Tim receptors, combined with the fact there exist starkly
different physiological circumstances under which PS becomes exposed (i.e. apoptosis
versus activation), suggest the possibility that the Tim proteins may mediate differential
responses to the different instances of PS exposure.
Figure 9.1: Schematic representation of the PS-
recognition mechanism of Tim proteins.
Notably, all three Tim proteins bind a
centrally-positioned PS lipid within a com-
pletely conserved Ca2+ binding pocket. In
support of a hypothesis of differential PS
recognition, we have recently shown that
there are significant differences in the sensi-
tivity of the Tim proteins to varying levels
of PS surface density, with Tim4 displaying
a distinctly sigmoidal binding response to
increasing PS surface density while Tim1
and Tim3 are nearly hyperbolic [395]. While we showed that Tim4 mediates its sigmoidal
binding response through the positioning of four peripherally located basic residues, the
structural mechanisms that differentiate Tim1 and Tim3 from Tim4 remain unclear.
Given the highly similar structures of these three proteins, resolving such subtle struc-
tural differences requires reaching a level of atomic accuracy not typically achievable in
protein/membrane interactions.
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To overcome this obstacle, we have employed a combination of interfacial X-ray scat-
tering and multiple molecular dynamics (MD) simulation based techniques in order to
determine potential molecular mechanisms for Tim1 recognition of PS-containing mem-
branes in a manner that is relatively insensitive to increasing PS surface density. We
demonstrate that by coupling interfacial X-ray scattering measurements and standard
MD simulations we can iteratively improve the quality of our X-ray analysis and achieve
a structural model well supported by existing biochemical data. We also employed MD
simulations using a recently developed highly mobile membrane-mimetic model (HMMM)
in order to capture spontaneous Tim1 binding to a PS membrane in an unbiased man-
ner [161]. Notably, this unbiased membrane binding procedure reveals two putative bind-
ing states, one of which would appear to require minimal interactions with peripheral PS
residues and thereby potentially provide a mechanism for Tim1’s ability to demonstrate
significant binding even at relatively low PS surface density. Collectively these approaches
allow us to develop a dynamic structural model for Tim1 recognition of PS membranes
that provides atomistic insight into the structural characteristics that facilitate the specific
recognition of PS membranes by Tim1.
9.2 Methods
9.2.1 System Preparation
Modeling of Tim1. The crystal structure of Tim1 [396] (PDB entry 2OR8) was ob-
tained from the RCSB Protein Data Bank [391]. The position of the missing Ca2+ ion and
its coordinating residues in Tim1 were modeled after the ion binding site of Tim4, which
shares the same residues in the ion binding site [397]. The protein structure was placed
in a box with dimensions of 80×80×90 A˚3 and containing ∼ 20,000 water molecules, gen-
erated with the SOLVATE plugin of VMD [117], and neutralized with 150 mM NaCl
ions using the AUTOIONIZE plugin. The system was then energy minimized for 10,000
steps and simulated for 100 ps with the Cαatoms of the protein harmonically restrained
(k = 1 kcal mol-1 A˚-2), and a 20 ns run with no constraints followed. The resulting struc-
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ture of Tim1 with a bound Ca2+ ion was used as the starting point for the subsequent
simulations.
Preparation of the HMMM Membrane. The HMMM membrane patch was
constructed by placing two leaflets of short-tailed lipids at the interface of water and
1,1-dichloroethane (DCLE), as described in detail elsewhere [161]. The lipids used in the
membrane patch were constructed starting from a palmitoyl-oleoyl-phosphatidylcholine
(POPC) and palmitoyl-oleoyl-phosphatidylserine (POPS) molecules as templates, by short-
ening lipid tails to only 5 carbons [161]. To match the experimental lipid concentration,
a lipid ratio of 7:3 PC:PS was employed in the simulations. The HMMM membrane
was assembled by constructing a DCLE box, with dimensions of 80×80×10 A˚3 containing
740 molecules of the organic solvent, and placing 160 short-lipids on its large faces, 80
lipids on each side. The resulting bilayer was then solvated using the SOLVATE plugin
of VMD [117], yielding a system with 36,000 atoms. The solvated membrane mimetic
systems was energy minimized for 10,000 steps and simulated for 2 ns without any con-
straints on the lipids, using an NPnAT ensemble with constant area, and with a target
pressure and temperature of 1.0 atm and 310 K, respectively. A constant area of 6,400 A˚2
(80x80 A˚2) was employed, yielding an area per lipid of 80 A˚2.
9.2.2 Simulation Systems
Initial Membrane Simulations of Tim1. After equilibrating the calcium ion bound
to Tim1, we next built a PS lipid into the central PS pocket, again based on homology to
Tim4 [397]. The CHARMM membrane builder GUI [398,399] was then used to construct
an atomistic lipid bilayer around the Tim1 protein. All-atom molecular dynamics (MD)
simulations on the membrane docked Tim1 system were performed using explicit water,
lipids, and ions. The simulated system was generated by using the CHARMM-GUI Mem-
brane Builder [398, 399] with the best-fit Tim1 orientation and included 136 lipids, 70
POPC in the non-protein interacting leaflet and 48 POPC-20 POPS in the leaflet where
the protein was bound; the two fewer lipids were to accommodate the cross-sectional area
taken up by partial insertion of Tim1 as calculated by the Membrane Builder. NaCl con-
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centration was set to 150 mM and then adjusted as necessary by the VMD AUTOIONIZE
plugin to neutralize the charge of the system. Periodic boundary conditions were used and
a 15 A˚ water cushion was included beyond both the protein and membrane structure to
prevent interactions between periodic cells. A constant NPnAT ensemble (P = 1 atm, A
= 4605 A˚2, and T = 303.15 K) was used to maintain appropriate system parameters, most
notably the area per lipid molecule which was set at 65 A˚/molecule to match both the
X-ray experimental value and an approximate value for a 7:3 POPC:POPS bilayer. The
system was equilibrated following the standard method produced by the CHARMM-GUI
Membrane Builder with 1 ns of production performed as the final step of equilibration.
200 ns of unrestrained simulation was then performed and data analysis were done using
both VMD (custom TCL code) and Matlab.
Membrane-Binding Simulations. The equilibrated structure of Tim1 was added
to the 7:3 PC:PS membrane. The protein was placed above the PO4 plane of the cis leaflet,
∼10 A˚ away from the membrane, with two different initial orientations. An additional
layer (20 A˚) of water was added using the SOLVATE plugin to the resulting structures
to ensure sufficient hydration. To neutralize the systems, 150 mM NaCl was added using
the AUTOIONIZE plugin of VMD [117]. The initial systems consisted of a box with
dimensions of 80×80×120 A˚3 containing ∼69,000 atoms.
The systems were energy minimized for 10,000 steps and simulated for 100 ps with the
Cα atoms of the protein harmonically restrained (emphk = 1 kcal mol-1 A˚-2), followed by
a production run of 50 ns. Each initial orientation was tested in seven independent simu-
lations, yielding a total of 14 simulations where membrane-binding of Tim1 was captured.
A harmonic constraint along the z-axis, with a force constant k = 0.01 kcal mol-1 A˚-2, was
applied to the carbonyl atoms of the PC and PS lipids to restrain the position of the
short-tailed lipids to better mimic the atomic distributions of a full lipid bilayer and to
prevent their occasional diffusion into the aqueous phase.
To further examine the stability of the resulting membrane-bound Tim1, simulations
employing a full POPC:POPS lipid bilayer were also performed. The last frame of the
HMMM systems in which a PS headgroup accommodated in the lipid binding pocket
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of Tim1 (4 systems) were employed as the starting structures for further simulations.
The short-tailed lipid bilayer was grown into a full lipid bilayer by removing the DCLE
molecules and adding the missing carbons of the lipid tails while preserving the positions
of the lipid atoms already present in the HMMM model (head groups and initial few
carbons of the lipid tails). To further optimize the process, the positions of the newly
added atoms in the lipid tails were adopted from the coordinates of randomly selected
lipid molecules from a separately equilibrated POPC:POPS membrane.
During these steps, the original contacts established between the lipids and Tim1
during the HMMM membrane-binding simulations were preserved. These systems were
then minimized and equilibrated for 100 ps while constraining (k = 1 kcal mol-1 A˚-2) the
heavy atoms of the protein and the short-tailed lipids (already present before adding the
new atoms) to allow for the newly added atoms to relax. Following this step, the systems
were equilibrated without constraints for 100 ns, with the last 50 ns used for structural
analysis.
9.2.3 Simulation Protocol
Simulations were performed using NAMD2 [127], with the CHARMM27 force field with
cMAP [400] corrections for proteins and CHARMM36 [113] force field parameters for
lipids. The TIP3P model was used for water [120]. All the HMMM simulations were
performed in NPnAT ensembles at 1.0 atm and 310 K, and with a time step of 2 fs.
The POPC:POPS systems were simulated as an NPT ensemble with similar parameters.
Constant pressure was maintained using the Nose-Hoover Langevin piston method [124,
125] and constant temperature was maintained by Langevin dynamics with a damping
coefficient γ of 0.5 ps-1. Non-bonded interactions were cut off after 12 A˚ with a smoothing
function applied after 10 A˚. The particle mesh Ewald (PME) method [126] was used for
long-range electrostatic calculations with a grid density of > 1 A˚-3.
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9.2.4 Summary of Experimental Methods
Our experimental collaborators at the Lee Lab (Uuniversity of Chicago) expressed Tim1
proteins for experiments. They also performed X-ray reflectivity measurements at the
Advanced Photon Source of Argonne National Laboratory, in order to characterize the
orienation and insertion depth of Tim1 incorporated into lipid monolayers. Data collection
and analysis was also performed, employing different custom analysis scripts.
9.3 Results and Discussion
9.3.1 X-ray Analysis of Tim1 Orientation Upon PS Monolayer
Binding
We have previously determined the orientation of Tim4 bound to a PS-containing lipid
monolayer utilizing a combination of interfacial X-ray scattering and MD simulations. [395].
We have also demonstrated that, in spite of their structural similarity and conservation of
the central PS binding pocket, Tim1, Tim3, and Tim4 have substantially different bind-
ing characteristics, presumably mediated by variations in peripheral membrane interacting
residues [395]. To determine the structural features that distinguish Tim1 PS membrane
binding from its homologues, we again employed interfacial X-ray scattering. Mixed lipid
monolayers comprised of 70% zwitterionic SOPC (stearoyl-oleyl-phosphatidylcholine) and
30% anionic SOPS (stearoyl-oleyl-phosphatidylserine) were deposited at a clean air/water
interface to a surface pressure roughly equivalent that of a bilayer (∼25 mN m-1) [401].
The reflected intensity of scattered X-rays was collected at a range of incident angles
initially for the lipid layers alone and then for lipid plus protein following injection of
recombinant murine Tim1 protein into the subphase; the protein used for all studies is
the Ig-like domain responsible for PS recognition. Consistent with a bound protein layer,
injection of Tim1 into the subphase led to a pronounced change in the reflectivity pattern
particularly at low Qz (Fig. 9.2, top left). Qz is the scattering wavevector in the direction
normal to the interface and is inversely related with the size of the scattering object; the
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protein is quite large (∼100 A˚) relative to the lipid (∼20 A˚), which accounts for the low Qz
protein signature. The low Qz peak was removable by calcium chelation with EGTA and
was dependent on the presence of PS (Fig. 9.2, top panels), suggesting that the change
in reflectivity was indeed due to a specific, calcium-dependent binding of Tim1 to the
PS-containing lipid monolayer.
Figure 9.2: X-ray reflectivity of membrane-bound Tim1. (Top left) Representative X-ray reflectivity
data for 7:3 SOPC:SOPS lipid monolayer alone, with 1µM Tim1, or after injection of EGTA to chelate
Ca2+ and remove the bound Tim layer. (Top right) Representative X-ray reflectivity data for pure SOPC
lipid monolayer alone or after injection of 1µM Tim1 in to the subphase. (Middle left) Heat map averaged
over 11 different data sets showing best fit θ and φ region for Tim1 orientation depicted in dark blue (dark
blue represents regions within 95% confidence window for best fit as determined by an F test comparison
of all protein orientations relative to the single best fit orientation). The axes used in the fitting relative
to the protein are shown in the inset. (Middle right) Atomistic model of Tim1 bound to a lipid monolayer
based on fit parameters derived from X-ray reflectivity analysis. The two-box lipid model is represented
in boxes of different colors, and the fitting paremeters are shown.
To determine the orientation of the monolayer-bound Tim1, we employed previously
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described methods that utilize an existing crystal structure to perform iterative model-
dependent fitting of X-ray reflectivity data [377,395]. In this method, the protein crystal
structure is first aligned to its principle axes and then rotated iteratively along two ro-
tational angles: θ (tilt from original Z axis, i.e. the membrane normal) and φ (rotation
about the proteins new tilted z-axis referred to as z’). For each rotated angle, a 1D
electron density profile is calculated along the membrane normal (z-axis), which is then
combined with a two-box model of the lipid electron density. Middle panel of Fig. 9.2 de-
picts a best-fit heat map averaged over 11 independent data sets obtained by performing
non-linear least-squares fitting of six fit parameters (lipid layer head group length, head
group electron density, tail group length, tail group electron density, protein depth of
penetration, and protein coverage). This fitting uses as input individual protein structure
files orientated through all rotations in θ and φ that give rise to unique 1D electron density
profiles. The heat map possesses a single well-defined region of best-fit with an average
protein orientation of θ = 38± 10 and φ = 108± 32 and depth of membrane penetration
of 8.3 A˚± 0.5 (± refers to 95% fitting confidence window) relative to the surface of the
lipid two-box model.
The general orientation of the protein appears reasonable given that the PS binding
pocket (formed by the FG and CC loops) is proximal to the membrane (Fig. 9.2, bottom
right). However, specific details of this model do not appear entirely consistent with
previous reports. In particular, the conserved hydrophobic residues W97 and F98 appear
to be quite shallow in their depth and do not penetrate into the hydrophobic tail region
of the monolayer as was previously observed in Tim4 models [395]. Additionally, this
model appears to suggest that the central PS pocket forms the only significant point of
membrane contact and that the peripheral BC loop is not associating with the membrane
in contrast to previous biochemical mutational analysis which suggested the BC loop did
significantly contribute to binding [402]. Collectively these modeling data suggest that,
while the general orientation of Tim1 produced by our X-ray analysis seems plausible,
key molecular features do not appear to be well supported by previous findings.
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9.3.2 In Silico Unbiased Tim1 Membrane Binding
While the preceding X-ray analysis appears to converge on a consensus Tim1 orienta-
tion, the iterative process employed effectively couples the two approaches such that it is
possible that we are biasing our analysis. In order to independently verify the molecular
details of the membrane bound structure, we next utilized a recently developed method
for allowing membrane-binding proteins to freely bind to a lipid layer in silico. In order
to study unbiased membrane binding of Tim1, we performed 14 independent, 160 ns MD
simulations with a membrane containing a 7:3 PC:PS lipid ratio. Tim1 was originally
placed ∼10 A˚ away from the membrane, and two sets of initial orientations (θ and φ),
selected from preliminary experimental data, were employed for two different sets of 7
simulations each (Fig. 9.3).
Figure 9.3: HMMM model provides unbiased simulation of spontaneous Tim1 membrane binding. Two
initial orientations of Tim1 were tested in membrane binding simulations. 7 independent simulations
were performed for each simulation. Spontaneous association of Tim1 to the membrane was observed
in 10 out of 14 runs, resulting in membrane-bound models of Tim1, where a lipid headgroup (PC or
PS) entered the binding pocket of the protein. Short-tailed lipids are shown in stick representation, and
DCLE is shown in yellow surface representation.
Here we have employed the highly mobile membrane-mimetic model (HMMM) to cap-
ture the spontaneous binding of Tim1 to the membrane within ∼50 ns of simulated time.
The HMMM model employs short-tailed lipids (five carbons in each tail) while an organic
solvent, e.g., with 1-1 dicloroethane (DCLE) replacing the hydrophobic core of the mem-
brane. This strategy provides enhanced lipid mobility that accelerates the association of
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Figure 9.4: Insertion and orientation of Tim1 in the membrane. (Top) Time series of the z-projection of
the center of mass (COM) of side chains W97/F98 and calcium ion for 10 simulations were Tim1 binds to
the membrane. Blue and red dashed lines indicate the average z-position of the PO4 and COO
− groups
of the lipid headgroups, respectively. (Bottom) Time series of the orientation of Tim1, characterized by
angles θ and φ, as defined in Fig ??. Dashed lines represent the average value for the angles obtained
from X-ray fitting.
proteins with the lipid bilayer while still maintaining the relevant lipid structural details
in the region accessed by the protein. Using this approach, we were able to repeatedly
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capture (in 10/14 simulations) the unbiased binding of Tim1 to the membrane, as deter-
mined by penetration of hydrophobic residues W97/F98 and positioning of the Ca2+ ion
within close proximity to the lipid PO4 layer (Fig. 9.4).
Figure 9.5: PS enters the binding pocket of Tim1. Zoomed view of the central short-tailed PS lipid
(DVPS), shown in stick representation, bound with the Tim1 PS pocket. Spontaneous PS binding to
Tim1 was observed in 4 HMMM simulations. Several key residues, shown in stick representation, are
identified, revealing that the PS lipid is bound very similarly to the crystal structure of Tim4 and
Tim3 [397]. Short-tailed lipids are shown in stick representation, and DCLE is shown in yellow surface
representation.
Notably, spontaneous binding of a PS headgroup to the lipid-binding pocket of Tim1
was observed during simulations with the 7:3 PC:PS membrane and the centrally bound
Ca2+. Due to the enhanced lipid mobility of the HMMM model, spontaneous binding
of a PS head group to the binding pocket of Tim1 (Fig. 9.5). This was observed in 4
different systems, while in the remaining systems the binding pocket was occupied by a
PC head group, which perhaps represents an intermediate state that has yet to reach full
equilibrium. The PS headgroup encountered the Ca2+ ion bound to Tim1, establishing
an ionic interaction, mediated by the phosphate group of the lipid, that allowed the lipid
to remain in the binding pocket, and to form additional interactions with R91.
Although the HMMM provides a robust approach to obtain a membrane-bound form of
Tim1, the flexibility of the membrane affects the convergence of the orientation (Fig. 9.4),
making a direct comparison to experimental measurements difficult. Therefore, in order
to evaluate the correspondence between the membrane binding simulations and the previ-
ously described standard MD/X-ray-derived model, the Tim1-bound HMMM membranes
were further extended to a 7:3 POPC:POPS lipid bilayer and simulated for 300 ns. Lipid
tail extension was done for the 4 simulations where Tim1 had a stably bound central
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PS, hereby referred to as systems Ext-1, Ext-2, Ext-3 and ext-4. To characterize the
orientation of the protein, the same two rotational angles θ and φ were calculated for
each simulation trajectory, using the same angle definitions employed in the experimental
measurements (Fig. 9.2). After lipid tail extension following unbiased membrane binding,
Tim1 adopts a similar orientation to that observed in the previously described standard
X-ray analysis (Fig. 9.6). Moreover, both the hydrophobic anchoring residues described
above (W97 and F98), as well as the residues forming the Ca2+ PS pocket (D100 and R91)
and the Ca2+ ion itself are all similarly positioned (Fig. 9.6, bottom panel). Considered
collectively, these results demonstrate that the unbiased HMMM simulations substantiate
our model of Tim1 membrane binding.
9.3.3 Molecular Mechanism of Tim1 Membrane Recognition
Having further substantiated our Tim1 membrane-binding model via unbiased simula-
tions, we next sought to determine the molecular mechanisms that distinguish Tim1. We
have previously identified the importance of peripheral (i.e. outside the central PS bind-
ing pocket) basic residues on the membrane binding characteristics of Tim4. Given that
the central PS binding pocket is strictly conserved between Tim1 and Tim4, we hypoth-
esized that the stark differences in sensitivity to changes in PS surface density observed
between Tim1 and Tim4 are mediated by differences in the number and/or positioning
of peripheral basic residues. Thus we explored our dynamic models to identify basic
residues positioned within close proximity (< 4 A˚ between basic residue amine and either
phosphate on any lipid or carboxyl on PS lipids) of the membrane.
In contrast to the 4 peripheral basic residues present in Tim4, Tim1 possesses 3 (R25,
R53 and K102) (Fig. 9.7). With respect to positioning within the membrane, R25 pene-
trates more deeply residing predominately at the level of lipid phosphate groups (distri-
bution shown in Fig. 9.7). K102 is positioned slightly more towards the head group region
likely biasing it towards PS lipid carboxyl groups similar to what we have previously ob-
served with Tim4. Notably absent are any basic residues on the C’C” beta sheet region of
the protein. In Tim4, R48 (located in this region) has a very strong influence on Tim4’s
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Figure 9.6: Orientation and insertion of Tim1 in POPC/POPS membranes. (Top) Time series of the
orientation of Tim1 (angles θ and phi, as defined in Fig. 9.2) in a 7:3 POPC:POPS membrane. Systems
Ext-1, Ext-2, Ext-3 and Ex-4 started by extending the lipid tails of the HMMM membrane of systems
were PS was found in the binding pocket of Tim1, as shown in Fig. 9.5. (Bottom) Average z-position of
identified anchoring residues W97 and F98, as well as elements of the PS binding pocket, Ca2+, R91 and
D100 for the 4 extended systems. The average was calcualted over the last 200 ns of simulation for each
system. Blue and red dashed lines indicate the average z-position of the PO4 and COO
− groups of the
lipid headgroups, respectively.
sigmoidal binding response to increasing PS surface density, as mutation of this residue
to alanine transformed the sigmoidal response to a largely hyperbolic one very similar
to Tim1 [395]. This site is presumably compensated by R53 in Tim1. Interestingly, the
simulations suggest that Tim1 adopts to distinct orientations in the membrane, as shown
in Fig. 9.6, where either K102 or R53 engage with the membrane, as seen on the sidechain
distribution in Fig. 9.7. This suggests that effectively only 2 additional basic sidechains
148
Figure 9.7: Basic residues interacting with the POPC/POPS membrane in Tim1 simulations. In
addition to R91, Tim1 has 3 additional basic residues that interact with the membrane upon binding,
namely R35, R53 and K102 shown in stick representations in the left panel. The distribution od the
z-position for the 4 extended systems (right panel) reveals that the basic residues adopt adopt different
positions with respect to lipid headgroups.
can interact with the membrane (R25 and either R53 or K102, but not both), as shown
in Fig. 9.8.
9.4 Summary
Accumulating evidence suggests that an immune response can be triggered by the pres-
ence of abnormal lipid components, such as phosphatidylserine (PS), in the outer leaflet
of the cellular membrane. The T-cell immunoglobulin and mucin domain (Tim) family of
proteins recognize PS exposed on the surface of the membrane. Tim proteins are expressed
by numerous cell types, and despite their close structural similarity, they are involved in
triggering different immune responses. These specific roles have been attributed to dif-
ferent factors, including differential binding modes of Tim proteins to anionic membranes
and their variable sensitivity to lipid composition of the membrane.
In order to study the mechanism of membrane binding by Tim proteins, we have
performed MD simulations of Tim1 employing the enhanced-dynamics HMMM membrane
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Figure 9.8: Two distinct orientations of Tim1. Representative snapshots of the 4 extended simulations,
showing the elements involved in membrane interaction. Lipids and Tim1 sidechains are shown in stick
representations. POPS molecule in the central binding pocket is shown in red. Lipids interacting with
R25 are shown in silver color, while lipids interacting with either R53 or K102 are shown in magenta or
green respectively.
model. We have performed a total of 14 independent simulations with different lipid
compositions (7:3 PC:PS), starting from 2 different initial orientations, providing robust
statistics to characterize the membrane-bound form of this protein. Importantly, the PS
binding-pose in the central pocket is not known for Tim1, and using the simulations we
were able to capture spontanous PS binding to the pocket. This simulations provided
an initial membrane-bound model that was further refined by extending the short lipid
tails to a full POPC/POPS membrane. In addition to MD simulations, the orientation of
Tim1 in model PS-containing membranes was characterized using X-ray scattering. The
agreement between the X-ray experiments and the MD simulations provide a detailed
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description of the membrane-binding mechanism of Tim proteins.
The results from the simulations reveal important details about the mechanism of
binding of Tim1. Hydrophobic sidechains W97 and F98 act as an anchor, inserting into
the membrane and stabilizing the protein in the membrane surface. In addition, R91, lo-
cated in the PS binding pocket, is able to interact with PS headgroups once Tim1 inserts.
The role of these residues has been suggested to meadiate binding of other members of
the Tim familiy [395]. Our simulations also revealed additional electrostatic interactions
that Tim1 forms with the membrane. R25, located away from the central binding pocket,
inserts into the membrane and interacts with negatively charged components of the lipids
(phosphate and carboxyl groups) in all simulations. Other two basic residues, R53 and
K102, were identified to interact with the membrane in an alternate fashion. The simula-
tions suggest that either of these sidechains can interact with the lipids, while positioning
the other away from the membrane (Fig. 9.8). This results in effectively forming 2 ad-
ditional binding interactions with charged lipids (with R25 and either R53 or K102), in
addition to the PS in the binding pocket. These details complement the models derived
by the analysis of the X-ray scattering data performed in parallel to the simulations.
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